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Non-adherence to immunosuppressive medication is a major risk factor for poor clinical outcomes 
post-transplantation, including graft rejection and graft loss. However, it remains a common issue. 
Patients can experience side effects that are problematic and there may be a range of other life and 
psychosocial factors that interfere with treatment regimens. Withstanding such issues, adherence is 
vital to provide the kidney with the best chance of survival and function. In addition to patient 
outcomes, ill health resulting from non-adherence is costly to the NHS, since dialysis services are 
more expensive than those required to support transplantation. The programme of work within this 
thesis aims to further explore what is known about adherence in adult transplant recipients in order to 
drive advances in patient support.  A series of studies were designed to assess different elements of 
adherence. This was achieved through: 1) a systematic review of existing research on adherence; 2) 
retrospectively considering the relationship between pre and post-transplant adherence in 
haemodialysis (HD) patients who later go onto receive a solid organ; 3) qualitative enquiry of the 
views and beliefs of clinical staff in relation to the importance of adherence for kidney transplant wait 
listing; 4) cross-sectional data collection with transplant recipients about treatment beliefs that may 
help understand behavioural patterns.  
 
The systematic review provided a comprehensive evidence synthesis of literature exploring non-
adherence to immunosuppressants among renal transplant recipients. A total of 60 studies were 
identified as relevant for inclusion. Studies varied in how they measured adherence, including self-
report, electronic monitoring, pharmacy refill, blood levels and collateral report, with some studies 
combining more than one measure in an attempt to increase reliability. The overall non-adherence 
prevalence ranged across studies from 0.06% to 89.2%, dependent on how adherence was measured 
and operationalised. Self-report was the most commonly utilised measurement method to assess 
adherence behaviour. Meta-analysis of 38 studies revealed the pooled prevalence of self-reported non-
adherence was 37.6%. The findings highlight a clear lack of consistency in how adherence is 
measured and defined, with greater guidelines needed across all measurement types.  
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A retrospective study examined the relationship between clinical measures of pre and post-transplant 
adherence in a group of patients who moved from HD to receive a transplant. Little previous research 
has explored if adherence behaviour transfers across modalities. Data was collected for 88 patients 
about adherence to HD regimens in the six months prior to transplantation, and for one-year post-
transplantation following return transfer to the post-transplant clinic from the transplanting centre. 
Pre-transplant definitions of non-adherence included if patients: on average shortened their dialysis 
prescription by >10 minutes; shortened by >15 minutes; missed two or more HD sessions; and had 
mean serum phosphate levels >1.8mmol/l. Post-transplant definitions of non-adherence included: 
mean tacrolimus levels outside 5-10ng/mL; missed one or more post-transplant clinic appointments. 
Non-adherence ranged from 25%-42% pre-transplant and 15.9%-22.7% post-transplant dependent on 
how it was operationalised. There was little relationship between pre-transplant data and post-
transplant adherence, with the exception of a significant relationship between pre-transplant 
phosphate and post-transplant clinic attendance. Patients who had missed one or more transplant 
clinic appointments had higher mean pre-transplant phosphate levels. Non-adherent patients with high 
phosphate levels pre-transplant and missed clinic appointments post-transplant were significantly 
younger.  
 
Qualitative inquiry was used to gain in-depth understanding of how clinicians recognise non-
adherence and whether or not pre-transplant adherence features in their decision making when 
determining if a patient is eligible for transplant listing. Thirty-six staff members who work closely 
with renal transplant recipients were recruited across two NHS trusts, and interviewed using a semi-
structured interview. Staff members included nephrologists, transplant surgeons, registrars, transplant 
nurse specialists and pharmacists. Interviews were transcribed verbatim and analysed using thematic 
analysis. Five main themes were extracted on understanding of non-adherence: “Barriers to 
adherence” (including risk factors and control in ensuring adherence messages are conveyed), 
“Striving for normality” (in terms of how patients view transplantation as an opportunity for 
normality and to avoid dialysis) , “Mutuality in maximising patient adherence” (through ensuring 
patients receive multi-disciplinary care, addressing barriers to adherence, and promoting patient 
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autonomy through education and peer support), “Complexity in shining light on adherence in wait 
listing” (highlighting subjectivity in the importance of adherence) and “Post-transplant normalization” 
(with patients less adherent due to perceptions of wellness and a lack of immediate consequences 
following missed medication doses). Findings demonstrate that clinicians recognise and understand 
the barriers that patients face with adherence, and work to try and make treatment management easier. 
Patient understanding and engagement was considered an effective way to promote adherence. 
Agreement on how adherence is viewed as part of eligibility for wait listing was lacking, with 
clinicians managing pre-transplant non-adherence in different ways.  
 
A cross-sectional study further elucidated the relationship between self-reported adherence and 
markers of adherence obtained from clinical data. Additionally, the association between psychological 
factors, including illness perceptions and beliefs about medicines, with adherence was explored. Self-
report measures used included the Medication Adherence Report Scale (MARS-5), Brief Illness 
Perceptions Questionnaire (Brief IPQ) and the Beliefs about Medicines Questionnaire (BMQ). Open-
ended questions were also utilised to investigate how patients conceptualise their post-transplant 
treatment. Patients were recruited from one renal unit during the post-transplant weekly clinic, with 
128 patients completing questionnaires. Findings showed no correlations between clinical data and 
MARS-5 adherence score. Certain illness perceptions were highlighted as independently predicting 
adherence behaviour. Perceptions of personal and treatment control were found to increase adherence. 
Conversely, perceptions of consequences and emotional representation were found to predict lower 
adherence. Patients reported higher scores on the necessity sub-scale than the concerns sub-scale of 
the BMQ, indicating they perceive the “benefits” of immunosuppressant medication to outweigh the 
“costs”, however, the BMQ sub-scales did not significantly predict MARS-5 adherence. The 
qualitative comments via open-ended questions provided a mixed view towards experience of 
transplantation. Those reporting positive experiences had feelings of regained life, however, for some, 
life after transplant did not meet their expectations due to e.g. symptom burden or side effects. The 
findings point to areas for potential intervention by considering whether illness perceptions in 
particular should be assessed to signal patients who may struggle to engage with treatment regimens.  
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In conclusion, it is clear that non-adherence is a prevalent issue among the renal transplant population. 
This thesis has advanced clear areas of inconsistency in adherence research, alongside chartering new 
courses for further research and the development of clinical practice. Clearer definitions and measures 
of adherence are needed to provide greater reliability in reported non-adherence prevalence rates, and 
to allow for comparisons to be made across studies. A longitudinal follow-up is necessary to explore 
how and at which point adherence behaviour changes post-transplant. Agreement is needed across 
clinicians on how to consider the importance of adherence in transplant eligibility for listing. Finally, 
promoting patient autonomy to self-manage treatment regimens through education and 


















Chapter 1: An introduction to Chronic Kidney Disease (CKD) 
 
1.1 Introduction 
This thesis presents a series of studies aimed at furthering understanding of adherence behaviour in 
kidney transplant recipients. As a starting point, an introductory chapter provides an overview of the 
kidneys and their function. The development of kidney disease and its treatment is also considered, 
with a specific focus on transplantation, as relevant to this thesis.  
 
1.1.1 The role of the healthy kidney 
To understand the significance of CKD, end stage renal disease and the need for transplantation, it is 
important to specify the structure and role of the healthy kidney(s). There are two kidneys situated on 
either side of the spinal column, around 10-12cm in length. They are bean shaped and about the size 
of a fist. The role of the kidney(s) is to remove waste and excess fluid from the body, including 
filtering food waste, toxins, medications and blood minerals (Fraser & Blakeman, 2016). This waste 
and excess fluid is removed via urine, a highly complex process involving excretion and re-absorption 
to maintain homeostasis of bodily levels and chemicals. In addition to removal of waste and fluid, the 
kidneys are responsible for regulating salt, potassium and acid levels in the body. Furthermore, the 
kidneys produce hormones that impact the functioning of other organs including, but not limited to, 
metabolism of calcium for bone health, production of red blood cells and blood pressure regulation 
(Ferguson & Waikar, 2012). They filter around 180 litres of blood daily. Glomerular Filtration Rate 
(GFR) is the volume of blood filtered by the kidney per unit of time (mL/min/1.73m2). Normal eGFR 
in young adults is considered to be around 125mL/min per 1.73m2 (Levey & Coresh, 2012). Across 
the adult population, healthy kidneys are considered to be able to filter more than 90mL/min/1.73m2.   
 
The “nephron” is a functional unit of the kidney, with each kidney containing up to a million. Each 
nephron contains a filter, called a glomerulus and a tubule, within which a two-step process occurs. 
Once the blood enters the nephron, it is filtered by the glomerulus and the remaining fluid is passed 
along the renal tubule. In the tubule, chemicals and water are added or removed from the filtered fluid 
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according to the body’s requirements. Needed substances including minerals and nutrients and almost 
all of the filtered water is reabsorbed into the blood. Waste products and extra water are removed for 
excretion via urine. This process ensures regulation of fluid volume, electrolyte balance and pH of 
bodily fluids. 
 
1.2 The failing kidney 
CKD is a long-term condition characterised by progressive decline in kidney function over time. The 
definition of CKD is based on the presence of decreased kidney function or damaged kidneys for 
more than three months (Levey & Coresh, 2012). The diagnosis implies persistently abnormal kidney 
function or structure. Complications and adverse outcomes can be delayed or prevented if CKD is 
detected early and treated (Levey et al., 2003). It frequently goes unrecognised, as it is often 
asymptomatic until later stages. The three-month duration is necessary to distinguish CKD from acute 
kidney injury (AKI). Whereas AKI is potentially reversible, CKD is progressive and irreversible. 
 
AKI usually occurs following a specific, abrupt acute event, and is characterised by a decline in 
kidney function within hours (NICE, 2018), encompassing both injury (structural damage) and 
impairment (loss of function) (Makris & Spanou, 2016). Classification of AKI includes pre-renal, 
acute post-renal obstructive nephropathy and intrinsic acute kidney diseases (Makris & Spanou, 
2016). Of these only intrinsic represents direct damage to the kidney, whereas pre-renal and post-renal 
AKI are a result of extra-renal diseases leading to decreased GFR. The most common cause of AKI is 
pre-renal due to reduced perfusion of the kidneys leading to decreased GFR often due to 
hypovolaemia, sepsis, reduced cardiac output or drugs reducing blood pressure or renal blood flow. If 
treated early, it is often reversible. Intrinsic renal is a consequence of structural damage to the kidney 
itself caused by toxins, immunological causes and drugs. Any of the main components of the kidney, 
vascular, glomerular or tubulointerstitial, may be involved. Post-renal, the least common cause of 
AKI accounting for 10% of cases, occurs as a result of acute obstruction, such as due to prostatic 
hypertrophy, impacting urine flow leading to intratubular pressure and decreased GFR (NICE, 2018). 
The incidence of AKI has been increasing over time. Previous views on AKI suggested it could be 
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completely reversible, however, more recent literature using animal and human studies has indicated 
that AKI can cause long-term damage and may also damage other organs (Coca, Singanamala & 
Parikh, 2012). In a systematic review of 13 studies, patients with AKI were at greater risk of 
developing CKD, end stage renal disease and early mortality, compared to patients without AKI 
(Coca, Singanamala & Parikh, 2012).  
 
1.2.1 Diagnosis and stages of chronic kidney disease 
CKD can be diagnosed using blood and urine tests, which are designed to look for high levels of 
substances that indicate the kidneys are not working correctly. Beginning treatment at the correct time 
in relation to CKD progression is crucial to prevent adverse outcomes (Levey et al., 2003). In clinical 
practice the primary test for kidney function is a blood test that measures the levels of creatinine, a 
waste product, in the blood. This result is used in a calculation along with age, gender and ethnic 
group to estimate how many millilitres of blood the kidneys are able to filter a minute. This is known 
as estimated glomerular filtration rate (eGFR). eGFR is considered to be the most efficient overall 
index of kidney function in health and disease (Levey & Coresh, 2012). Urine tests check for blood 
and protein, and levels of albumin and creatinine (known as albumin:creatinine ratio). Alongside 
eGFR, this provides a more accurate understanding of how well the kidneys are functioning. 
Additional tests that can be used to diagnose CKD and assess kidney damage include a kidney biopsy, 
where a small sample of tissue is extracted to examine for signs of damage, or scans including 
ultrasound, magnetic resonance imaging (MRI) or computerised tomography (CT). These scans are 
used to look for structural damage and obstruction (NHS, 2016). CKD is classified into five stages 













Table 1.1: Chronic Kidney Disease stage classification (Levey & Coresh, 2012) 
Stage eGFR Disease status 
1 >90mL/min per1.73m2 No CKD (unless signs of kidney damage) 
2 60-89mL/min per 1.73m2 No CKD (unless signs of kidney damage) 
3a 45-59mL/min per 1.73m2 CKD (mild-moderate loss of function) 
3b 30-44mL/min per 1.73m2 CKD (moderate-severe loss of function) 
4 15-29mL/min per 1.73m2 CKD (severe loss of function) 
5 <15mL/min per 1.73m2 ESKD (kidney failure) 
 
In stages one and two kidney function is considered normal, however, there are other abnormalities 
which indicate kidney damage, including the presence of blood and protein in the urine and structural 
damage indicated by imaging (Levey et al., 2003). Patients are treated for any underlying conditions 
with the aim of slowing progression of CKD. Stage three is considered moderate decrease in kidney 
function, and clinicians aim to evaluate and treat complications. Stage four represents severely 
reduced kidney function, and at this stage preparations are made for renal replacement therapy (RRT). 
The final stage of CKD, stage five, is commonly referred to as “end stage renal disease”. Kidney 
failure is defined as either an eGFR less than 15mL/min per 1.73m2 usually accompanied by 
symptoms of uremia or the need to begin RRT. 
 
1.2.2 Risk factors and causes of chronic kidney disease 
Risk factors for CKD can be categorised into two groups: initiating factors that increase patient risk of 
developing CKD, and perpetuating factors increasing the risk of CKD progression to end stage renal 
disease (Taal & Brenner, 2006; Evans & Taal, 2011) The different factors associated with each group 













Table 1.2: CKD initiating and perpetuating factors (Taal & Brenner, 2006; Evans & Taal, 2011) 




Family history of CKD 
Socio-economic status 
Metabolic syndrome 
High normal urinary albumin excretion 
Dyslipidaemia 
Nephrotoxins 















CKD may occur as a consequence of primary renal disease e.g. glomerulonephritis (inflammation of 
the glomeruli), polycystic kidney disease, and reflux nephropathy, or as a consequence of other 
chronic conditions such as high blood pressure (hypertension); diabetes; atheromatous vascular 
disease, chronic urinary obstruction, and long-term use of particular medications/drugs (NHS, 2016). 
Despite advances in diagnostic techniques and increasing knowledge of the disease, unknown 
aetiology of disease remains high in many countries. The most reliable and consistent data reporting 
prevalence rates of causes for CKD comes from incident renal replacement therapy patients and from 
countries where there are good renal registries.  
 
Diabetes and hypertension are the leading causes of CKD in high and many low and middle income 
countries (Evans & Taal, 2011; Jha et al., 2013). Around 40% of patients with diabetes will develop 
CKD. Glomerulonephritis, a wide term used to define primary and secondary conditions that cause 
inflammation and damage to the glomerulus, accounts for the cause of CKD in around 12% of 
incident renal replacement patients in the UK (Evans & Taal, 2011). Of genetic diseases, adult 
polycystic kidney disease is the most common monogenetic disorder causing CKD, usually presenting 
in the third or fourth decade of life. It is often experienced alongside other symptoms such as liver 
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cysts, cerebral aneurysms and cardiac abnormalities. Patients and family members of those diagnosed 
are screened via ultrasound to identify renal cysts. Long-term use of certain medications can cause 
AKI and CKD, often by provoking interstitial nephritis. These can include penicillin’s, non-steroidal 
anti-inflammatory drugs (NSAIDs), proton pump inhibitors, diuretics and anti-retrovirals (Evans & 
Taal, 2011). Patients who are most at risk for CKD should be screened regularly. These include older 
patients and those with diabetes and hypertension. 
 
1.2.3 Progression of chronic kidney disease and comorbidities 
The progression of CKD is associated with a number of potential adverse outcomes with 
complications leading to increased risk or mortality and poorer quality of life. Treatment to slow 
progression of kidney function decline and of co-morbid conditions, including to reduce risk for 
cardiovascular disease should begin during CKD stages 1 and 2 (Levey et al., 2003). As hypertension 
is considered both a cause and complication of CKD, this should be monitored and controlled across 
all patients. Additional complications of declining kidney function should be monitored and treated as 
appropriate during stage 3 CKD, as the prevalence of these complications increases when kidney 
function declines to less than 60mL/min per 1.73m2. These can include for example, cardiovascular 
disease (CVD), hypertension, bone mineral disorder, anaemia, kidney failure resulting in a need for 
renal replacement therapy (Bello et al., 2017).  
 
1.2.4 Complications of chronic kidney disease 
Patients with CKD have a high risk of developing complications, and therefore is essential to monitor 
risk factors in this patient population. Hypertension is a major complication which causes significant 
progression of CKD and decline in kidney function. Detection and control of high blood pressure is 
less than optimal, risking continued damage to kidney function (Muntner et al, 2010). Hypertension is 
associated with cardiovascular risk, and contributes to the increased cardiovascular risk associated 
with CKD. Cardiovascular disease (CVD) is the leading cause of mortality in CKD patients. As 
kidney function declines, the prevalence of CVD increases (Go et al., 2004). Cardiovascular mortality 
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rates are significantly higher in dialysis patients compared to age and sex matched individuals without 
CKD in the general population (Thomas, Kanso & Sedor, 2008).  
 
Anaemia is a common complication experienced alongside progressive CKD, with a strong 
correlation between the prevalence of anaemia and the severity of CKD (Thomas, Kanso & Sedor, 
2008). The overall prevalence of CKD anaemia is around 50% (McClellan et al., 2004). The most 
important cause of CKD associated anaemia is decreased erythropoietin synthesis, essential for 
stimulation and growth of red blood cells. This increases the risk of cardiovascular mortality and 
morbidity, and may lead to further deterioration of renal function (Thomas, Kanso & Sedor, 2008). 
CKD associated anaemia can be treated with erythropoiesis stimulating agents (ESAs) to reduce 
transfusion requirements and anaemia symptoms.  
 
CKD associated bone and mineral disorders, including hyperphosphatemia, hyperparathyroidism, 
adynamic bone disease, and vascular calcification are common. Phosphate retention and impaired 
renal secretion of 1, 25 dihydroxy-vitamin D are major driving factors (Thomas, Kanso & Sedor, 
2008). Bone disease can reflect high or a low bone turnover states. Osteitis fibrosa cystica is a high 
turnover condition and occurs as the result of hyperparathyroidism. Adynamic bone disorder is a low 
turnover state and associated with high calcium and low parathyroid hormone levels.  Osteomalacia, 
in which there is a bone mineralisation disorder, can also occur. Mixed stated (mixed osteodystrophy) 
are not uncommon. Vascular calcification is an associated condition, also contributed to by 
hyperphosphatemia, which is also a major risk factor for cardiovascular disease in CKD.   
 
1.2.5 Prevalence of chronic kidney disease 
CKD has been identified as a major public health problem worldwide. The 2010 Global Burden of 
Disease Study ranked CKD 18th in the list of causes of total number of global deaths (annual death 
rate 16.3 per 100,000) (Lozano et al., 2010; Jha et al., 2013). A systematic review exploring the global 
prevalence of CKD indicated a high global prevalence with a consistent estimated rate of between 11-
13%, the majority of patients diagnosed with stage three CKD (Hill et al., 2016). The mean global 
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prevalence was 13.4% (11.7%-15.1%) in populations measuring prevalence by all five CKD stages 
(N=44) and 10.6% (9.2%-12.2%) in populations measuring stages 3-5 (N=68) (Hill et al., 2016). 
These estimates indicate that global prevalence of CKD could be greater and therefore more common 
than diabetes (estimated prevalence 8.2%).  
 
1.3 End stage renal disease 
End stage renal disease (ESRD) occurs within stage five CKD when the kidneys are no longer able to 
support the needs of daily life in filtering waste and excess fluid from the body. At this stage, the 
kidneys are usually functioning at <10% of their healthy normal capacity (Timmers et al., 2008). At 
the end of 2016, approximately 63,162 adult patients were receiving renal replacement therapy in the 
UK (Renal Registry, 2017; 2018). Of these 40% were receiving haemodialysis, 6% peritoneal dialysis 
and 54% transplantation. The renal diagnoses in incident renal replacement therapy (RRT) patients 
were diabetes (29%), glomerulonephritis (14%), hypertension/renovascular disease (12%), 
pyelonephritis (6%), other (14%) and aetiology uncertain (14%).   
 
1.3.1 Pathways to treatment 
Patients with ESRD require RRT in order to survive. RRT includes two dialysis modalities: 
haemodialysis and peritoneal dialysis, and kidney transplantation. At the end of 2016, transplantation 
remained the most common form of RRT in the UK (see above). This pattern is similar across other 
northern European countries (USRDS, 2018). Dialysis involves filtering the blood, extracorporeally 
using an artificial membrane (haemodialysis), or using a natural, in-situ membrane (the peritoneal 
membrane), in peritoneal dialysis, to remove the toxins and fluids that the kidneys can no longer 
remove due to loss of function (Timmers et al., 2008). Patients will usually be able to choose which 
type of dialysis is most appropriate for them. Kidney transplantation involves receiving a healthy 
kidney from a donor when the recipient has little or no kidney function. A summary of the different 
dialysis modalities and of transplantation is provided below. 
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1.3.2 Haemodialysis  
Haemodialysis (HD) involves purifying the blood via an external artificial kidney. Prior to starting 
HD, patients often have an ateriovenous fistula (AV fistula) created in their arm, a blood vessel 
created by connecting an artery to a vein which is used in the HD treatment. The AV fistula makes the 
blood vessel stronger and larger, making the transfer of blood into the dialysis machine and then back 
into the patient easier. Ideally the AV fistula is created around 8 weeks before starting HD.  
 
HD is the most common form of dialysis and involves three sessions per week lasting around four 
hours. Time spent on HD varies from patient to patient dependent on how much fluid needs to be 
removed (NHS, 2018). HD can take place in hospital or can be completed at home, however, hospital 
HD is most common. Two needles are inserted into the AV fistula: one needle removes blood and 
transfers it to the dialysis machine from which the machine filters the blood removing waste and 
excess fluid; the second needle is used to return the filtered blood back into the body. 
 
Patients receiving HD must follow strict fluid and diet restrictions, as the dialysis machine is unable 
to remove a high volume of excess fluid consumed over dialysis free days. Excess fluid build-up can 
lead to serious complications in the tissue, blood and lungs. Fluid allowance is determined on patient 
size and weight, and the patient’s residual urine volume. Most patients are restricted to 1000ml-
1500ml fluid per day. Salt restriction is usually required. Other dietary restrictions must be followed 
as minerals normally filtered by the kidneys can build up and become problematic between dialysis 
treatments. These include potassium and phosphate. Medications are often also needed to manage 
such issues. 
 
Advantages of HD include having four treatment free days. However, as HD is usually carried out in 
hospital at a dialysis clinic, patients must travel regularly for treatment and plan around the need for 
four-hour treatment sessions. Additionally, this can impact on patients’ daily routines, including work 
and family life. 
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1.3.3 Peritoneal dialysis 
Peritoneal dialysis (PD) uses the peritoneal membrane to act as an artificial kidney. There are two 
types of PD: continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis 
(APD). Both treatments can be administered at home following patient training (NHS, 2018). Prior to 
starting CAPD or APD, an opening is made in the abdomen through which a catheter is inserted. This 
allows dialysis fluid to be infused into the peritoneal cavity. In CAPD, this is performed by the patient 
or helper. The fluid remains for a few hours and waste and excess fluid in the blood passing through 
the lining of the cavity are removed from the blood into the dialysis fluid. After the fluid has remained 
for a few hours, it is drained into a waste bag. New dialysis fluid then replaces the old fluid until the 
next draining session. Most patients on CAPD repeat this process around four times per day. The 
catheter is sealed, and bags disconnected between treatment sessions (draining old fluid and replacing 
new fluid). 
 
APD is similar to CAPD, however, a machine is used to drain and replace fluid whilst the patient 
sleeps. A dialysis fluid bag is attached to the APD machine overnight during sleep and performs a 
number of draining and replacing fluid replacements over a period of 8-10 hours. Following treatment 
completion, some dialysis fluid will remain in the abdomen which is drained in the following 
treatment. 
 
Fewer diet and fluid restrictions are required for patients receiving PD compared with HD, as 
treatment is being performed more continuously. Further advantages of PD include the ability to 
administer treatment from home requiring fewer hospital visits, and portable equipment (CAPD) 
allowing travel to be more accessible. Disadvantages of PD include risk of infection, such as 
peritonitis (an infection of the membrane lining the abdomen), the potential upsetting nature of having 
a catheter permanently inserted in the abdomen, and the need for everyday treatment. 
1.3.4 Patient experience of dialysis 
Due to the chronic nature of dialysis and the lifestyle it imposes, it has been related to poor health 
outcomes such as poorer health related quality of life and psychological well-being, with patients 
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often needing help and support to cope. Incident haemodialysis patients report feelings of emotional 
distress, treatment-related concerns and the need for social support (Lai et al., 2012).  
Fatigue is common impacting between 42-89% of patients (Artom, Moss-Morris, Caskey & Chilcot, 
2014). Symptoms of fatigue include tiredness, reduced physical activity and motivation and a lack of 
energy. This symptom may be related to the change in bodily function caused by renal failure and the 
side-effects of dialysis treatment. Higher levels of fatigue are reported by females and by older 
patients. However, it is possible that this is simply due to females being more likely to report 
symptom experiences compared to males (Van Wijk & Kolk, 1997). Patients are often affected by 
fatigue post-dialysis, with some patients taking many hours to recover.   
 
Research has shown that 20-30% of patients with ESRD receiving dialysis experience depressive 
symptoms (Cukor, Coplan, Brown, Peterson & Kimmel, 2008). In terms of risk factors, younger 
patients are at greater risk of developing depression, as ESRD and the need for dialysis causes 
significant disruption to everyday life, notably to social aspects including changes to family and work 
roles, loss of time and a decline in mobility (Chilcot et al., 2008). These disruptions are in addition to 
other factors patients must manage, including medication, diet and fluid restrictions and potential side 
effects of treatment. Additionally, depression has been identified as a significant predictor of 
medication adherence, with patients who report greater symptoms of depression to report poorer 
medication adherence (Cukor, Rosenthal, Jindal, Brown & Kimmel, 2009). HD patients reported 37% 
“less than perfect adherence” to their prescribed treatment and medication regime. This included diet, 
fluid intake, medication and hospital or medical appointments.  
 
Treatment methods to reduce depressive symptoms include anti-depressant medication and talking 
therapies, such as cognitive behavioural therapy (CBT). There have been mixed results in the 
effectiveness of pharmacotherapy studies in reducing depressive symptoms in ESRD patients. 
Findings must be interpreted with caution as some studies fail to use a placebo control group, have 
small sample sizes or fail to use the Diagnostic and Statistical Manual (DSM) criteria to diagnose 
major depressive disorder (Hedayati, Yalamanchili & Finkelstein, 2012). As anti-depressants can 
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have cardiac side-effects such as hypertension and arrhythmias, they must be carefully prescribed to 
ensure they are appropriate and safe to take for people with ESRD (Hedayati, Yalamanchili & 
Finkelstein, 2012). More recently, there has been consideration as to whether anti-depressants are 
doing more harm than good in terms of patient outcomes (Chilcot & Farrington, 2019), and that 
withdrawal strategies should be considered requiring careful risk assessment, patient education and 
counselling and an appropriate tapering regimen to mitigate any symptoms of withdrawal (Horowitz 
& Taylor, 2019). 
 
CBT studies to treat depression in dialysis patients have shown some success. Cukor (2007) found 
patients showed significantly lower depressive symptoms following a 15-week CBT intervention, 
which were sustained at three-month follow-up. A randomised controlled trial (RCT) has investigated 
the effectiveness of group CBT for ESRD HD patients with a diagnosis of major depressive disorder 
(Duarte, Miyazaki, Blay & Sasso, 2009). They found a reduction in depressive symptoms and 
increase in quality of life at the end of the three-month treatment. This was sustained at six months 
follow-up. Currently, feasibility of routine CBT delivery remains unclear (Chilcot & Hudson, 2019). 
No studies or trials have explored the combined effects of CBT and anti-depressants. Further 
depression treatment trials are needed in dialysis patients with increased patient numbers to clearly 
establish effective and safe treatment methods for this patient population. 
 
1.3.5 Transplantation 
Transplantation involves receiving a healthy kidney from a donor when the recipient has little or no 
kidney function (i.e. is classified as having end stage renal disease). An operation is performed to 
transplant the donated kidney into the recipient. The donor kidney is placed in the lower abdomen. 
Typically, the patient’s kidneys are left in their body unless there is need for removal, such as 
infection or pain. The blood vessels from the donor kidney are attached to nearby blood vessels in the 
body to ensure blood supply for the kidney to function suitably. The donor kidney vein is attached to 
the recipients iliac vein and the donor artery is attached to the recipients iliac artery. The ureter of the 
donated kidney is attached to the bladder, which carries urine from the kidney to the bladder. A stent 
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is sometimes placed to ensure good flow of urine and is removed 4-6 weeks post-transplantation 
(Kidney research UK, 2017; NHS, 2018). This is complex surgery which can take up to three hours to 
complete. Following the operation, patients begin taking immunosuppressant medication to prevent 
rejection of the transplanted organ. These can sometimes take time to become effective, and acute 
rejection is experienced typically within the first six weeks following transplantation. In most cases, 
the transplanted kidney will begin working immediately following surgery, however, in some cases it 
can take some time, a few days to a few weeks. This is known as delayed graft function. During this 
interim, patients may need to receive dialysis until the transplanted kidney begins to function. Patients 
are usually required to stay in hospital following the operation for around one week, and require 
regular appointments at the transplant clinic to check how the kidney is functioning and on 
immunosuppressant medication levels. During the first month post-transplantation, patients can be 
required to attend the transplant clinic more regularly, at least once per week, however, this reduces 
over time once kidney function is established and stable. Following one-year post-transplantation, 
patients can be seen every three to six months if there are no problems.  
 
Kidney transplantation is suggested to be the most desired and cost-effective treatment option 
(Abecassis et al., 2008), above HD and PD. Patients who receive a transplant often have a longer life 
expectancy and improved quality of life (Jindal et al., 2003), including increased energy and a less 
restrictive diet in comparison to dialysis patients. Most patients with ESRD placed on the waiting list 
are healthier patients, therefore long-term survival is greater among patients on the waiting list 
following transplantation when compared to dialysis patients (Wolfe et al., 1999).  
 
1.3.6 Patient experience of transplantation 
In comparison to patients receiving treatment via dialysis, kidney transplantation is associated with 
improved clinical outcomes (Wolfe et al., 1999), better quality of life (Reimer et al., 2002) and fewer 
reports of psychiatric problems, such as depression. Despite this, kidney transplantation requires 
psychological adjustment and presents medication and treatment challenges (Chilcot, Spencer, Maple 
& Mamode, 2014), which can produce feelings of distress, fear and guilt. Recent studies have 
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reported depression prevalence rates 22% (Szeifert et al., 2010) and 26.6% (Palmer et al., 2013). 
Although percentages are lower in comparison to in dialysis patients, it still represents a significant 
number of transplant patients. Chilcot et al., (2014) suggest that although there is variation in 
prevalence estimates, approximately one in four patients screened positively for depression across the 
advanced kidney disease spectrum. This makes it one of the most common co-morbidities 
experienced by both patients on the transplant waiting list and transplant recipients. There are a 
number of factors associated with depression in kidney transplant recipients. Chilcot et al., (2014) 
summarise the common demographic, clinical and psychological correlates of depression identified in 
previous literature (see Table 1.3). 
 
Table 1.3: Factors associated with depression in kidney transplant recipients (Chilcot et al., 2014) 
Demographic Clinical Psychological 
Age 

















Poor psychological well-being has been related to poor clinical outcomes in kidney transplant 
recipients. Depression has been associated with a greater risk of mortality (Dobbels et al., 2008; 
Novak et al., 2010; Zelle et al., 2012). Additionally, it has been associated with a return to dialysis, 
twofold increase in graft failure and increased risk of mortality with a functioning graft (Dobbels et 
al., 2008). Explanations for these poorer health outcomes in patients with depression include non-
adherence to treatment. Non-adherence is three times more likely among kidney transplant patients 
diagnosed with depression (DiMatteo et al., 2000).  
 
Symptom occurrence, i.e. side effects, are regularly experienced by kidney transplant recipients, often 
due to medications being taken including immunosuppressants. These can range from physical 
symptoms such as muscle weakness, impotence, increase in hair growth, fatigue, tremors and increase 
in appetite to name a few (Kugler et al., 2009). Different symptom experiences effect patients in 
differing ways, with younger patients impacted by different symptoms than older patients, but all 
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leading to symptom distress. Patients can alter or stop taking medication taking in order to prevent 
symptom experiences and reduce symptom distress. This increases the risk of poorer health outcomes. 
Younger patients and females in particular have been identified as finding side-effects particularly 
distressing and are therefore the most at risk group for non-adherence and potentially poorer health 
outcomes (Kugler et al., 2009). Greater understanding of symptom experiences and appraisal of 
immunosuppressant medication side-effects is required in order to develop strategies to reduce the 
risk of non-adherence triggered by symptom experiences and distress, reduce the risk of non-
adherence related graft rejection, and improved quality of life by individualised symptom 
management. Patients on immunosuppression are more vulnerable to infection and have an increased 
long-term risk of some types of cancer. 
  
1.4 Kidney organ donation 
There are 24 centres providing kidney transplantation in the UK. Between 1 April 2017 and 31 March 
2018 the median waiting time from patient dialysis start date to deceased donor transplant was 1148 
days. This varied across transplanting centres ranging from 576 to 1661 days (NHS Blood and 
Transplant, 2018). Waiting time differs across ethnicities due to availability of donor organs, with 
BAME groups waiting the longest for a well-matched graft (Morgan et al., 2015). In the UK, the 
kidney is the most commonly transplanted organ, and additionally is the most common living 
donation transplant.  
 
1.4.1 Types of donation 
Patients can receive a kidney via living or deceased organ donation. Deceased donations can be 
received from either a patient following brain death (known as DBD donors) or following circulatory 
death (known as DCD donors). Operations using deceased donor kidneys tend to be emergency 
procedures and patients can be notified at any time of day that an organ is available and given a short 
window of time to attend the transplanting centre. Living donation requires significant preparation 
and therefore operations can usually be scheduled and occur during the daytime. 
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DBD donation, previously known as heart beating donors, is a more traditional form of deceased 
donation and is therefore better known. Donors will have typically undergone a sudden catastrophic 
event which has led to loss of brain function, requiring them to be placed on a ventilator to maintain 
respiration. They will undergo testing to assess if brain function can be recovered and to establish if 
they will be able to breathe again unaided. If it is found that the donor has extensive brain damage 
which is deemed irreversible, they will be considered as a potential organ donor. If consent is gained, 
the organs are cooled for preservation prior to the ventilator being turned off and are then removed 
(Kidney Research UK, 2017). 
 
DCD donation, previously known as non-heart beating donors, occurs again where donors have 
experienced irreversible brain damage and are on ventilator to aid breathing and heart and lung 
function, however, they do not meet the criteria following testing to be classified as brain-stem death. 
If the damage is deemed irreversible with no likelihood of recovery, the patient will be considered for 
organ donation. If consent is provided, the patient will be disconnected from the ventilator. The heart 
must stop beating within a suitable period of time for them to be considered eligible for donation, 
following which the organs are cooled for preservation and removed.  
 
DCD consists of two types, controlled and uncontrolled. The clinical circumstances in which DCD 
can occur can be understood via the Maastricht classification (see Table 1.4). Uncontrolled DCD, 
consisting of categories one and two, refers to organ retrieval following unexpected cardiac arrest in a 
patient who cannot or should not be resuscitated. Controlled DCD, consisting of categories three and 
four, takes place after death following planned withdrawal of life sustaining treatments. These 






Table 1.4: The Maastricht classification of donation after circulatory death (Hoogland et al., 2011) 
Category Type Circumstances Typical location 
I Uncontrolled Dead on arrival  Emergency 
department 
II Uncontrolled Unsuccessful resuscitation Emergency 
department 
III Controlled Awaiting cardiac arrest (following planned 
withdrawal of life sustaining treatments)  
Intensive care 




The UK focuses primarily on controlled DCD. The higher number of controlled DCD in the UK is 
likely due to the number of deaths in intensive care where life sustaining treatment is limited or 
withdrawn. The number of DCD has continued to increase year on year, with the number of kidney 
donors increasing to 624 in 2018/2019 from 596 in 2017/2018 (NHS Blood and Transplant, 2019) 
allowing for more organs to be available for transplantation and thus reducing the number of patients 
on the transplant waiting list. 
 
DCD kidney transplants are allocated via local allocation arrangements. These vary dependent on size 
of DCD centre programmes. DBD donors are allocated via the National Kidney Allocation Scheme, 
which determines allocation of all kidneys available for transplantation from donors following brain 
death. The National Allocation Scheme was introduced in April 2006 and aims to reduce waiting 
times for deceased donor kidney transplants across the UK. Patients are listed nationally through the 
scheme and prioritises patients with ideal tissue matches. Points are assigned to patients based on the 
level of tissue match between the donor and the recipient, the age of the recipient and location of the 
patients to the retrieval centre. A reduction of points is applied to patients over the age of 30 years, 
and to those that are located further away from the donor kidney retrieval centre. Patients with a 
higher total number of points based on the criteria listed above are offered the donated kidney (NHS 
Blood and Transplant, 2018).  
 
There has been some hesitation around DCD grafts due to high incidence of delayed graft function 
and early graft loss (Mallon, Summers, Bradley & Pettigrew, 2013) and therefore are sometimes 
viewed as inferior to grafts received from DBD donors (Summers et al., 2015). Due to ischaemic 
 34 
injury suffered by solid organs following circulatory death in the time interval between treatment 
withdrawal and cold perfusion, recipients of DCD kidney grafts experience a higher incidence of 
delayed graft function compared to recipients of DBD kidney grafts. This often requires a short period 
of post-transplantation dialysis, however, evidence indicates long term graft survival is similar to 
recipients of DBD kidney grafts. Schaapherder et al., (2018) found higher incidences of graft loss and 
delayed graft function in DCD grafts did not impact long-term survival and 10-year graft survival 
post-transplantation was similar between DCD and DBD grafts. The UK has developed a controlled 
DCD transplant programme to increase transplants and reduce the number of patients on the 
transplant waiting list. Data from UK transplant registry has also shown first-time recipients of kidney 
grafts from controlled circulatory-death donors have good outcomes in relation to graft function and 
survival that should be viewed as equivalent to recipients of DBD grafts (Summers et al., 2010). 
Additionally, data from UK transplant registry has shown kidney function at five years and graft 
survival at ten years post-transplantation is similar between DCD and DBD grafts (Summers et al., 
2015).  
 
Living donation can be received via directed or non-directed donation. Directed donation occurs 
where the donor specifies who they are donating the kidney to. This commonly occurs in living 
donations from close family members or friends. Non-directed donation, which is known as altruistic 
donation, occurs where the donor volunteers to donate their organ and does not specify who the organ 
is to be donated to, it can be given to anyone who is a match. Altruistic donors are therefore not 
usually acquainted with the recipient. This type of living donation is much less common than directed 
living donation. Patients preparing for RRT will be asked if they have any close relatives or friends 
who would be willing to be a living donor. Kidneys via living donation provide the transplanted 
kidney with the best chance of success and survival compared to kidneys from deceased donation 
(Kidney Research UK, 2017). Preparations for this begin early to allow ample time for testing to be 
completed with the potential donor to see if they would be eligible to donate and are a match for the 
recipient. Additionally, this time increases the likelihood that patients requiring transplantation can be 
transplanted prior to the need to start dialysis. Living donor grafts have very good kidney function 
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prior to removal, and the time period between removal from the donor and transplanting into the 
recipient is much shorter than between retrieval and transplantation from deceased donors. For these 
reasons, long-term graft function and likelihood of immediate function following transplantation is 
greater from living donor grafts.  
 
Patients requiring kidney transplantation can be transplanted pre-emptively before the need for 
dialysis initiation or following receiving dialysis. Pre-emptive transplantation is established to be 
associated with more optimal outcomes in relation to patient and graft survival post-transplant 
(Abecassis et al., 2008). Pre-emptive transplants from living donors are more likely to be performed 
before the need for dialysis arises. This is often due to waiting time being longer for deceased donor 
transplantations, whereas living donor transplantations can often take place more quickly once a 
donor is established.  
 
1.4.2 Rates of donation 
In 2017/18, 3,272 adult kidney transplants were performed in the UK. This was an increase of 7% in 
comparison to the previous year. Of these 2,320 were from deceased donors (940 DCD; 1,380 DBD), 
and 952 from living donors. The majority of transplanted patients were male (63%) and white (75%). 
The average rate of graft survival at five years from deceased donor transplantation is 86%, compared 
to 93% from living donor transplants. Additionally, the average graft survival rate at 10 years post-
transplant is 75% via deceased donation.  
 
Due to a shortage in deceased donor kidneys available for transplantation, this has resulted in patients 
receiving kidneys from less well-matched donors which potentially results in poorer transplant 
outcomes. A donor risk index has been developed which categorises kidneys based on anticipated 
outcome, allowing clinicians greater information to make decisions regarding organ allocation, and to 
better inform potential recipients of the organ(s) they are being offered. The donor index determines 
factors that influence transplant survival and time from transplant to either graft failure or patient 
death, depending on which comes first (Watson et al., 2012; NHS Blood and Transplant, 2018). 
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In an attempt to improve rates of organ donation and number of patients waiting for a transplant, the 
law in England is changing in Spring 2020 to an opt out system, meaning all adults will be considered 
an organ donor when they die unless they have recorded they do not wish to be one (opted-out) or if 
they fall into one of the categories meaning they are excluded from being a potential donor 
(Department of Health and Social Care, 2019). Families will be consulted and will provide consent 
for the retrieval. An opt-out system for organ donation is already in place in Wales, enacted in 2015. 
An initial increase in consent rates has been observed in Wales, however, success is dependent on 
patient families supporting the decision of their deceased relatives’ decision regarding donation made 
when alive (Noyes et al., 2019). Whilst the law has been shown to be successful in encouraging 
potential donors to register a decision regarding organ donation, or to verbally express their wishes, 
barriers such as family members over-riding decisions or health issues have been shown to prevent 
successful donation (Noyes et al., 2019). This will need to be considered when the law is introduced 
in England.   
  
1.5 Summary  
CKD is a complex and progressive condition. Patients diagnosed with ESRD require RRT in the form 
of dialysis or transplantation. Both HD and PD are debilitating treatments and patients often 
experience lower health related quality of life and issues with psychological well-being alongside 
other restrictions and challenges as a result of their condition and treatment. Transplantation is 
considered the best and most cost-effective treatment option. Although challenges remain in 
managing long-term medication taking, coping with any side-effects associated with treatment and 
attending clinic for regular monitoring post-transplantation, quality of life, psychological well-being 
and patient experiences tend to be greater compared to those receiving dialysis. Rates of kidney 
donation are slowly improving year on year, however, the demand in terms of the number of patients 
on the waiting list still greatly outnumbers the supply of grafts available from donors. Due to this, 
donor grafts are considered a precious resource and it is important to ensure they have the best chance 
of survival. Therefore, it is essential that donor grafts are well matched to potential recipients, and that 
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they are given to recipients who will do their best to preserve kidney function long-term. However, 
clinical experience tells us that many grafts are lost due to potentially modifiable factors that are 
patient behaviour driven, such as adherence to immunosuppressant medication. This thesis aims to 
explore adherence behaviour in transplant recipients further. Specifically, through a series of studies, 
the programme of research will consider: how non-adherence is defined in this patient population, 
measured and estimated, how much clinicians consider adherence in wait listing decisions in light of 
retrospective data related to adherence pre- and post-transplant. A mix of quantitative and qualitative 
designs will yield knowledge that can help enhance service design in relation to optimising success of 
































Medication non-adherence is widely acknowledged as a common concern for all health care 
professionals, particularly those working with patients with long-term health conditions (Lehene & 
McCarthy, 2007). There are a number of empirical studies, comprehensive literature reviews and 
meta-analyses exploring adherence to treatment and the extent of non-adherence across a wide range 
of conditions. These studies aim to highlight the ‘problem’ and contributing factors so as to better 
inform health care providers about challenges to treatment engagement. In this chapter, attention is 
given to providing an overview of: 
 
• How adherence has been operationalised and measured; 
• Summarising what is known about the rate of non-adherence among the kidney transplant 
population;  
• Considering implications of non-adherence for transplant recipients in terms of outcomes.  
 
2.2 Definitions of adherence 
Adherence to medication and treatment regimens is an important part of health care (Jimmy & Jose, 
2011), particularly in long-term conditions (Lemay et al., 2018) such as kidney disease, including 
transplant recipients. The terms compliance and adherence are commonly used interchangeably by 
health care professionals; however, it is important to understand and differentiate the two (WHO, 
2003). Compliance has been defined as “the extent to which the patient’s behaviour matches the 
prescriber’s recommendations” (p. 12, Horne et al., 2005), however, the use of this term is slowly 
declining as it suggests a lack of patient involvement in decision making processes. Adherence has 
been defined as “the extent to which the patient’s behaviour matches the agreed recommendations 
from the prescriber” (p. 12, Horne et al., 2005). This term is now regularly being used as an 
alternative to compliance as it aims to emphasise patient involvement and the need for agreement 
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between patient and doctor in treatment recommendations (WHO, 2003). Adherence implies that 
patients have the freedom to choose whether or not to see through recommendations. Additionally, 
failure to follow the treatment regimen prescribed should not provide cause to blame the patient 
(Horne et al., 2005). The WHO indicates that patients should be “active partners” with health care 
professionals in determining their own care and that good communication between these two parties is 
essential for successful clinical practice. 
 
Non-adherence is complex and can emerge due to a multitude of reasons. The causes of non-
adherence fall into two overlapping categories: intentional and unintentional (NICE, 2009). These two 
categories of non-adherence have been widely researched in the literature in relation to long term 
conditions. Unintentional non-adherence is often considered to occur when the patient intends or 
wants to follow the recommendations, but due to factors beyond their control are prevented from 
doing so. Such barriers can include forgetting, poor memory, difficulty understanding instructions, 
problems using medication/treatment, and inability to pay for treatment (NICE, 2009). Intentional 
non-adherence occurs when a patient consciously chooses not to follow the treatment regimen or 
treatment recommendations. It is suggested that this could be due to patient beliefs or preferences that 
then influence their perceptions of treatment or medication and motivation to either commence or 
continue treatment (Molloy et al., 2014).  
 
Among the kidney transplant population, unintentional non-adherence is significantly more common 
than intentional non-adherence (Griva, Davenport, Harrison & Newman, 2012). Of 218 kidney 
transplant patients, 62.4% of patients self-reported unintentional non-adherence, compared with 
13.8% who reported intentional non-adherence. Unintentional non-adherence most commonly 
occurred when patients found themselves outside of their normal daily routine, and mostly involved 
taking medication at the incorrect time. This finding has been confirmed in other studies, where 
forgetfulness was identified as the most common reason for non-adherence (Loghman-Adham, 2003; 
Lalic et al., 2014). Intentional non-adherence occurred when patients had concerns about their 
medication regimen (Griva et al., 2012). In addition, patients diagnosed with depression reported 
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higher intentional non-adherence. Low beliefs in necessity of medications were predictive of 
intentional non-adherence, and necessity beliefs were more important than concerns about medication 
in determining adherence behaviour (Griva et al., 2012). 
 
2.3 Rates of non-adherence in kidney transplant population 
Research suggests that between 30-50% of medications prescribed for patients with long term 
conditions are not taken as prescribed (WHO, 2003; NICE, 2009). Non-adherence to treatment, 
notably immunosuppressant medication, has been identified as a common issue within the kidney 
transplant population. Dew et al., (2007) reported that non-adherence to immunosuppressants is one 
of the most regular areas of study and is among the highest non-adherence rates in solid organ 
transplantation. Previous systematic reviews have been conducted to explore non-adherence 
prevalence rates among renal transplant recipients reported in existing literature. In a systematic 
review of 36 studies, Butler et al., (2004) reported a median non-adherence rate of 22.3% (IQR 17.7-
25.9%) for cross-sectional studies, and median non-adherence rate of 15% (IQR 4.7-19.5%) for 
cohort studies. A review of adherence assessment methods, their significance and prevalence of 
studies published from January 2009 to December 2014 analysed 37 studies and found non-adherence 
rates ranging from 1.6% to 96% (Belaiche et al., 2017). 
 
Non-adherence to immunosuppressive drugs was a common problem and identified as a risk factor for 
late acute rejection and graft loss in kidney transplant recipients within a review summarising data 
from across 38 studies (Denhaerynck et al., 2005). Non-adherence prevalence rates ranged widely 
from 2-67% dependent on measurement method used, how non-adherence was defined and 
operationalised, and case findings. Additionally, a mean prevalence calculated over ten studies 
measuring non-adherence by self-report was 28%. Rates of non-adherence are higher in renal 
transplant patients compared with other solid organ transplant recipients, with non-adherence rates to 
immunosuppressants estimated at 36 cases per 100 patients per year (Dew et al., 2007). This rate is 
twice than among heart transplant recipients and over five times greater than among liver transplant 
recipients. A key question then arises as to why kidney transplant recipients appear to be less adherent 
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than other organ recipients? This may be because the risk and consequences of rejection and graft loss 
is less catastrophic than rejection of, for example, a heart or lung, where options for sustaining life 
following rejection are more limited (Dew et al., 2007). However, it should be noted that a systematic 
review of qualitative studies revealed that prevailing fear of consequences was at the forefront for 
patients, but there may also be some negotiation of acceptable risks coupled with trivialization 
(Jamieson et al, 2016). Dew et al., (2007) also found that the estimated rate of non-adherence to 
appointments was 5.8 cases per 100 patients per year, however, this was determined by a small 
number of older studies including kidney (N=11), heart (N=7) and heart/lung (N=1) transplant 
recipients. When explored individually by transplant type, this was shown to be lower for kidney (4.7 
cases) compared to heart transplant recipients (8.5 cases). Overall, Dew et al., (2007) indicate that 
post-transplantation, clinicians can expect on average 23 non-adherent patients for every 100 solid 
organ transplant recipients during a one-year follow up. This has significant implications for health 
services in terms of managing the added burden that comes with the consequence of intentional or 
unintentional deviation from suggested regimens.   
 
Adherence to immunosuppressants are essential for kidney transplant recipients to prevent rejection of 
the transplanted organ. A meta-analysis of 21 studies suggested a strong relationship between 
adherent behaviour to medication and treatment for a number of different illnesses and lower 
mortality rates (Simpson et al., 2006). Additionally, hospitalisation rates shown across patients with 
varying chronic conditions are lower among adherent patients (Sokol et al., 2005; Ho et al., 2007). 
The WHO (2003) report on medication adherence indicated that “increasing the effectiveness of 
adherence interventions may have far greater impact on the health of the population than any 
improvement in specific medical treatments”. The odds of graft loss among non-adherent kidney 
transplant recipients is five to seven times greater than in adherent patients (Butler et al., 2004; 
Chisolm et al., 2007).  
 
Non-adherence has consequences for both the individual in terms of personal costs, and additionally 
economic costs for society (NICE, 2009). Poor clinical benefit of medication is intimately related to a 
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lack of health improvement, and increased risk of morbidity and mortality for the patient. For society, 
medication wastage and increased costs on healthcare systems due to excess demands from patient ill 
health and deterioration are notable. In the UK context where health care is free at the point of need, 
there is an economic driver to improve adherence in transplant recipients. Kidney services consume 
3% of the NHS budget. This is a sizeable proportion of budget as compared to the prevalence of 
kidney related conditions. The cost of treatment to the NHS between those receiving dialysis and 
those receiving immunosuppressant medication in subsequent years following transplantation are 
vastly different. Where dialysis costs on average £30,000 per patient per year, this can be compared to 
£17,000 for a kidney transplant and £5,000 per patient per year for immunosuppression required by a 
patient with a transplant. Therefore, kidney transplantation is suggested to lead to a cost-benefit in the 
second and subsequent years of ~£25,000 per annum (NHS England, 2013). As such, a non-adherent 
transplant patient risks graft failure, which adds excess burden to NHS resources as compared to 
doing the organ justice. Of course, there may be biological reasons impacting graft failure but 
research so far suggests that patient factors such as adherence behaviour also have a role to play. 
Morally, to do organs best service, patient adherence should also be ideal. Organ donation, both living 
and deceased, often has consequences e.g. emotional for donors and their families. For such reasons, 
donation is highly personal and indeed many governments try and keep a neutral stance on whether 
choosing not to donate is a ‘bad thing’ (Shaw, 2015). It could be argued that non-adherence, at least 
intentional, is a disservice to a donated organ and the donor. Curiously, research has shown that 
kidney transplant patients are more likely to be at risk of non-adherence when receiving organs from a 
live related donor (Denhaerynck et al., 2007). The personal, ethical and economic drivers make it 
paramount that effort is made to measure and support adherence behaviour.  
 
2.4 Measuring adherence 
A number of different methods exist for measuring adherence, however, each method has strengths 
and limitations that require consideration when used and when interpreting results (Kreys, 2016). The 
measurement method used can impact non-adherence prevalence rates reported (DiMatteo, 2004). 
Existing methods can be categorised into two types: direct and indirect measurement, offering 
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differing levels of sensitivity (Osterberg & Blaschke, 2005). Direct measurements involve first-hand 
observation of, for example, medication intake and biological assay of medication levels or 
medication metabolites in biological fluids such as blood or urine (Osterberg & Blaschke, 2005). This 
method is considered to be more accurate, however, it is also more expensive, requires more time 
from health care providers and is a more complex measurement process. Based on this, it is a less 
suitable method to use when researching large populations. 
 
Indirect measurements, such as self-report, collateral reports from family members or clinicians, 
electronic monitoring, prescription refills and pill counts to name a few examples, are more 
commonly used due to their less complicated nature in terms of implementation, and are generally 
less expensive (Osterberg & Blaschke, 2005; Schafer-Keller et al., 2008; Kreys, 2016). However, 
indirect measures, such as self-report, do not provide a clear and accurate representation of non-
adherence rates and provide limited information on individual medication taking behaviour (Farmer, 
1999; De Geest & Vanhaecke, 1999). A brief description and consideration of strengths and 
limitations of the different measurement methods are provided below. 
 
Self-report measures can include, for example, questionnaires and diaries. These measurement 
methods are straightforward and easy to implement. Additionally, they are usually cheap to 
administer and feasible in most clinical settings (Schafer-Keller et al., 2008). However, limitations of 
this measurement method include susceptibility to recall and social desirability bias, notably via 
questionnaires. Furthermore, self-report measures tend to over-estimate adherence levels. DiMatteo 
(2004) found that self-report measures yield the highest non-adherence rates for immunosuppressant 
medication. Patients may also find expectations to regularly and continually answer questions or 
record their medication taking tiresome, providing potential barriers to recruitment processes (Kreys, 
2016) and data accuracy. Diaries, although may be used to monitor medication taking, could be used 
as an intervention to improve adherence rates, and therefore may report higher levels of adherence 
compared to individuals not recording and monitoring medication taking via diaries or similar 
methods (Kreys, 2016).  
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Pill counting is a simple method to determine adherence to medication in tablet form. However, a 
limitation of this method is that it requires patients to bring their medication to every appointment 
with their health care professionals, and is reliant on patients not tampering with medication by 
storing or disposing of medication that has not been taken as prescribed (Schafer-Keller et al., 2008).  
 
Prescription refill measurement methods do not require patient involvement and provides a 
naturalistic objective measure of adherence (Kreys, 2016). It can be used to assess adherence in large 
populations of patients and over multiple time points, such as longitudinal studies. However, 
limitations of this measurement method include lack of information on actual medication taking, as 
only information on collection of medication can be obtained. This method is suitable for observing 
adherence behaviour among patients with chronic conditions who require long-term medication, 
however, can be challenging to accurately track and record medications which require frequent 
changes to dosage, such as immunosuppressant medications – an essential medication for kidney 
transplant recipients. It also requires complete and accurate pharmacy records which can be difficult if 
patients are using a number of pharmacies for medication collection (Kreys, 2016).  
 
Electronic monitoring including the medication event monitoring system (MEMs) are medication 
bottles which record every time the bottle is opened via a specialised microchip. Electronic 
monitoring is recommended as the reference standard for medication non-adherence (Cramer, 1995) 
that should be used to validate other adherence measures, as it can provide detailed information on 
individual(s) medication taking therefore providing a more accurate record of medication taking 
behaviour (Schafer-Keller et al., 2008). Additionally, reported adherence via MEMs are lower than 
self-reported adherence measures, and as self-reported adherence is often overestimated, medication 
adherence recorded via MEMs is considered to be a more accurate representation (Kreys, 2016). 
Furthermore, medication adherence rates recorded via MEMs have also been found to associate with 
clinical levels of medication in a number of treatment areas. However, this is provided that when 
patients open the bottle thus referencing a medication taking record, the medication is actually taken 
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and not discarded or transferred elsewhere. In addition, this method is expensive and often requires 
regular downloading of recorded information from the microchip. Furthermore, electronic monitoring 
could impact medication taking either negatively, by impacting established routines, or positively, by 
improving medication taking behaviour due to an intervention effect of being closely monitored 
(Deschamps et al., 2006), therefore effecting the validity of adherence rate reports. However, despite 
these potential limitations, due to its consideration as a superior method in measuring (non)adherence, 
it remains the reference standard (Schafer-Keller et al., 2008). 
 
Clinician reporting/Observations of patient’s medication taking behaviour can be used as a marker of 
adherence. Recordings or reports of adherence can be monitored during routine visits with health care 
professionals. Regular monitoring e.g. of drug levels, may exist as part of routine treatment already by 
clinicians as a tool for monitoring treatment of illness or disease. This measurement method can 
verify adherence but, as with pill counts, requires patient-clinician interaction or meeting, requires 
familiarity with the patient and their treatment regimen (De Geest & Vanhaecke, 1999; Schafer-Keller 
et al., 2008), and is unable to explain the complexities of medication taking (Farmer, 1999). However, 
it may allow for severe non-adherence to be detected.  
  
Biological assay involves monitoring drug medication levels via e.g. blood levels. This measurement 
method portrays the patient’s state of e.g. immunosuppression (Schafer-Keller et al., 2008). However, 
as every patient is individual and responds to medication in different ways including individual drug 
target levels, levels and assay, results can be impacted by a number of variables such as metabolic 
rate, drugs half-life, drug-drug interactions and “white-coat” adherence (i.e. patients demonstrating 
better adherence prior to clinical appointments or visits) (De Geest & Vanhaecke, 1999; Kreys, 2016). 
This can therefore make it challenging to determine non-adherence and accurate variance from 
medication prescription (Osterberg & Blaschke, 2005).  
 
Using a combination of adherence measures - The differing adherence measures mentioned above, 
although commonly used, often report variable rates of (non)adherence due to their individual 
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characteristics and definitions/cut-off points for non-adherence applied. Garber et al (2004) conducted 
a meta-analysis comparing a number of differing measures of adherence and found that less than half 
of the self-reported measures and non-self-reported measures were categorised as highly agreeable. 
Previous literature has indicated that utilising more than one method to measure adherence at the 
same time can improve accuracy of reported rates (Lam & Fresco, 2005) as using multiple methods 
can balance out measurement methods addressing limitations of individual measures (Kreys, 2016).  
 
Across the previous literature within the kidney transplant population, there is a wide range of 
reported non-adherence prevalence rates. This is in part due to differences in measurement methods 
used and definitions of (non)adherence used (Schafer-Keller et al., 2008). Existing literature with 
transplant recipients has mostly used patient self-reporting as a method to measure adherence. Fewer 
studies have utilised direct measures, such as immunosuppressant blood levels, to measure non-
adherence in existing transplant literature (Butler et al., 2004; Shemesh et al., 2004; O’Carroll et al., 
2006).  
 
Due to the importance of non-adherence to immunosuppressants in the kidney transplant population 
and the associated consequences, such as graft rejection and graft loss, Schafer-Keller et al., (2008) 
conducted a study to assess the diagnostic accuracy of adherence measures, including blood assay, 
self-report, collateral reporting and composite adherence scores (composite scores for combining 
various methods of non-adherence assessment) and compared these to electronic monitoring among 
adult kidney transplant recipients. All patients included were more than one-year post-transplant and 
taking immunosuppressants, with electronic monitoring data recorded. Findings showed a large 
variation in non-adherence prevalence rates across the differing measurement methods and cut-off 
points used. Additionally, the study assessed patient’s adherence to one immunosuppressant drug 
only, which although providing a valuable indicator of medication taking behaviour, may not fully 
reflect adherence to the full immunosuppressive regimen (as patients often take a combination of two 
or three immunosuppressant drugs).  
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In addition, the approach highlighted as detecting the highest rate of non-adherence was the use of 
composite adherence scores, combining non-adherence information from patient self-reports, clinician 
or nurse’s collateral reports and non-therapeutic blood assay results. Low sensitivity to non-adherence 
was reported when one measure only was used to record non-adherence, meaning it is likely truly 
non-adherent patients were not identified. High specificity was found to be best achieved by 
combining several methods, by combining a number of clinicians’ reports of “fair” adherence, or by 
evaluating patients’ self-reports. Schafer-Keller et al., (2008) concluded that for maximum validity, 
electronic monitoring should be combined with other measurement methods, as opposed to using it as 
a reference standard to evaluate them. These findings provide guidance on the efficacy of methods to 
measure adherence and some of the limitations and challenges with various measures that need to be 
considered in order to enhance understanding and detection of non-adherence, when researching in 
the kidney transplant population.   
 
2.5 Models of non-adherence  
As well as noting the occurrence of non-adherence, it is helpful to be able to conceptualise why such 
behaviour is frequent.  There are a number of health psychology theoretical frameworks that have 
been used in previous literature to understand, predict and explain medication adherence (Munro et 
al., 2007) and are potentially useful in renal transplantation settings. The most commonly used models 
are social cognition, including the health belief model (Rosenstock, 1966; Becker & Maiman, 1975), 
theory of reasoned action (Ajzen & Fishbein, 1980) and theory of planned behaviour (Ajzen, 1991). 
Additionally, the self-regulation model (Leventhal, Nerenz & Steele, 1984) and the transactional 
model of stress and coping (Lazarus & Folkman, 1987) may be useful. Holmes, Hughes & Morrison 
(2014) suggest there are benefits to theory-led research findings that can then inform the development 
of interventions to improve adherence. This could be achieved through consolidating existing theories 
and behavioural models. In a meta-analysis of theory use in medication adherence intervention 
research, Conn et al., (2016) found that the models and theories most commonly linked to medication 
adherence were social cognitive theory, health belief model, transactional model, self-regulation 
model and motivational interviewing. However, a review of two of the most widely applied 
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theoretical frameworks in renal settings are reviewed as they may usefully inform the decisions taken 
in this programme of research when selecting methods to explore adherence in more detail.  
 
2.5.1 Health Belief Model 
The health belief model (HBM) is one of the most influential social cognition models to explain 
health behaviours (Rosenstock, 1966). The model was developed to predict preventive health 
behaviours and the behavioural response to treatment in patients both with acute and chronic illnesses. 
The model was developed further by Becker (1974) and applied to other health behaviours, such as 
medication/treatment adherence. The HBM suggests a set of core beliefs predicts behaviour. The 
original core beliefs are summarised in Table 2.1. According to the HBM, the core beliefs should be 
used as indicators of the likelihood that health behaviour changes will occur (Ogden, 2012). 
 
 
Table 2.1: Components of the HBM. 
Components of the HBM Definition 
Susceptibility How susceptible the individual perceives they are to illness. 
Severity The perceived beliefs about the severity of the illness. 
Costs The perceived costs or negative aspects involved in carrying 
out the change in health behaviour. 
Benefits The perceived benefits involved in carrying out the change in 
health behaviour and the effectiveness of this. 
Cues to action The cues that cause or lead the individual to take action. These 
can be internal or external. This contributes to the individual’s 
perception of threat. 
 
The original model has been revised in response to criticism. The constructs “health motivation” and 
“perceived control” were added to the model as a result as part of further developments by Becker and 
colleagues. Health motivation refers to the individual’s readiness to be concerned with health-related 
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issues, and perceived control refers to the individual’s perceived control of the health issue and 
control over their ability to change their behaviour (Ogden, 2012).  
 
The HBM effectiveness in predicting and explaining behaviour has been explored in previous 
literature via meta-analyses. In a meta-analysis of 18 studies, Carpenter (2010) found perceived 
barriers and benefits were the strongest predictors of behaviour. Perceived severity was found to be 
weakly predictive, and perceived susceptibility was found to be unrelated to behaviour. This is an 
interesting finding as perceived susceptibility is one of the most common constructs targeted via 
interventions (Jones, Smith & Llewellyn, 2013). The HBM has been used to inform the development 
and implementation of health behaviour change interventions, however, it is argued there is only weak 
evidence to support the HBM as being effective in predicting behaviour and behaviour change. This is 
due to the weakness of two constructs in predicting behaviour (Carpenter, 2010).  
 
A systematic review of 18 intervention studies using the HBM as a theoretical basis to inform design 
explored the efficacy of these interventions to improve health care adherence (Jones, Smith & 
Llewellyn, 2013). Fifteen (83%) of the studies reported adherence to have significantly improved, 
with large effects reported in studies using health-care professional led interventions. Perceived 
benefits and perceived susceptibility were the constructs most commonly addressed via interventions, 
followed by perceived barriers. However, the review reported that success of the intervention was 
unrelated to the HBM constructs addressed and implemented. This finding is in contrast to some of 
the previous meta-analyses such as by Carpenter (2010), however, this review explored interventions 
to improve adherence behaviour only, whereas Carpenter (2010) reviewed studies exploring any 
health-behaviour. Most studies target certain constructs of the HBM, with very few studies using the 
HBM in its entirety when designing and implementing interventions. Jones, Smith & Llewellyn 
(2013) concluded in their review that evidence to support the use of the HBM in adherence enhancing 




The HBM has been used in previous literature to investigate treatment/medication adherence across a 
number of different chronic illness groups, including hypertension (e.g. Kamran et al., 2014), diabetes 
(e.g. Chao, Nau, Aikens, & Taylor, 2005) and renal disease (e.g. Kiley, Lam & Pollak, 1993; Welch, 
2001). Kiley, Lam & Pollak (1993) found lower perceived benefits from the treatment regime to be 
associated with graft failure among renal transplant recipients. Elliott et al., (2015) found health 
beliefs associated with diet adherence among haemodialysis patients included perceived benefits and 
self-efficacy. Self-efficacy was the only health belief associated with phosphate control. Studies using 
the HBM have often found differing constructs or differing combinations of the HBM are predictive 
of adherence behaviour, rather than an effective interaction of the entire model (Holmes, Hughes & 
Morrison, 2014). Limitations of the model could explain some of the conflicting findings in studies 
using the HBM (Ogden, 2012). The model focuses on cognitive processing and fails to consider the 
role of emotional factors. Additionally, the model focuses on the individual and fails to include a 
component relating to the role of the environment. Health behaviours may be predicted by other 
factors, such as self-efficacy or potential prospective outcomes. Furthermore, the model suggests 
health behaviour change is due to individual factors, whereas there is evidence to suggest it is due to 
the perception of symptoms. Despite the limitations of the HBM, previous research has used the 
model to predict behaviour across a number of different healthcare contexts, including, for example, 
interventions to address screening of hypertension, exercise behaviours and smoking cessation. 
 
2.5.2 Beliefs about Medicines 
The beliefs about medicines questionnaire (BMQ) (Horne, Weinman & Hankins, 1999) was 
developed as an extension of the HBM. The measure was developed due to the need for a 
psychometric tool for operationalising and scoring beliefs that are commonly held about medication, 
assessing both specific and general beliefs about medication. The BMQ addresses the cost-benefit 
analysis of individual’s perceived benefits and barriers of taking medication. The core themes that 
were identified in the development of the BMQ relating to medication prescribed for patients were: 
beliefs about the necessity of taking medication prescribed to maintain health (specific-necessity) and 
concerns about prescribed medication (specific-concerns). The BMQ-general scales indicated 
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negative views of medicines as overused (in terms of prescription by doctors) and harmful in the 
development of the measure.  
 
Horne and Weinman (1999) used the BMQ to explore patients’ beliefs about medicines and their role 
in adherence to treatment. This was explored using a chronic illness sample (N=324) of asthmatic, 
renal (haemodialysis), cardiac and oncology patients, chosen as adherence is known to be low in all 
four groups and to provide a representation of different conditions and treatment characteristics. 
Findings showed specific beliefs about medicines were more predictive of reported adherence than 
clinical and sociodemographic variables, accounting for 19% of the variance explained in adherence.  
A meta-analysis of studies (N=94) using the BMQ explored perceptions of necessity for medication 
and concerns about possible side-effects (known as necessity-concerns framework) in relation to a 
measure of adherence to medication in patients with long-term conditions (Horne et al., 2013). 
Findings showed greater adherence levels were associated with stronger perceptions of the necessity 
of the treatment, and fewer concerns about treatment medication. This framework could therefore be 
useful to further understand patients’ views on prescribed medications, providing clinicians with 
information to increase patient involvement in treatment decision making to support adherence.  
 
2.5.3 Self-regulation model  
The self-regulation model (SRM) of illness cognition and behaviour was proposed by Leventhal, 
Nerenz and Steele (1984). It is often referred to as the common-sense model (CSM) due to its 
emphasis on personal, common-sense beliefs about illnesses. The model focuses on how individuals 
perceive and monitor behaviour over time to cope and make progress towards their goals. Research 
has identified the cognitive representations and behaviour that form illness representations (Moss-
Morris et al., 2002; Broadbent, Petrie, Main & Weinman, 2006). Illness representations refer to 
organised beliefs surrounding an illness, following an illness threat. These beliefs guide coping 
procedures in an attempt to control the illness threat. Illness representations stored in memory are 
activated by stimuli (e.g. symptoms of disease). A summary and representation of the persons 
condition is created through considering current symptoms and context-based information, and then 
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matching this to pre-existing beliefs. This then informs coping and therefore which coping behaviours 
are selected to manage the current condition. The outcomes of these strategies are then reviewed in 
relation to how well they control the illness and e.g. symptoms.  The outcomes of these evaluations 
result in changes and refinements of the illness representations and the adoption of new coping 
behaviours. The model consists of five key components of illness representations (Cameron & Moss-
Morris, 2013). Table 2.2 summarises the definitions of the five key components. 
 
Table 2.2: Illness representations of the self-regulatory model. 
Illness Representation Definition 
Illness identity The illness label or diagnosis used by the patient and associated 
symptoms attributed to the illness. 
Consequences The perceived or expected effects of the illness and outcomes such as 
physical, social and psychological well-being. 
Timeline The perceived expected duration of the illness, whether the illness is 
perceived to be acute, cyclical or chronic (long-term). 
Control or cure The perceived controllability and curability of the illness through 
treatment measures and behaviours. 
Cause The perceived causal factors or conditions of the illness. 
 
Later versions of the model (Illness perceptions questionnaire-Revised: IPQ-R) have included further 
components representing perceptions in relation to illness coherence (understanding of the illness), 
the cyclical timeline of illness (symptoms can be acute, cyclical or chronic) and emotional 
representation (Moss-Morris et al., 2002). Illness concern (perceived concerns about the illness) has 
also been included in refined versions of the scale (Brief IPQ) (Broadbent, Petrie, Main & Weinman, 
2006). The original illness perceptions questionnaire only investigated cognitive components, and 
therefore it was felt that this did not fully encompass patients’ responses to illness. The IPQ-R was 
therefore developed to address this issue and the Brief IPQ later developed to provide a more concise 
version to measure illness representations.  
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The SRM suggests that how patients perceive their illness may influence how they manage it, 
including adaptation, coping and health behaviour. Previous literature has highlighted that patient 
behaviour is influenced by illness representations and could therefore be used to inform interventions 
in chronic illness groups (Petrie, Broadbent & Meechan, 2003). A meta-analysis of 45 empirical 
studies explored the intercorrelations between components of the SRM and categories of coping 
strategies finding significant relationships between certain illness representations and certain 
categories of coping strategies, and additionally between certain illness representations and illness 
outcomes (Hagger & Orbell, 2003). Specifically, they found perceptions of controllability/curability 
positively associated with cognitive reappraisal, problem-focused coping and emotion expression.  
 
Existing literature has explored illness perceptions across a number of different chronic illness groups. 
Much research has been conducted in renal settings, notably dialysis patients. Illness perceptions has 
been associated with survival in haemodialysis patients, with treatment control predicting survival and 
reducing the risk of death by 11% (RR=0.91) (Chilcot, Wellstead & Farrington, 2011). Additionally, 
illness perceptions have been linked to psychosocial outcomes, including quality of life and 
depression in this patient population. Depression has been associated with lower perceived control 
and illness coherence and greater perceived consequences (Chilcot, Wellstead, Davenport & 
Farrington, 2011). Furthermore, quality of life is shown to be significantly lower in dialysis patients in 
comparison to the general population (Fowler & Baas, 2006), with quality of life associated with 
greater consequences, lower personal control and strong illness identity (Timmers et al., 2008).  
 
Existing evidence has also explored illness perceptions in relation to adherence to treatment across a 
large number of different chronic illness patient populations. For example, in diabetes, medication 
adherence was associated with lower perceived consequences, higher personal control, fewer illness 
symptoms and lower distress levels (Broadbent, Donkin & Stroh, 2011). Hypertension studies have 
shown lower personal control, a strong sense of concern over illness and emotional reaction to illness 
to be associated with lower adherence levels (Ross, Walker & McLeod, 2004). In renal settings, 
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negative illness perceptions of disease have been associated with non-adherence to dietary restrictions 
in haemodialysis patients (Kim & Evangelista, 2010). Much of the literature within renal settings 
exploring illness perceptions and adherence has been among dialysis patients, less has been conducted 
in the kidney transplant population. Griva et al., (2012) found receiving a kidney transplant lead to 
greater positive perceptions of illness identity, consequences, intrusiveness and controllability, 
compared to receiving dialysis. Higher adherence has also been associated with higher perceived 
personal control and emotional response, and greater perceived consequences associated with non-
adherence (Massey et al., 2013). Additionally, poorer illness perceptions have also been associated 
with lower quality of life and psychological distress (Knowles et al., 2016). As non-adherence to 
immunosuppressants is recognised as such a problematic issue within the kidney transplant population 
with potentially serious consequences, it would be beneficial to further investigate whether illness 
perceptions could play a role in non-adherent behaviour. Perhaps even more useful would be to track 
illness perceptions pre-transplant and over a longitudinal course post so that we are better informed 
about some of the reasons that patients may start to negotiate risks over-time (Jamieson et al., 2016).  
 
Much of the existing literature in this area is cross-sectional in design, therefore longitudinal studies 
are needed in order to follow patient’s treatment journeys and experiences from long term condition 
diagnosis to treatment management and self-management. It is also important to note that most long-
term conditions have differing aetiology, trajectories and treatments. Experiences may therefore be 
varied across different long-term condition populations. As a result, illness representations associated 
with coping with long term conditions may vary across diseases. Evaluation of findings in relation to 
illness representations should therefore potentially be considered in respect to individual long-term 
conditions.   
 
2.6 Summary 
Adherence post kidney transplantation is essential for the patient, economy and society. It is essential 
to understand adherence behaviour more in this patient group to drive better outcomes and value for 
health services and organ donors alike. There are a number of different ways to measure adherence, 
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each associated with strengths and limitations. Although electronic monitoring is considered the most 
valid measurement method for adherence and should be used as a reference standard, previous 
literature has indicated a combination of measurement methods may be more reliable. Within this 
programme of research, different measurement methods will be used to assess (non)adherence to 
treatment across studies. These include clinical markers via blood assay, treatment and clinic 
attendance and self-reported adherence. 
 
Previous literature has used health psychology models to understand and explain non-adherent 
behaviour. Questionnaire measures have been created associated with these models which have been 
validated and commonly used in previous research across a number of different chronic illness 
populations, including in renal settings. Within this programme of research, measurement methods 
informed by some of the health psychology models, such as the HBM and SRM, will be used to 
explore (non)adherence to treatment regimens in kidney transplant recipients. The following chapter 



























The methodological features that relate to the studies within this programme of research are 
summarised within this chapter. The thesis overall aims to report a series of studies that are designed 
to assess different elements of adherence in renal transplant recipients. This will be achieved through: 
• A systematic review of existing research on adherence in this patient population. 
• Retrospectively considering the relationship between pre and post-transplant adherence in 
haemodialysis patients who later go onto receive a kidney transplant. 
• Qualitative enquiry of the views and beliefs of clinical staff in relation to the importance of 
adherence for kidney transplant wait listing. 
• Cross-sectional data collection with transplant recipients to unearth more about their belief 
structures that may help understand adherence behaviour. 
A mixed-methods approach is being advanced. In summarising the thoughts of the main leaders in the 
field, Johnson et al., (2007, p118) state that “mixed methods research is the type of research in which 
a researcher or team of researchers combines elements of qualitative and quantitative research 
approaches (e.g., use of qualitative and quantitative viewpoints, data collection, analysis, inference 
techniques) for the broad purpose of breadth and depth of understanding and corroboration”. It is 
recognised that adherence behaviour is likely complex, with intentional and unintentional factors from 
the patient side. It is also important to acknowledge that patients are placed within a health care 
system with providers also holding their own beliefs, structures and processes which may directly or 
indirectly also impact patient behaviour.  In order to drive attempts at strengthening self-management 
in patients for medicine taking, it is useful therefore to gain data that is rich in different perspectives 
and that which allows for scoping patterns in behaviour as well as depth of experience. As such, 
mixed-methods is the approach used within the thesis. It draws on a range of methodological 
paradigms- systematic review methods, questionnaires, descriptive data audit, and qualitative 
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interviews. The focus of this chapter is on clearly defining the patient population of interest, alongside 
an overview of each of the research designs being used within individual elements of the thesis.  
3.2 Patient population  
The kidney transplant patient population was chosen for the focus of this programme in recognition 
that much of the research surrounding patients treated for end stage renal disease tends to feature 
those receiving dialysis. Since transplantation is considered the ‘gold standard’, this perhaps reflects a 
bias in research driven by the known challenges that are associated with dialysis. However, as 
discussed previously, there are a number of patient, societal and economic factors that should drive 
focus on adherence in transplant recipients. Literature to date in the kidney transplant population has 
highlighted that there are many complexities surrounding the treatment and follow-up process, 
notably non-adherence to immunosuppressants (Denhaerynck et al., 2005). The evidence clearly 
indicates that non-adherence to immunosuppressants is a major risk factor for poor clinical outcomes, 
including graft rejection and graft loss (Loghman-Adham, 2003; Butler et al., 2004) and that patients 
are informed of these consequences. However, despite this awareness, non-adherence remains a 
prevalent issue. This research programme was therefore designed to gain a deeper understanding of 
this issue from both patient and medical professionals’ perspectives. In terms of justice to donated 
organs, the thesis was specifically interested in mapping patterns of pre and post-transplant treatment 
adherence to unearth whether any issues can be anticipated in advance of solid organ transplantation 
and how much clinicians prioritize adherence behaviour before listing for transplantation. Factors that 
impact transplant recipients in intentional or unintentional non-adherence were also of interest, all 
following on from a comprehensive mapping of studies that have considered adherence in the kidney 
transplant setting. It is hoped that the body of research reported in this thesis would pave the way for 
targeted interventions that support clinical staff and patients to partner in enhancing adherence and 
ultimately health related quality of life and organ longevity.  
 
All patient data included in this programme of research were collected from Lister Hospital, East and 
North Hertfordshire NHS Trust. The post-transplant service cares for nearly 400 patients. On average, 
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60-70 patients are transplanted each year, with up to 30% of these from living related/unrelated 
donors. Patients are cared for pre and post-transplantation, however, receive their kidney transplant 
elsewhere as Lister Hospital is not a transplanting centre. The kidney transplant team prepare patients 
and prospective live donors for transplantation via assessment and work-up, including providing 
information, observations and testing, before handing over to the transplant centre. Patients can be 
transplanted at one of three hospitals, Addenbrookes Hospital (Cambridge University Hospitals NHS 
Foundation Trust), Royal Free London NHS Foundation Trust or West London Renal and Transplant 
centre, Hammersmith Hospital (Imperial College Healthcare NHS Trust), with most patients 
transplanted at Addenbrookes Hospital compared to the other centres. Additionally, the majority of 
patients are transplanted following receiving HD. Between April 2013 and March 2016, of these three 
transplant centres, Addenbrookes Hospital was shown to have the shortest median waiting time to 
adult kidney transplant (95% CI 266-362 days), followed by Royal Free London (95% CI 611-843 
days) and West London Renal and Transplant centre (95% CI 873-1061 days) (NHS Blood & 
Transplant, 2019). Patients return to Lister Hospital for post-transplant follow-up care once 
discharged from their transplanting centre. This is often between three and six months post-transplant. 
 
3.3 Study Methodology 
3.3.1 Systematic review (Study 1) 
Existing literature clearly indicates that non-adherence to immunosuppressant medication is a major 
risk factor for poor outcomes post transplantation and is a common issue among renal transplant 
recipients. Three core reviews have previously been published in 2003 (Jindal et al., 2003), 2004 
(Butler et al., 2004) and 2017 (Belaiche et al., 2017), which aim to highlight the prevalence and extent 
of non-adherence in the kidney transplant patient population. Recognition of non-adherence as a 
problematic issue with potential serious consequences in renal care settings has resulted in increased 
research interest in recent years and subsequently a larger evidence base. Prior to planning and 
commencing any empirical studies for this programme of research, it was essential to highlight what 
existing literature had identified as key issues leading to non-adherence in this patient population. An 
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updated synthesis of the current existing body of literature in this area was therefore deemed 
necessary to gain a better understanding of non-adherence to immunosuppressants in the kidney 
transplant patient population. 
 
It was considered that in addition to informing the programme of research for this thesis, the results 
from a review would be useful for clinical practice as a guide to inform the nature of interventions to 
address this issue. The results of an updated review in this area could provide a greater understanding 
of prevalence rates of non-adherence, methods employed for measuring adherence and factors 
impacting on non-adherence behaviour. Importantly, an updated review would take account of the 
proliferation of research into psychosocial factors that impact on patients- particularly as health 
psychology as a discipline has seen a rapid rise in the last decades (Thielke, Thompson & Stuart, 
2011). Since the previous three reviews, it is also interesting to note any changes in the way that 
adherence has been reported across studies e.g. single versus multiple methods and cost effective 
versus accuracy trade-off.  
 
A systematic review of quantitative studies was considered the best method for synthesising the 
existing literature on this topic area. The specific aims of the review were as follows: 
1. Summarise the methods used to assess non-adherence and discuss how non-adherence is 
operationalized across studies. 
2. Identify the prevalence of non-adherence by pooling data from across studies and consider 
whether reported non-adherence varies as a function of measurement source. 
3. Provide a narrative summary of the main factors associated with non-adherence. 
 
Systematic reviews involve comprehensive and detailed planning and a search strategy devised a 
priori (Uman, 2011). The aim is to reduce bias by identifying, evaluating and synthesising all existing 
literature on a topic area. Systematic reviews often follow a set of stages (Uman, 2011) and these 
were applied in this thesis as outlined below: 
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1. Formulating the research question – Defining a research/review question, devising a 
hypothesis and defining the systematic review title.   
2. Defining inclusion and exclusion criteria – Defining inclusion and exclusion criteria so it is 
clear what types of studies should be included and excluded. PICO (population, intervention, 
comparison, outcomes) can be useful when determining this, and is often used to determine 
the key concepts prior to starting a review.  
3. Developing a search strategy and locating studies – Developing a list of key search terms 
relating to each concept relating to your review question. These can be free text terms or 
specific key terms, such as MeSH terms (medical subject headings). Searches are often 
conducted in electronic databases, searching reference lists, considering grey literature, hand 
searching key journals or personal communication with experts in the field. 
4. Selecting studies relevant for inclusion – Titles and abstracts of citations identified through 
the searches are reviewed to determine studies that appear to meet inclusion criteria and 
therefore need to be retrieved for full-text review. Full texts are then screened to determine 
studies that meet inclusion criteria for the review. This stage is usually completed by two 
reviewers to ensure inter-rater reliability. 
5. Extracting data – Data is extracted from each of the studies relevant for inclusion in the 
review. This is usually extracted into a data table. Again, this stage is usually completed by 
two reviewers to check for data entry accuracy and to avoid errors, and to ensure inter-rater 
reliability.  
6. Assessing study quality – Studies included in reviews are assessed for study quality via a 
quality assessment tool. Various quality assessment tools exist, and reviewers will choose an 
appropriate tool dependent on the type of review undertaken. Again, this stage is usually 
completed my two reviewers to ensure inter-rater reliability.  
7. Analysing and interpret findings – Narrative summaries of the findings including key 
features of studies included relating to the review question are synthesised and interpreted. 
Data from independent studies can be combined, known as meta-analysis. Meta-analysis uses 
statistical techniques to synthesise data from a number of studies into one quantitative 
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summary effect size or estimate. Included studies of the same topic reporting similar data can 
be examined to determine overall trends. Meta-analysis is often included in systematic 
reviews when appropriate data is available to analyse. 
8. Disseminating findings – Summarising the findings and providing recommendations for 
future research or informing practice.  
 
Knowledge and training on conducting systematic reviews appropriately was supported in two main 
ways. The researcher already had some prior experience from an MSc which included learning the 
principles of running a systematic review and conducting a mini systematic review as part of the 
required assessments. Additionally, support was provided from colleagues with expertise in designing 
and running systematic reviews and meta-analyses. These methods also underwent external review 
during publication of the protocol (Hucker et al., 2017) for the review. 
 
Following identification of the aims and research questions for the systematic review, the inclusion 
criteria was determined. Studies eligible for inclusion were quantitative studies (excluding 
interventions) that measured non-adherence to immunosuppressants among adult kidney transplant 
recipients aged 18 years and over. A search strategy was developed by consulting existing relevant 
review search terms, previous literature and experts in the patient population and topic of adherence. 
A combination of free text and medical subject heading (MeSH) search terms were used in all 
databases. Appropriate MeSH terms used were identified via the PubMed index. Electronic databases 
in which the search strategy was run, such as PubMed and Scopus, were selected based on University 
or free access availability. Lateral search techniques, including checking reference lists and searching 
for grey literature, were also used to ensure all potentially relevant articles were captured.  
 
The search strategy was run in each of the selected databases and citations imported into Endnote 
reference management software. Following removal of duplicates, the titles and abstracts were 
screened to identify suitability for inclusion. These were organised into three folders for full text 
screening: “yes” title and abstract appear to meet inclusion criteria, “maybe” meets inclusion criteria, 
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“no” clearly does not meet inclusion criteria. The full texts of citations allocated to the “yes” and 
“maybe” folders were subsequently accessed for review. A screening proforma (inclusion/exclusion 
table) was used to assist with the full text screening process. Questions based on the inclusion criteria 
were included in the table to assist the screening process and to easily determine which citations were 
relevant for inclusion. This provided a clear record of which citations were relevant for inclusion, as 
well as which were excluded and why. A data extraction form was used to extract the relevant 
information from each study to be included in the review. Studies were rated for quality assurance 
using the Downs & Black (Downs & Black, 1998) checklist. A detailed summary of the systematic 
review methodology is provided in Chapter 4 of this thesis.  
 
In addition to providing a narrative summary of the findings from the eligible studies included within 
this updated review, meta-analysis was also used to pool together study outcomes to assess prevalence 
of non-adherence rates across studies. Endnote V7 was used to import and screen citations. 
Recognising the ‘Open Science’ movement that is gaining momentum in many disciplines, including 
Psychology, the review methods were pre-registered on Prospero - an open access online database for 
systematic review protocols that are in health-related areas. The systematic review protocol was also 
published in the BMJ Open (Hucker et al., 2017). Open science encompasses a range of practices 
aimed at making science more reliable, including wider availability of research data and materials, 
valuing replicability, consideration of power in relation to statistical analysis, the use of double-blind 
peer review and the use of open access publishing (Allen & Mehler, 2019).   
 
3.3.2 Retrospective data analysis (Study 2) 
A retrospective research design involves starting the study after data collection or follow-up has been 
completed. Eligible participants are identified retrospectively, and data measurements are retrieved to 
form a baseline. Following this, the data for the research is assessed and studied during the historical 
observation period, for example disease occurrence or death (Euser, Zoccali, Jager & Dekker, 2009). 
There are strengths and weaknesses to this type of methodology. A strength of retrospective studies is 
that data collection can be completed more quickly and can be used to answer new research questions 
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using existing data. Limitations include that data is not collected in real time and researchers can only 
use data that has previously been measured and recorded, often for a different purpose or different 
research study.  
 
There is much previous literature exploring non-adherence in haemodialysis patients, and the impact 
this has on patient’s physical well-being, quality of life and outcomes, including mortality. 
Additionally, the same can be said for research exploring non-adherence to immunosuppressants 
among kidney transplant recipients including graft rejection and graft loss (Loghman-Adham, 2003; 
Butler et al., 2004). Limited research has explored if there is a relationship in patterns of 
adherent/non-adherent behaviour in patients when on haemodialysis and again following kidney 
transplantation i.e. within patient variability across different treatment modalities. It was considered 
important to assess if non-adherent haemodialysis patients become non-adherent transplant recipients 
since a high percentage of HD patients can be expected go on to receive a donor organ. Within a year 
of starting dialysis, 45% of patients under 65 years are listed for a transplant (Renal Registry, 2014). 
This increases to 57% by two years, and 66% by five years. Clinical data from electronic patients’ 
records was used to assess such within patient adherence patterns across treatment types. Clinical data 
collected as part of routine care can provide accurate measurements and representations of patient’s 
behaviour. As these measurements are taken regularly at treatments and appointments, it provides 
evidence of behaviour over time and therefore potential patterns of behaviour. However, as mentioned 
previously, every patient is individual and responds to medication in different ways including 
individual drug target levels, levels and assay, and so results can be impacted by a number of 
variables and should be interpreted with caution (De Geest & Vanhaecke, 1999; Schafer-Keller et al., 
2008; Kreys, 2016). Notwithstanding this, such data is cost effective and the method represents a less 
intrusive approach to addressing an important question. As the treatment and medications required for 
haemodialysis patients and transplant recipients are different, markers and measurements of 
(non)adherent behaviour vary pre-transplant, when on haemodialysis, compared to post-transplant.  
Effort was made to address this difference when interpreting findings from retrospective data analysis.  
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In clinical data, there is no standardised methodology for defining and measuring (non)adherence. 
Previous literature was used as a guide to develop criteria (Leggat et al., 1998; Saran et al., 2003; 
Hecking et al., 2004; Schafer-Keller et al., 2008; Wileman et al., 2011). This included using data such 
as time actually spent on dialysis during a session, compared to prescribed time, dialysis attendance 
and medication taking of phosphate binders as measurements for pre-transplant adherence to 
haemodialysis, and immunosuppressant drug levels and attendance to clinic appointments as 
measurements for post-transplantation adherence. Explanations of the definitions, measurements and 
cut-off points used, including how these measurement values were determined and calculated using 
the clinical data from electronic records are described in chapter five of this thesis.  
 
Research questions 
To examine the relationship between clinical measures of pre-transplant adherence to haemodialysis 
and clinical measures of post-transplant adherence, the following research questions were addressed: 
1. Do non-adherent haemodialysis patients become non-adherent transplant recipients? 
2. Are there particular patterns of non-adherence to haemodialysis which are more likely to 
associate with poor adherence following transplantation? 
 
3.3.3 Qualitative Interviews (Study 3) 
Qualitative research is now recognised as important in understanding human behaviour and 
psychological experiences (Rohleder & Lyons, 2015). In health and medical settings, it is considered 
as a way of understanding the perspectives, experiences and contexts of illness and well-being from 
the patient’s viewpoint. Where quantitative research aims to answer a pre-determined hypothesis 
using statistical and/or experimental research methods, qualitative research uses in depth and rich data 
to answer questions on experiences and meaning, to develop ideas or hypotheses, or in health and 
medical settings for example, to inform clinical practice. The most common forms of data collection 
in qualitative research is in-depth interviews, focus groups and observations, with the most widely 
used in psychology being individual interviews with participants (Lyons, 2015).  
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Interviewing can be used to understand the lived experiences of others, and the meanings that they 
make of that experience (Seidman, 2006, as cited in Lyons, 2015). There are different styles of 
interviewing, including structured, semi-structured and non-directive (unstructured) (Lyons, 2015). 
Structured interviews are quick to capture data and uses a pre-prepared interview schedule that is 
followed exactly as written. Interaction is often kept to a minimum. The interview is interviewer-led 
(Adhabi & Anozie, 2017) and is easy to analyse. Often, structured interviews are a precursor to more 
open-ended discussions, such as non-directive (unstructured) interviews. Semi-structured interviews 
can be slow and time-consuming to capture data and to analyse. A list of questions (interview 
schedule) is devised along with probes (Jamshed, 2014). Probing of views can be used to encourage 
participants to expand on their responses. The interview can be interviewer-led or interviewee led, 
allowing give and take within the discussion. Participants are able to respond to questions and probes 
as they see fit with minimal interference. Not all questions devised may be asked, and additional 
questions can be included by the interviewer. This type of interview style allows for exploration of 
subjective meaning. Non-directive (unstructured) interviews are used to explore topics in depth, 
however, questions are not usually pre-planned (Gray, 2018). There are objectives to the research and 
what will be addressed. Participants are allowed to talk freely, and interviewer input is kept to a 
minimum. The interviewer may check or rephrase answers to ensure understanding. This style of 
interview can be more challenging to analyse. Of these interview styles, semi-structured interviews 
are most commonly used in qualitative analysis especially in healthcare and medical settings 
(Dejonckheere & Vaughn, 2019) and were utilised in this thesis.  This approach, in the context of 
CKD and transplant more specifically has already been successfully applied. For example, several 
studies have gleaned insights into patient experiences, such as positive and negative consequences of 
transplantation (Schipper et al., 2014) and with medical professionals research using semi-structured 
interviews has yielded studies exploring, for example, perceptions around self-management by kidney 
transplant recipients (Ndemera & Bhengu, 2018) and barriers to living donor kidney transplantation 
(Sandal et al., 2019). 
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The one-to-one interviews were integral to understanding clinicians’ and healthcare professionals’ 
views surrounding non-adherence in the kidney transplant population. The interviews provided rich 
and detailed data from staff perspectives on non-adherence, techniques that are or should be 
implemented to improve adherence, and the importance of non-adherence in patient eligibility for 
transplantation. One-to-one interviews were deemed appropriate over group interviews or focus 
groups to explore this topic area as the research was interested in the views of diverse staff from 
differing positions and it was felt that they may feel more comfortable on a 1-1 basis. This also 
avoided a power imbalance e.g. that may occur between transplant surgeon and nurses, senior medical 
staff versus junior.   
 
The growth of technological platforms has led to a range of interview modes such as face-to-face, 
telephone, skype, written interviews over email, and can by synchronous (conducted with the 
researcher and the participant at the same time) or asynchronous (where the researcher and the 
participant are not completing the interview at the same time e.g. via email). Face-to-face interviews 
were chosen to ensure rapport development and flow, and to allow for non-verbal cuing and body 
language to be identified and responded to appropriately during the interview. With consent from 
participants, all interviews were audio recorded. Transcription of the interviews was conducted 
verbatim, that is, interviews were transcribed word for word.  
 
Thematic analysis as described by Braun and Clarke (2006) was used to analyse the one-to-one 
interviews. Thematic analysis provides a systematic method for identifying patterns of meaning 
(themes) across a data set (Braun & Clarke, 2012), and can be used to understand mutual and shared 
experiences and meaning. Thematic analysis aims to look for similarities or commonalities in relation 
to a topic area across a whole data set. Themes identified from the data are related and help answer 
the research question. Thematic analysis offers flexibility to the researcher and can report on semantic 
meanings of data or latent meanings (the assumptions or meaning underpinning what is actually being 
stated by the participant). Additionally, it can be used within different theoretical networks (Braun & 
Clarke, 2006). Due to this flexibility, thematic analysis was considered as the appropriate form of 
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analysis for this programme of research compared to other alternative forms (such as Grounded 
Theory, Discourse Analysis, Interpretative Phenomenological Analysis or Narrative Analysis) which 
are related to pre-existing theoretical frameworks and/or assumptions. There are a number of different 
ways in which thematic analysis can be conducted which span across three continuums: inductive vs 
deductive; realist vs. constructionist and semantic vs. latent. A summary of each approach is provided 
below (Braun & Clarke, 2006; Braun & Clarke, 2012): 
 
Inductive vs. deductive thematic analysis: 
• Inductive – Bottom-up approach. Analysis is data-driven and does not fit a pre-existing 
coding framework. Coding and themes are derived from the data content.  
• Deductive – Top-down approach. Analysis is driven from pre-existing concepts/ideas/topics. 
Coding and themes are derived from existing theoretical concepts and ideas.  
 
Semantic vs. latent themes: 
• Semantic  – Codes and themes are derived from explicit or surface level meaning. Analysis is 
descriptive does not go beyond what has been said or written.  
• Latent  – Goes beyond semantic content and considers deeper meaning. Codes and themes 
are derived from underlying ideas, assumptions and conceptualisations. Analysis and theme 
development involves interpretation.  
 
Essentialist/realist vs. constructionist epistemology 
• Essentialist/realist – Analysis reports reality of participants data, including experiences and 
meanings.  
• Constructionist – Analysis reports how experiences, meanings and realities are an effect of 




Coding and analysis can use a combination of approaches. However, this programme of research 
adopted an inductive thematic analysis approach, due to the lack of previous literature in relation to 
clinician/health care professionals understanding and experience of non-adherence, as experienced by 
kidney transplant recipients. Additionally, there is little evidence of the importance of non-adherence 
in transplant eligibility for transplantation. Latent themes were developed considering the ideas and 
concepts underpinning the data. 
 
In doing qualitative research, it is essential for a researcher to acknowledge their own position in 
relation to the topic area. Reflexivity is important for developing awareness of how the researcher 
may have informed the research, for example, considering personal circumstances, identity and 
experiences (Dodgson, 2019). Recognition that the researcher brings subjectivity to the research 
process should be viewed as a strength, rather than a weakness.  
 
In order to ensure quality in qualitative research, tools and criteria’s have been developed to assess 
quality. One example includes the COREQ (COnsolidated criteria for REporting Qualitative research) 
developed by Tong, Sainsbury & Craig (2007) as a formal reporting checklist for in depth interviews 
and focus groups (often the most common form of qualitative data collection in health research). The 
aim of the checklist is to improve rigor, credibility and comprehensiveness of interview and focus-
group research, and to promote clear reporting among researchers. 
 
There are six phases to conducting thematic analysis (Braun & Clarke, 2006): 
 
1. Familiarisation with the data: Immersing with the data to ensure familiarisation with breadth 
and depth of content. This involves reading and re-reading the data in an active way, 
searching for meanings and patterns. Data should be read through at least once prior to coding 
(phase 2). Note taking or initial ideas about what is in the data can be marked down during 
this phase ready for coding.  
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2. Generating initial codes (coding): Production of initial codes from the data. This stage 
involves generating codes for interesting and important features of the data. The entire dataset 
is coded in a systematic fashion collating relevant codes and data extracts ready for further 
phases of analysis.  
3. Searching for themes: Evaluating and collating the different codes into potential themes, and 
collating relevant coded data extracts with the relevant identified potential themes. Here the 
researcher is analysing codes and exploring how they could be combined to form an 
overarching theme. This phase also involves considering the relationship between codes, 
themes and between different levels of themes (e.g. themes and sub-themes). Initial codes 
may be used to form main themes, sub-themes or may be discarded. The phase ends with a 
group of candidate themes, sub-themes and data extracts coded in relation to these to be 
reviewed in the subsequent phase.  
4. Reviewing themes: This phase involves refinement of the themes generated in phase 3. 
Candidate themes are reviewed against the data to ensure there is enough data to support them 
and answer the research question(s). Themes may be combined, refined and separated, or 
discarded during this phase. Data within themes should be related in a meaningful way, and 
there should be clear and distinct differences in data between themes. By the end of the phase 
there should be a clear understanding of the different themes, how they may fit together and 
the story they tell in relation to the research question(s). 
5. Defining and naming themes: Define and further refine themes, and analysing data within 
them. This means capturing and identifying what the underlying essence of each theme is 
about and the focus. The “story” of each theme is identified both within the theme and in the 
broader context of the data in relation to the research question(s), ensuring no overlap 
between themes. This phase also involves clearly defining and naming the themes.    
6. Producing the report (writing up): This final phase involves the final analysis and write-up 
of this in a report. The analytic narrative and data extracts should be used to provide a concise 
and interesting representation of the “story” the data tells both within and across themes. Use 
of data extracts (quotes) should be used to indicate the prevalence of each theme. The analytic 
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narrative should go beyond simply describing the data, and provide an argument in relation to 
the research question(s) relating to previous literature in order to contextualise the findings.  
 
This process was followed during analysis of the one-to-one qualitative interviews. All analyses were 
conducted in NVivo version 12.  
 
The researcher had prior experience of qualitative research through both undergraduate and MSc 
studies which included learning about qualitative research and analyses techniques, completing an 
advanced qualitative research methods module and undertaking a mixed-methods dissertation using 
thematic analysis. Training sessions on how to use NVivo to support qualitative analysis were also 
completed. Additionally, support was provided from members of the PhD supervisory team who have 
expertise in qualitative research and analyses. 
 
Research questions 
Semi-structured interviews with clinicians working closely with adult renal transplant recipients 
aimed to address the following research questions: 
1. How do clinicians understand the term non-adherence in relation to renal transplant 
recipients? 
2. What factors do clinicians believe influence adherence to treatment regimens following 
transplantation? 
3. How important is patient adherence to clinicians when determining eligibility for 
transplantation? 
4. Do clinicians believe non-adherent patients pre-transplant are likely to be non-adherent post-
transplant? 
 
3.3.4 Cross sectional questionnaire (Study 4) 
Self-reported questionnaires are easy to administer and feasible in most clinical settings (Schafer-
Keller et al., 2008). Due to this, data can be collected from a large number of participants during a 
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short period of time. This makes cross-sectional questionnaires an important methodology to elucidate 
patterns in patient behaviour and predictors of the same. A core aim of the thesis was to pave the way 
for more attempts at intervening to help strengthen adherence behaviour. As such, a questionnaire 
study was designed in order to glean relationships between patient beliefs about their treatment and 
how this might relate to self-reported adherence. Notwithstanding the limitations of self-report 
measures, these are the most pragmatic way to assess adherence behaviour especially in clinical 
settings where time and resource pressures are real. Bringing together core themes from the thesis and 
existing literature, a study was designed to explore how beliefs about immunosuppressants and 
towards medication in general, illness representations and clinical factors related to self-reported 
adherence among kidney transplant recipients. Due to limited previous literature exploring 
psychological factors such as these on adherence among this patient population, this study aimed to 
identify predictors of adherence/non-adherence, potentially highlighting areas which could be targeted 
for intervention to improve adherence behaviour.  
 
Validated measures were chosen for use in this programme of research that have previously been used 
and tested in the transplant population. Permission to use the questionnaires was sought from the 
original developer for those not in the public domain. 
 
Due to the infrequency of hospital appointments, the optimum time to collect questionnaire data from 
kidney transplant recipients is when they are attending for a clinic appointment to check their 
transplant function etc. During this visit, patients often have to wait to be seen by a consultant 
nephrologist, and therefore have time between having their observations taken (e.g. blood pressure 
and weight) and being called for their appointment. This time was therefore seen as the optimum 
recruitment period. In order to ensure relevance of the study focus and acceptability of measures, the 
public involvement in research group (PIRg) hosted within the school of health and social work at the 
University were consulted for feedback on the appropriateness and feasibility of the final 
questionnaires chosen for administration. The PIRg group aims to provide feedback and a direct voice 
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from service user’s experiences in contributing to the development of research projects. A summary 
of the questionnaires used within this programme of research are detailed below.   
 
Medication adherence report scale (MARS-5) 
The medication adherence report scale (Horne & Weinman, 2002) was used to assess adherence to 
immunosuppressant medication among renal transplant recipients. The wording of the questionnaire 
items was adapted to fit this context as is common practice. Adherence is commonly explored within 
chronic illness populations, as often non-adherence can have serious consequences in terms of 
treatment, quality of life and life expectancy. Various self-report questionnaires have been devised to 
measure adherence. The MARS elicits patient’s reports of non-adherence and originated as a 9-item 
scale, however, a reduced five item version was created providing for a more concise version of the 
measure (Horne & Weinman, 2002). The scale assesses both intentional and unintentional non-
adherence. Questions assessing unintentional non-adherent behaviour include: “I forgot to take them”. 
Questions assessing intentional non-adherent behaviour include: “I alter the dose”; “I stop taking 
them for a while”; “I decide to miss out a dose”; “I take less than instructed”. Each question is rated 
on a five-point scale ranging from 1 (very often) to 5 (never). Scores are then combined to give a total 
score ranging from 5-25. Lower total scores on the scale indicate high levels of non-adherence.  
 
Questions are phrased in a non-threatening manner to avoid patients feeling pressure to report high 
adherence, and patients are reassured that responses are anonymous and confidential. The following 
statement precedes the scale items: “Many people find a way of using their medicines that suits them. 
This may differ from the instructions on the label or from what their doctor has said. Here are some 
ways in which people have said they use their medicines. For each statement, please tick the box 
which best applies to you” (Horne & Weinman, 2002). 
 
The scale has been shown to have high internal reliability (Horne & Weinman, 2002). The MARS-5 
has been used in previous literature to measure adherence behaviour across a number of different 
chronic illness settings, including renal settings within haemodialysis patients (e.g. Wileman et al., 
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2015) and kidney transplant recipients (e.g. Butler et al., 2004; Griva et al., 2012; Vankova et al., 
2018) showing good internal reliability. The MARS-5 was therefore deemed an appropriate and 
concise questionnaire to measure adherence within this programme of research. 
 
Beliefs about Medicines Questionnaire (BMQ) 
The beliefs about medicines questionnaire (Horne, Weinman & Hankins, 1999) was developed using 
a sample of patients with long term health conditions comprised of six different groups, of which 
dialysis patients was one. The self-report questionnaire aimed to assess the commonly-held beliefs 
about medicines, exploring beliefs and views people hold about general and specific medication. The 
BMQ was used to assess perceived necessity of and concerns about immunosuppressant medication. 
The wordings of the items were adapted to fit this context. The BMQ is comprised of two sections: 
BMQ-general and BMQ-specific. The sections each represent two sub-scales. The specific section 
measures how necessary patients perceive their specific medication to be (specific-necessity) (5 
items) and how concerned they are about potential negative effects of taking it (specific-concerns) (5 
items). The general section measures the way in which doctors use medication and whether patients 
perceive medication is overused (general-overuse) (4 items) and degree to which people perceive 
medication is harmful (general-harm) (4 items). Each item is rated on a five-point scale, ranging from 
1 (strongly disagree) to 5 (strongly agree). Satisfactory validity and reliability of this questionnaire 
has been demonstrated previously. Cronbach’s alpha for internal consistency and test-retest reliability 
of the scales was reported within accepted limits (Horne, Weinman & Hankins, 1999).  
 
To score the BMQ, responses on the scales are summed to give a scale score. Higher scores indicate 
greater beliefs in the concepts of that scale. On the BMQ-specific section, items 1, 3, 4, 7 and 10 
relate to the specific-necessity scale, and items 2, 5, 6, 8 and 9 relate to the specific-concerns scale. As 
each of these scales has 5 items, total scores range from 5 to 25. On the BMQ-General section, items 
11, 14, 17 and 18 relate to the general-overuse scale, and items 12, 13, 15 and 16 relate to the general-
harm subscale. As each of these scales has 4 items, total scores range from 4 to 20.  
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Much previous literature across a number of different chronic illness settings has shown associations 
between beliefs about medicines and adherence (Horne & Weinman, 1999), including stroke 
(Sjolander, Erikkson & Glader, 2013) diabetes and rheumatoid arthritis (Wei et al., 2017) and heart 
disease (Dias, Pereira, Monteiro & Santos, 2014). The relationship between beliefs about medicines 
and adherence has been somewhat explored within the kidney transplant population showing 
perceived necessity of medications to be high and concerns low (Lennerling & Forsberg, 2012; 
Massey et al., 2013). Perceptions of necessity have been shown to decease over time (Massey et al., 
2013). Additionally, one study has explored beliefs about medicines in both dialysis and kidney 
transplant recipients (Drangsholt et al., 2019). However, much of this previous research has been 
within European samples. Therefore, within this programme of research it was considered important 
to explore this relationship further within a UK sample of kidney transplant recipients, recognising 
that healthcare and cultural context may have some role to play on how patients shape their beliefs 
about medicines over assuming that patterns are similar across different settings.  
 
Brief Illness Perceptions Questionnaire (Brief IPQ) 
The brief illness perceptions questionnaire (Broadbent, Petrie, Main & Weinman, 2006) was used to 
assess patients’ illness perceptions to renal transplantation. The wordings of the items were adapted to 
fit the context of renal transplantation. The brief IPQ is a nine-item questionnaire designed to measure 
patients cognitive and emotional representations of their illness. The psychometric properties of the 
scale were evaluated across six chronic illness groups, including renal disease. The items were created 
by forming one question that represented each sub-scale of the revised Illness perceptions 
questionnaire (IPQ-R) (Moss-Morris et al., 2002). The brief IPQ has eight items and one item that 
was part of the causal scale used in the IPQ-R. The eight items are rated using a 0 to 10 response 
scale. The first five items assess cognitive illness representations: consequences (item 1), timeline 
(item 2), personal control (item 3), treatment control (item 4) and identity (item 5). Two items assess 
emotional representations: concern (item 6) and emotions (item 8). One item assesses coherence (item 
7). The causal representation (item 9) is an open-ended question, which asks the patient to list three 
causal factors in their illness (the ones they consider most important). The final open-ended question 
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was adapted to “perceived causes of kidney disease/ graft rejection”. Pearson correlations found the 
items to have good test-retest reliability, and the results also demonstrated good predictive and 
concurrent validity (Broadbent, Petrie, Main & Weinman, 2006). A subset of patients were asked to 
complete the Brief IPQ and the IPQ-R and found that both correlate highly showing that the brief 
version is equally tapping into the same constructs as the full. 
 
It is possible in some circumstances to compute an overall score representing the degree to which the 
illness is perceived as threatening or benign. Internal consistency of this score should be checked and 
is dependent on the illness studied. Computing the score requires reverse scoring items 3, 4 and 7 and 
adding these to items 1, 2, 5, 6 and 8, with a higher score indicating that the illness is perceived as 
more threatening (Broadbent, Petrie, Main & Weinman, 2006). This allows exploration of illness 
perceptions as a whole when analysing as well as or as an alternative to exploring individual illness 
perception constructs. 
 
Illness perceptions have been widely explored in the literature across a number of different long term 
conditions, including renal settings within dialysis and kidney transplantation. However, much of the 
literature has focused on the role and importance of illness perceptions in HD patients (Chilcot, 2012), 
with less exploring the role of illness perceptions in kidney transplantation. Additionally, there is 
limited existing literature exploring the relationship between adherence and illness perceptions within 
kidney transplant recipients. Therefore, as research indicates that a multitude of factors can contribute 
to (non)adherent behaviour, it was considered important to explore this within a UK sample for this 
programme of research. 
 
Open-ended questions 
Open-ended questions included within questionnaires allow participants to provide more detailed 
responses, including information, attitudes, feelings and understanding on a topic area. This can allow 
the researchers to gain a better understanding of the participant’s true feelings on a topic issue, and 
can be of notable use when most questionnaires use closed questions with, for example, Likert scale 
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responses. Five open-ended questions were included for patients to provide detailed written responses 
relating to adherence to treatment. A summary of the open-ended questions that were included is 
provided in chapter seven of this thesis. The questions themselves were analysed using thematic 
content analysis (as described by Braun & Clarke, 2006) to assess for common themes across the 
written responses. Further explanation of the questionnaire study and a summary of the study findings 
are provided in chapter seven of this thesis.  
 
Research questions 
The questionnaire was used to address the following research questions:  
1. Is self-reported adherence associated with markers of adherence obtained from clinical data? 
2. Are illness perceptions associated with self-reported adherence to immunosuppressants? 
3. Are medication beliefs associated with self-reported adherence to immunosuppressants? 
4. How do patients conceptualise their post-transplant treatment? 
 
3.4 Statistical Analysis 
Statistical analysis for the retrospective and questionnaire studies were conducted in SPSS version 25 
and in Open Meta-Analyst for the systematic review and meta-analysis. For all quantitative studies, 
descriptive data was first analysed alongside patterns of normality in the data. Each individual study 
details the precise analyses that were undertaken to address the research questions being considered. 
In the main, the thesis draws on descriptive statistics and multiple regression techniques as analyses 
for describing trends in behaviour, highlighting associations between variables, and predicting 
behaviour.  
 
3.5 Statement of contribution 
All studies that form this thesis were conceptualised and designed collaboratively by the PhD student 
(AH) and supervisory team. The PhD student (AH) completed: all University and NHS ethics 
documentation and applications to gain study ethical approvals, data collection and analysis for all 




This body of work aims to make a broad contribution to the understanding of adherence in kidney 
transplant recipients. The individual studies that comprise the thesis have specific questions that are 
best addressed using diverse methods ranging from a systematic review, qualitative analysis, to 
quantitative data gathered through both retrospective and live data collection techniques. In doing so, 
the value of mixed-methods research is highlighted as a useful approach at a time when healthcare 
delivery and complexity is ever increasing. The mixed-methods nature of the research alongside 
breadth of quantitative techniques used to map patterns in patient behaviour yields useful insights. 
These could make a novel and pragmatic contribution to driving clinical understanding of adherence 




























Chapter 4: Non-adherence to immunosuppressants following 
renal transplantation: A systematic review and meta-analysis 
 
 
4.1 Introduction  
Non-adherence to immunosuppressive medication is as a major risk factor for poor clinical outcomes 
post-transplantation. However, it remains a common issue in this patient population, identified as the 
second most common cause of late graft failure (Loghman-Adham, 2003). As with all medications, 
patients can experience side effects that are problematic (National Kidney Foundation, 2015). This 
can include an increased risk of infection, diabetes, and increased susceptibility to certain types of 
cancers, increased blood pressure and weight gain (National Kidney Foundation, 2016). It is also true 
that the process of immunosuppression itself may add to the burden of co-morbidity (Silkensen, 
2000). Despite the nuances of medication, adherence to the immunosuppressive regimen is vital to 
provide the kidney with the best chance of survival and function following transplantation.  
 
A previous review estimated the prevalence of non-adherence in renal transplant recipients at 2-67%, 
dependent on measurement method used (Denhaerynck et al., 2005). In a meta-analysis, the odds of 
graft failure were seven times greater in non-adherent patients compared to adherent patients (Butler 
et al., 2004). Factors identified as determinants of non-adherence post-transplant were consistent with 
more recent literature, such as younger age, being unmarried and perceiving low social support 
(Denraeynck et al., 2005; 2007), as well as high emotional distress and high transplant related stress 
(Jindal et al., 2003). In addition to this, having a donor graft from a living relative has also been 
identified as a risk factor for non-adherence (Denhaerynck et al., 2007). This perhaps seems counter-
intuitive, as you might expect patients receiving transplants from living-related donors to feel greater 
motivation and responsibility to look after the transplant and likely receive more pressure from e.g. 
family members to be adherent to treatment. Furthermore, ill health resulting from non-adherence is 
costly for the NHS, since dialysis services are considerably more expensive than those required to 
support a functioning transplant (Jindal et al., 2003). Moreover, a prerequisite for optimal adherence 
is access to medication where in localities such as the United States, as patients do not benefit from 
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insurance coverage to support access to immunosuppressive medication, they are at greater risk of 
graft failure due to non-adherence driven by financial barriers  (Gill & Tonelli, 2012). 
 
There are a number of reasons as to why patients may not adhere to their immunosuppressant 
regimen, some of which have already been touched on above. It is important to mention that non-
adherence can be unintentional or intentional. Unintentional non-adherence is significantly more 
common than intentional non-adherence (Griva et al., 2012), and most often occurs when patients find 
themselves outside of their normal daily routine. In contrast, intentional non-adherence occurs when 
patients have concerns about their medication regime. Psychological distress, notably anxiety, 
hostility and depression, have been identified as having an impact on medication adherence (Achille 
et al., 2006), with depression also being associated with higher intentional non-adherence (Griva et 
al., 2012). In addition, non-adherent patients have a greater symptom burden, higher distress levels 
(Lee et al., 2015), and report higher frequency of stress (Brito et al., 2015). Hence renal transplant 
recipients may require a range of support to help them maintain a lifestyle associated with their health 
status. A recent systematic review evaluated interventions to improve medication adherence in adult 
renal transplant patients (Low et al., 2014), suggesting that those targeting behavioural risk factors or 
multidimensional interventions (Chisholm et al., 2001; Chisholm-Burns et al., 2013) combining 
educational, behavioural and emotional factors are more likely to be effective in improving non-
adherence to medication. 
 
Clearly the consequences of non-adherence are far reaching for patients in terms of reduced health 
related quality of life and survival. Added to this is significant cost burden related to increased care 
needs (Gill & Tonelli, 2012). It is vital therefore that the clinical community has access to the most 
up-to-date evidence to help guide efforts at supporting patients. There are two core reviews available, 
published in 2003 (Jindal et al., 2003) and 2004 (Butler et al., 2004), which aim to highlight the extent 
of non-adherence in this patient group. Additionally, a more recent review published in 2017 
(Belaiche et al., 2017) explored factors relevant to medication non-adherence, however, search dates 
were limited between January 2009 to December 2014 to account for the most recent literature at the 
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time of the search. It is fair to say that progressive recognition of non-adherence in the renal care 
setting has resulted in a larger evidence base. A synthesis of the full body of existing research in the 
area would therefore be welcome to further guide clinical practice and to inform the nature of 
intervention.  
 
In light of this, the systematic review and meta-analysis provides the most comprehensive evidence 
synthesis of what is known about non-adherence in adult renal transplant recipients. The review:  
• Summarises the methods used to assess non-adherence and discusses how non-adherence is 
operationalized across studies.  
• Identifies the prevalence of non-adherence by pooling data from across studies and considers 
whether reported non-adherence varies as a function of measurement source.  
• Provides a narrative summary of the main factors associated with non-adherence.  
 
4.2 Methods and Design 
The systematic review has been written using the PRISMA guidelines (Preferred Reporting Items for 
Systematic Reviews and Meta-analyses) (Liberati et al., 2009) and was registered on the PROSPERO 
database (registration number: CRD42016038751). Study eligibility criteria are highlighted below.  
 
4.2.1 Types of Studies 
The review included published peer reviewed studies and grey literature in the English language. A 
language based criterion was used due to the resources required to manage data published in different 
languages. All quantitative studies that examined non-adherence to immunosuppressant’s in renal 
transplant patients were included (cross-sectional, cohort and case series studies were included). All 
studies included a measure of non-adherence as a primary outcome. Randomised controlled trials 




The review included patients aged 18 years and over who had received a solid organ kidney 
transplant. Participants were included irrespective of graft function (functioning or failed) at the time 
of entry into the study. Children and adolescents were excluded from the review as evidence suggests 
that different challenges contribute to non-adherence in this group (Dobbels et al., 2010).  
 
4.2.3 Outcomes 
Primary Outcomes:  
Studies were included if one of the outcomes was the degree of non-adherence to 
immunosuppressants. It was anticipated that this would be measured in a number of ways across 
studies including self-report, electronic monitoring of pill bottles and observations to name some 
examples.  
 
Secondary Outcomes:  
For the studies that met the primary inclusion criteria, the following outcomes were also assessed if 
sufficient information was available: whether non-adherence was intentional or unintentional 
(forgetting), risk factors for non-adherence, for example, age, time since transplantation, 
comorbidities, psychological correlates of non-adherence (e.g. depression, illness perceptions), and 
clinical outcomes such as graft failure, graft survival and mortality. 
 
4.2.4 Information Sources 
Searches included the following electronic databases: PubMed, Scopus, CINAHL, The Cochrane 
library, PsychARTICLES, and Google scholar. There were no date limits on the searches in all 
databases, and databases were searched until December 2017. In addition, lateral search techniques 
were utilized, such as checking reference lists for related articles and using Google scholar to conduct 
key word and citation searches.  
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4.2.5 Search Strategy  
A combination of free text terms and medical subject headings (MeSH) were used in all databases. 
The search strategy used in PubMed is included in table 4.1. This was adapted accordingly to the 
subject headings of the remaining databases. Only free text terms were used in Scopus, as MeSH 
terms were not an option. Search terms within concepts were combined using “OR”. The three search 
concepts were combined using “AND”.  
 
Table 4.1: Search strategy for systematic review of quantitative studies assessing levels of adherence 
in adult renal transplant recipients 
 
Concept 1 – Population Concept 2 – Adherence (Outcome) Concept 3 - 
Immunosuppression 
kidney transplantation (MeSH) adherence, medication (MeSH) immunosuppression 
(MeSH) 
“kidney transplant*” (free-text 
term) 
 




non-adherence (free-text term)  
 noncompliance (free-text term) 
 
 
 compliance (free-text term) 
 
 
 “treatment refusal” (free-text term) 
 
 

















 concordan* (free-text term)  
(free-text term) = free-text term/text word 
(MeSH) = medical expert subject heading 
* = Truncated terms 
 
4.2.6 Study screening and selection process 
Citations from all database searches were imported into Endnote V7 reference management software. 
A check was run to identify, note and remove any duplicate citations. Retrieved records were 
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screened by title and abstract by two reviewers independently in order to assess suitability for 
inclusion. The second reviewer was an UG researcher who was trained in how to assess studies for the 
review. Any disagreements were resolved by discussion or consultation with a third reviewer (a 
member of the supervisory team). Full texts of potentially relevant citations were independently 
assessed for inclusion in the review using a piloted screening proforma. The second reviewer 
independently screened 25% of the titles and abstracts and full texts for quality assurance. Figure 4.1 


























Figure 4.1: PRISMA flow chart displaying systematic review screening process. 
Records identified through 
database searching  























n Additional records identified 
through other sources  
(n = 0) 
Records after duplicates removed  
(n = 5741) 
Records screened  
(n = 5741) 
Records excluded  
(n = 5495) 
Full-text articles 
assessed for eligibility  
(n = 246) 
Full-text articles 
excluded 
(n = 186) 
Studies included in 
narrative synthesis  
(n = 60) 
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4.2.7 Data collection process 
A pre-piloted form was used to extract the relevant information from each study to be included in the 
review. The form was created in Microsoft excel. One reviewer (AH) independently extracted the 
relevant information from the full text papers into the data extraction table. The second reviewer 
independently extracted relevant information from 25% of the full text papers. This was pilot tested 
on a few studies prior to the review to ensure consistency between the two reviewers, and to ensure 
the correct information was included. The use of two reviewers for data extraction was used to reduce 
the risk of error. Any disagreement was resolved by discussion with a third reviewer.   
 
4.2.8 Data items 
Data was extracted using the following categories, if available:  
• General information: study title, author and year of publication, country of origin, 
• Study methods/ characteristics: study design (including how adherence was defined and 
measured), study aims and research questions, inclusion/ exclusion criteria, sampling 
methods, 
• Demographics about the participants (age, sex, ethnicity, socio-economic characteristics), 
• Number of non-adherent patients, 
• Outcomes of the study, correlates and any other clinical measures (such as graft survival, 
number of graft failures (assessed as caused by non-adherence) and mortality/ survival). 
 
4.2.9 Outcomes and prioritisation 
The primary outcome was the degree of non-adherence to immunosuppressants. For studies that met 
the primary inclusion criteria, the following outcomes were also assessed if available: whether non-
adherence was intentional or unintentional (e.g. forgetting), which was most often reported via self-
report; psychological correlates such as depression or anxiety (measured using any validated scale); 
illness perceptions; clinical outcomes (e.g. graft rejection, graft failure and mortality).  
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4.2.10 Risk of bias in individual studies 
Studies were rated for quality assurance using the Downs and Black (Downs & Black, 1998) checklist 
for non-randomised studies, case-control, cross-sectional and cohort studies. This consists of five 
domains: study quality, external validity, study bias, confounding and selection bias and study power. 
Since the studies included in this review did not examine the effectiveness of health care 
interventions, all items on the checklist that related to interventions or comparative groups (e.g. 
blinding, randomisation) were not used. One reviewer rated all the studies, and a second reviewer 
independently rated 25% of the studies chosen at random. Any discrepancies between reviewers was 
resolved by discussion with a third reviewer.   
 
4.2.11 Data synthesis 
A narrative synthesis was used to summarise the studies relevant for inclusion and the different 
methods of measuring adherence. In addition, we investigated how studies define non-adherence, 
whether this was consistent across studies, and factors associated with non-adherence.  
 
Meta-analysis was used to pool together study outcomes to assess prevalence of non-adherence rates 
across studies. Heterogeneity was assessed using the I2 test (Higgins & Thompson, 2002). An I2 value 
of 25% is categorised as low, 50% moderate and 75% high (Higgins et al., 2003). The analysis was 
conducted using Open Meta-Analyst. As the review included observational studies, random effects 
meta-analysis was used to account for studies varying due to differences in patient populations.  
 
4.3 Results 
A narrative review will be used to summarise the findings from the sixty studies included within the 
review. Only factors significantly associated with non-adherence have been reported. In addition, a 
one-group meta-analysis will be used to estimate the pooled prevalence of non-adherence across 
studies using self-report measures only. Further meta-analysis and meta-regression could not be 
performed due to heterogeneity in methods of non-adherence assessment and reported outcomes 
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across studies. Study outcomes and statistical analysis varied, from studies reporting no statistical 
analysis while others univariate or multivariate associations, or both.  
 
4.3.1 Narrative synthesis 
Summary of studies 
A total of 6,864 citations were identified through database searching. Following removal of 
duplicates, 5,741 were screened by title and abstract leading to 5,495 removed due to not meeting the 
inclusion criteria. The full texts of 246 articles were assessed for eligibility, with 186 excluded. Sixty 
studies published between 1997 and 2017 were included within the final review (see Table 4.2).  
 
Study characteristics 
The included studies were conducted in a range of countries, with the majority conducted in North 
America (N=26, 43.3%) and Europe (N=24, 40%). The most studies were conducted in the USA 
(N=24, 40%). Only three studies included in this review were conducted in the UK. Across the 60 
studies, study sample sizes ranged from 18 to 31,913. The two studies with the largest sample sizes 
included 17,181 (Chisolm et al., 2016) and 31,913 (Spivey et al., 2014), however, both of these 
studies involved analysis of pharmacy refill data via medication possession ratio. The remaining 58 
studies sample sizes ranged from 18 to 3676.  
 
The majority of studies were cross-sectional in design (N=36, 60%). A smaller number of 
observational (N=14, 23.3%) and longitudinal (N=8, 13.3%) studies were included. The majority of 
studies had more males than females, with percentage of males ranging from 45% (Russell et al., 
2006) to 83.3% (Chisolm et al., 2000). Only seven studies had more females than males (Greenstein 
& Siegal, 1998; Feldman et al., 1999; Siegel & Greenstein, 1999; Siegal et al., 2002; Russell et al., 
2006; Chisolm-Burns et al., 2010; Weng et al., 2017). Between April 2018 and March 2019, across all 
transplant centres in the UK more males (53% to 73%) received a kidney transplant than females 
(27% to 47%) (NHS Blood & Transplant, 2019). The majority of studies included in this review 
therefore seem to represent the true difference in rate of transplants between males and females. 
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Measurement methods  
Adherence was assessed via a variety of methods including self-report, electronic monitoring, blood 
levels, physician rating and prescription refill. The most commonly used measure across studies was 
self-report, with 43 (71.7%) studies using a self-report measure. Electronic monitoring was used in 12 
(20%) studies, pharmacy refill in eight (13.3%) studies and blood levels in nine (15%) studies. 
Physician rating/collateral report was the least commonly used measurement method used in seven 
(11.7%) studies. One study used an investigator rating (see Table 4.2). Twelve (20%) studies 
measured adherence through an association of methods (Butler et al., 2004; Chisolm et al., 2005; 
Rosenberger et al., 2005; Schafer-Keller et al., 2008; Gelb et al., 2010; Schmid-Mohler et al., 2010; 
Griva et al., 2012; Ortega et al., 2013; Marsciano et al., 2015; Pabst et al., 2015; Silva et al., 2016; 
Lehner et al., 2017). Authors often provided a prevalence rate for each of the individual measurement 
methods used as well as a composite score (combination of all measures utilised).  
 
The most commonly used self-report measure was the Basel Assessment of Adherence with 
Immunosuppressive Medication Scales (BAASIS) used in 13 (21.7%) studies (Schmid-Mohler et al., 
2010; Lennerling & Forsberg, 2012; Massey et al., 2013; Burkhalter et al., 2014; Tielen et al., 2014; 
Marsciano et al., 2015; Massey et al., 2015, Massey et al., 2015; Pabst et al., 2015; Reber et al., 2016; 
Silva et al., 2016; Lehner et al., 2017; Scheel et al., 2017). This was closely followed by the 
Immunosuppressant Therapy Adherence Scale (ITAS) used in ten (16.7%) studies (Chisolm et al., 
2005; Chisolm-Burns et al., 2010; Chisolm-Burns et al., 2012; Cheng et al., 2012; Gorevski et al., 
2013; Weng et al., 2013; Hamedan & Aliha, 2014; Tsapepas et al., 2014; de Fatima et al., 2016; Little 
et al., 2016). Less commonly used measures included the Morisky Medication Adherence Scale 
(MMAS) used in five (8.3%) studies (Butler et al., 2004; Goldfarb-Rumyantzev et al., 2011; Couzi et 
al., 2013; Liu et al., 2015; Adhiraki et al., 2016), the Transplant Effects Questionnaire (TxEQ) used in 
three (5%) studies (Gelb et al., 2010; Pabst et al., 2015; Demian et al., 2016), the Medication 
Adherence Report Scale (MARS) used in two (3.3%) studies (Butler et al., 2004; Griva et al., 2012), 
and the Simplified Medication Adherence Questionnaire (SMAQ) used in one (1.7%) study (Lalic et 
al., 2014). Other self-report measures were utilised in 11 (18.3%) studies (Siegal & Greenstein, 1997; 
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Greenstein & Siegal, 1998; Siegal et al., 2002; Rosenberger et al., 2005; Gremigni et al., 2007; 
Schafer-Keller et al., 2008; Tielen et al., 2011; Morales et al., 2012; Calia et al., 2015; Teng et al., 
2015; Weng et al., 2017).  
 
Studies using pharmacy refill and electronic monitoring were less clear in how they defined non-
adherence, or only reported adherence. In some studies, using pharmacy refill data, patients with 
<80% refill were characterised as non-adherent (Chisolm et al., 2000; Chisolm et al., 2005; Chisolm 
et al., 2007; Chisolm et al., 2016). Similarly, with electronic monitoring, different reporting was used 
to report adherence or non-adherence. Some studies reported the percentage of openings e.g. >85-
100%, 50-85%, <50% (Weng et al., 2005; Israni et al., 2011), whilst others similarly reported 
medication adherence scores above/below 0.90 or 0.80 (Russell et al., 2006; Russell et al., 2009; 
Russell et al., 2010; Russell et al., 2013). One study reported that those missing at least 20% of days 
medication were determined as non-adherent participants (Butler et al., 2004), whilst another reported 
using an algorithm to yield a non-adherence prevalence rate (Schafer-Keller et al., 2008).  
 
Prevalence of non-adherence 
The prevalence of non-adherence was dependent on the measurement method used. Non-adherence 
ranged from 0.06% to 89.2%. Non-adherence ranged from 7.4% to 89.2% in studies using self-report 
measures, and from 1.6% to 86% in studies using Electronic monitoring. Slightly narrower ranges 
were identified in studies using immunosuppressant blood levels (7% to 49%), pharmacy refill data 
(5% to 58%) and physician ratings (0.9% to 41%). 
 
Factors associated with non-adherence 
Studies that identified factors associated with non-adherence are summarised below. The remaining 
studies either did not explore or assess the factors or identified them as not significantly associated. 
 
Gender - Eight (13.3%) studies associated male gender with non-adherence (Denhaerynck et al., 
2007; Griva et al., 2012; Hamedan & Aliha, 2014; Burkhalter et al., 2014; Spivey et al., 2014; Liu et 
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al., 2015; Chisolm et al., 2016; Demian et al., 2016; Weng et al., 2017). These studies mostly used 
self-report measures to assess adherence rates. Only three (5%) studies associated female gender with 
non-adherence (Chisolm et al., 2005; Pabst et al., 2015; Lehner et al., 2017). All studies used a self-
report measure alongside other measures of adherence, including blood levels, physician ratings and 
prescription refill records.  
 
Age - Younger age was associated with non-adherence in seventeen (28.3%) of the included studies 
(Siegal & Greenstein, 1997; Greenstein & Siegal, 1998; Denhaerynck et al., 2007; Gremigni et al., 
2007; Gelb et al., 2010; Goldfarb-Rumyantzev et al., 2011; Chisolm-Burns, 2012; Griva et al., 2012; 
Couzi et al., 2013; Massey et al., 2013; Russell et al., 2013; Burkhalter et al., 2014; Hamedan & 
Aliha, 2014; Spivey et al., 2014; Massey et al., 2015; Demian et al., 2016; Lehner et al., 2017). 
However, three (5%) studies identified older age as a predictor of non-adherence (Chisolm et al., 
2005; Chisolm-Burns et al., 2008; Chisolm et al., 2016). 
 
Education and employment - Lower education levels were associated with non-adherence in two 
(3.3%) studies (Griva et al., 2012; Weng et al., 2017). In comparison, one (1.7%) study identified 
higher education level as associated with non-adherence (Greenstein & Siegal, 1998). More studies 
commented on employment and income. Five (8.3%) studies associated full time/part-time 
employment with non-adherence (Greenstein & Siegal, 1998; Goldfarb-Rumyantzev et al., 2011; 
Griva et al., 2012; Massey et al., 2015; Demian et al., 2016) with one (1.7%) study further specifying 
white collar occupation (Greenstein & Siegal, 1998). In relation to income, low household income 
was associated with non-adherence in three (5%) studies (Weng et al., 2013; Marsciano et al., 2015; 
Weng et al., 2017) with one (1.7%) study also specifying lack of employment (Weng et al., 2013). 
Higher income was only associated in one (1.7%) study (Chisolm et al., 2005). 
   
Transplant vintage – Eight (13.3%) studies associated greater transplant vintage with non-adherence 
(Siegal & Greenstein, 1997; Greenstein & Siegal, 1998; Chisolm et al., 2005; Chisolm-Burns et al., 
2008; Griva et al., 2012; Burkhalter et al., 2014; Hamedan & Aliha, 2014; Weng et al., 2017) 
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suggesting patients who have been transplanted for longer are more likely to be/become non-adherent 
over time. However, the time it takes to become non-adherent post-transplant is not clearly specified. 
Conversely, two (3.3%) studies associated non-adherence with shorter transplant vintage (Tielen et 
al., 2014; Liu et al., 2015) with one (1.7%) study specifying a lower two-year graft survival (Tielen et 
al., 2014). 
 
Donor type - Receiving a transplant from a living donor was associated with non-adherence in seven 
(11.7%) studies (Butler et al., 2004; Denhaerynck et al., 2007; Goldfarb-Rumyantzev et al., 2011; 
Griva et al., 2012; Spivey et al., 2014; de Fatima et al., 2016; Lehner et al., 2017). Two of the seven 
studies specify this as a living related donor graft (Denaherynck et al., 2007; Griva et al., 2012), 
however although this is not specified in the remaining five studies, living related donations are more 
common than unrelated donations (altruistic donors).  
 
Medication related factors - Side effects were associated with non-adherence in three (5%) studies 
(Siegal & Greenstein, 1997; Rosenberger et al., 2005; Cheng et al., 2012) and with feeling worse in 
one study (Lalic et al., 2014). Type of immunosuppressant taken was associated with non-adherence 
in four (6.7%) studies. Taking the immunosuppressant tacrolimus was identified in one study 
(Chisolm et al., 2005) whereas taking the immunosuppressant cyclosporine was identified in two 
studies (Chisolm et al., 2005; Denaherynck et al., 2007). Additionally, not taking tacrolimus was 
associated with non-adherence in one study (Spivey et al., 2014). Furthermore, experience of rejection 
(Chisolm et al., 2005) and adverse events (Couzi et al., 2013) were also associated in two (3.3%) 
studies. 
 
Issues with taking and timing of medication (Massey et al., 2013) and having to take 
immunosuppressants too many times per day and having too many tablets to take at one time 
(Morales et al., 2012) were associated with non-adherence. Additionally, two (3.3%) studies 
identified treatment regimen inconvenience (Ortega et al., 2014) and interruption to daily routine 
(Schmid-Mohler et al., 2010) as associated with non-adherence. Forgetfulness was associated with 
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non-adherence in eight (13.3%) studies (Siegal & Greenstein, 1997; Butler et al., 2004; Russell et al., 
2009; Chisolm-Burns et al., 2010; Schmid-Mohler et al., 2010; Chisolm-Burns et al., 2012; Couzi et 
al., 2013; Lalic et al., 2014). Forgetting to take medication can often occur when patients find 
themselves outside of their normal routine. 
 
Psychological factors - Experience of psychological distress was related to non-adherence. 
Depression was associated with non-adherence in eight (13.3%) studies (Gelb et al., 2010; Griva et 
al., 2012; Gorevski et al., 2013; Weng et al., 2013; Burkhalter et al., 2014; Pabst et al., 2015; Reber et 
al., 2016; Little et al., 2017) and one (1.7%) study associated it with ongoing feelings of sadness 
(Siegal & Greenstein 1997). Anxiety was associated with non-adherence in two (3.3%) studies (Pabst 
et al., 2015; Reber et al., 2016), increased stress in one (1.7%) study (Weng et al., 2013) and symptom 
distress in three (5%) studies (Rosenberger et al., 2005; Denaherynck et al., 2007; Teng et al., 2015). 
Additionally, lower self-efficacy was associated with non-adherence in three (5%) studies 
(Denaherynck et al., 2007; Russell et al., 2013; Silva et al., 2016) and lower quality of life in one 
(1.7%) study (Hamedan & Aliha, 2014). 
 
Patient beliefs 
Beliefs, attitudes and concerns have been reported as factors associated with non-adherence. Low 
beliefs in the need for immunosuppressants were associated in three (5%) studies (Greenstein & 
Siegal, 1998; Butler et al., 2004; Griva et al., 2012). Two (3.3%) studies suggested perceiving 
immunosuppressants disruptive or having a negative impact on daily life is associated with non-
adherence (Gremigni et al., 2007; Chisolm et al., 2012). Additionally, those who perceived low social 
support were more likely to be non-adherent. This was identified in three (5%) studies (Rosenberger 
et al., 2005; Chisolm et al., 2010; Pabst et al., 2015). Furthermore, greater experience of barriers 
(Chisolm et al., 2012; Weng et al., 2013) and concerns about the treatment regimen (Griva et al., 
2012; Weng et al., 2017) were associated with non-adherence. Perceptions of less autonomy in 
treatment management (Gremigni et al., 2007) and less control over taking immunosuppressants 
(Chisolm et al., 2007) were also associated. 
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Table 4.2: Summary characteristics of included studies 
Authors 
Country of 






(years) Men (%) NA rates % (N) Factors associated with NA 




















scale 0-100 926 
59.7 median 
(IQR 50.26-
67.77) 63% 35% 
Younger age, male gender, 














monitoring 58 48.0 (13.0) 66% 
12% (7) missed at least 20% of 
days medication 
Living donor transplant, low 




























EM 12% (n=7); 37% MARS; 
33% MMAS; Cyclosporine 
levels (range of the last six 



























(ITAS) 412 51.5 (12.0) 52.90% 21.4% (88) 




Chisholm et al., 








adherent) 18 48.1 (9.3) 83.30% 
At 5 months 5% NA each 
month, at 7 months 25%, at 12 




















sample 65) 52.52 (14.02) 64% 
35% (48) ITAS; (sub-sample 
ITAS 23%, refill records 37%) 
Older age, female, tacrolimus 
immunosuppressant, higher 
income, poor refill record, 
further since transplantation, 








Chisholm et al., 






adherent) 33 50.4 (8.8) 72.70% 
12% ciclosporin and 5% 
tacrolimus. At 12 months post-









Chisholm et al., 









70) 51.0 (12.4) 60.10% 27% of subsample 
Less favourable attitudes, 
less control over taking 
immunosuppressants, weaker 






















adherent) 17181 50.2 (14.3) 59.1%% 
16.8% MPR <.80. At 12 
months mean MPR 0.91 (0.17) 
Male gender, not medication 
therapy management eligible, 
taking fewer prescription 
drugs, older age 
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(ITAS) 61 48.85 (11.44) 47.50% 
Mean score 11.1 (2.0) (Total 
score 12 - higher score indicates 
high adherence) 













(ITAS) 512 52.37 (10.74) 60.27%) 
34.5% (177). Average ITAS 
score 11.27 (SD =1.15) 
Forgetting, greater 
experience of barriers, 
younger age, perceiving 
immunosuppressants 










(MMAS) 312 49.5 (13.2) 68.30% 
increase in NA over time: 
17.3% (Month3), 24.1% (M6), 
30.7% (M12), and 34.6% 
(M24)  
Forgetting, younger age, 









(ITAS) 151 40.33 (11.7) 51.7%% 60.3% (91) 
Living donor transplant, 







Demian et al., (2016) Canada Observational 
Self-report 
(TxEQ) 96 52.77 (12.56) 56.20% 
TxEQ M = 20.89 (SD = 3.77), 
75% (74) score indicating less 
than ‘perfect’ self-reported 
adherence 
Younger age, male gender, 
higher levels of employment, 












monitoring 249 53.6 (12.7) 56.60% 
Taking 1.6%, dosing 3.8, 
timing 8.1%. Mean number of 
drug holidays per 100 
monitored days was 1.1 days 
(SD=3.2). 
Younger age, male gender, 
low self-efficacy, high self-
reported NA, busy lifestyle, 
living related donor, 
symptom distress 
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Taking NA overall 0.06%; 










Feldman et al., 
(1999) USA Observational 
Electronic 
monitoring 25 47.9 (11.6) 48% 
 
 
On average 6.8% of 
cyclosporine doses, 9.8% of 















levels 103 50.07 (12.38) 52.4 
Mean self-reported adherence 
score 20.8 (SD = 3.60); serum 
concentrations 15.5% (16) NA; 
refill 5.98% NA 
Younger age, depressive 
symptoms, poorer everyday 





Rumyantzev et al., 
(2011) USA Observational 
Self-report 
(MMAS) 199 43 (14.2) 67% 
Taking NA 21%, timing NA 
33% 
Younger age, greater 
comorbidity, having a living 










(ITAS) 86 50.3 (12.4) 67% 43% (37) 

















Likert scale 1402 46.6 (12.5) 49.40% 22.4% (314) 
Younger age, greater 
transplant vintage, higher 
education level, employed, 
white collar occupation, 
living related donor 
transplant, history of 









items 34 48.0 (12.0) 61.80% 
forgetting 24%, taking exactly 
as prescribed 24% 
Younger age, perceptions of 
less autonomy in treatment 
management and higher 
negative impact of 
medication in daily life, 




















blood levels 218 49.67 (12.28) 59.60% 
51.4% (112) admitted less than 
perfect adherence (≤23 MARS-
Total); 25.4% (52) NA by 
blood levels 
Forgetting, concerns about 
treatment regimen, younger 
age, male gender, lower 
education, employment, 
cohabiting/marital 
relationships, low belief in 
necessity of medication, high 
medication concerns, shorter 
dialysis vintage, depression, 
living related donor graft, 
low ESRD severity index, 











(ITAS) 230 41.69 (12.17) 55.20% 57.8% 
Low quality of life, younger 








Israni et al., (2011) USA Cohort 
Electronic 
monitoring 243 47.7 (11.9) 63% 
At 6 months: 68% <15% NA, 
20% 15-50% NA, 12% >50% 









(SMAQ) 60 44.45 (11.37) 63.30% 28.3% (17)  Forgetfulness, feeling worse 
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levels 153 51.1 (12.3) 62.70% 
Composite score: 67.7% (88). 
Self-report: 44.9% (57). 
Investigator rating as "poor": 
1.5% (2). Tacrolimus 
concentration: 49% (75)   
Female gender, aged <50, 

































group 56.40% 31% (12) not perfect adherence 
Higher BDI scores, positive 









(MMAS) 209 41.7 (10.3) 63.2%) 31.3% (65) 
















levels 100 45.0 (13.5) 65% 
Composite score: 51%. Self-
report: 34%; collateral report: 














(range 19-75) 64.60% 
17% (19) at 6 weeks post-
transplant. 27% (29) at 6 
months post-transplant.  
Younger age, re-
transplantation, increase in 






























































































Issues with taking and timing 




(range 19-75) 64.60% 
31% (26) at 18 months follow 
up 
Younger age, being in paid 
employment, low goal 
importance likely to be NA 
over time 
Morales et al., (2012) Spain 
Cross-
sectional Self-report 1983 53.0 (11.9) 60.70% 7.4% NA 
Barriers: having to take 
immunosuppressants too 
many times per day, having 













judgement 207 53.35 (12.8) 61.20% 
Blood levels: 31.1%, physician 
judgement 29.1% 
Low levels of satisfaction, 
















rating 238 53.15 (13.66) 65% 
37.4% (89) BAASIS; TxEQ 
M=4.37 (SD=0.66); 9.2% (22) 
physician rating 
Female gender, non-native 
language speakers, 










(BAASIS) 74 54.1 (12.8) 66.20% 24.3% 
















rating 139 47.7 (11.7) 58.10% 
Self-report: 31.7% (44); 
physician rating: 41% (57); 
Combination of patient self-
report and physician rating: 
54% (75) 
High stress from adverse 
effects of 
immunosuppression, less 
satisfaction with social 
support, fair self-reported 
health, male gender 
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Russell et al., (2006) USA Longitudinal  
Electronic 













monitoring 73 61.37 (5.6) 58% 
Mean medication score for 
patients who perceived MEMS 
had negative/neutral effect on 
medication taking 0.76 (0.13) 
(max 1), patients who perceived 
MEMS had a positive effect 
















monitoring 121 51.12 (12.35) 63% 
61% adherence score <0.90 and 
41% <0.80.  










Schafer-Keller et al., 








levels 249 53.6 (12.7) 56.60% 
EM 17.3%, blood levels 33%, 
self-report 12.4%, collateral 











(BAASIS) 267 52.8 (13.7) 65% 33% (89)  
Rejection associated with 
younger age at 
transplantation and higher 














report 114 53.6 (11.9) 64.90% 
Self-report: 23.7% (27); 3.8% 
(4) collateral report; composite 
score 26.4% (28) 
Forgetfulness, interruption to 
daily routine 
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Siegal & Greenstein 
(1997) USA 
Cross-
sectional Self-report 519 45.0 (13.0) 56% 18% (96) 
Forgetfulness when away 
from home, younger age, 
post-transplant physical 
symptoms: weight gain, 
ongoing feelings of sadness, 





Siegal et al., (2002) USA Cohort 
Self-report 6 
items 3676 Not reported 47.60% 
57% (NA reported at least some 



















score 88 47.2 (12.9) 63.60% 
70.5% (62) NA through at least 
one method. BAASIS 46.6% 
(41) NA; collateral report 
38.6% (34); blood levels 34.1% 
(30) 
Lower self-efficacy, chance 
















refill data) 31913 48.0 (13.7) 58.6%% 
Mean MPR for the sample 0.56 
(0.29) with a median of 0.58 
(risk of graft failure when 
<0.80) 
Younger age, male gender, 
non-white ethnicity, living 










items 231 44.91 (10.75) 60.60% 
89.2% had at least one aspect of 
NA 












4 items) 26 
73 median 










(BAASIS) 113 Not reported 64.60% 16.8% (19) Lower 2 year graft survival 
 101 
Tsapepas et al., 
(2014) USA Longitudinal  
Self-report 











(IQR 39-57) 61.20% 
Average daily percentage 
adherence: >95 to 100% 114 
(41%); >80-90% 90 (32.4%); 
>50-80% 36 (12.9%); 0-50% 38 
(13.7%) 
Black ethnicity, transplant 
centre, renal disease cause, 















62.9) 59.90% 14.3% (36)  
Depression, increased 
perceived stress, lower 
household income, lack of 
employment, greater 











items 145 45.5 (11.8) 45.50% 
Mean score 29.73 (SD 4.01). 
(Total score 35 - higher score 
indicates higher adherence). 
Male gender, low income, 
low education level, greater 













4.3.2 Meta-analysis  
A one group meta-analysis was conducted to estimate the pooled non-adherence prevalence rate 
across studies using self-report measures only. As self-report measures were the most commonly used 
measure used across studies, there was a large number of studies that could be included in the 
analysis. Additionally, most authors using self-report measures provided a prevalence rate (%) for 
those categorised as non-adherent by that measure. Only studies providing a prevalence rate for the 
total measure were included (whereas some studies provided prevalence per question of the measure 
or a mean score on the measure). Where longitudinal studies using self-report measures were 
included, non-adherence prevalence at the final time point was used. Additionally, where studies used 
more than one method of assessment to measure adherence, only the reported non-adherence rate on 
the self-report measure was recorded for the analysis. It was not possible to run an analysis on studies 
using electronic monitoring or prescription refill, as definitions of non-adherence/cut-off points via 
that measure was not always clear (studies reported score or % for refill/medication taking). A 
random effects model was used based on the assumption that studies are likely to differ in ways that 
may impact the results, and the true effect size will likely vary from study to study therefore we 
cannot assume a common effect size (Borenstein et al., 2010).  
 
Of the 60 studies included in the review, 38 were eligible for inclusion, which used the proportion of 
non-adherent patients from each study to give an estimate of the pooled non-adherence prevalence 
rate across studies. The overall pooled estimate was 0.376 (95% CI 0.30 to 0.45, P<.001), meaning 
across studies the pooled prevalence of non-adherence was 37.6%. The studies were heterogeneous, Q 
(37) = 4244.03, P<.001, with an I2 value of 99.13. The forest plot is shown in figure 4.2. 
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Figure 4.2: Forest plot of non-adherence to immunosuppressants prevalence rates 
 
4.3.3 Quality Assessment 
 
All studies included in this review were assessed for quality using the Downs and Black quality 
assessment checklist (Downs & Black, 1998) (see figure 4.3). Generally, the studies were good 
quality, with almost all reporting clear aims, patient characteristics and outcome measures. Studies 
were representative of the renal transplant population. Appropriate analyses were conducted across 
the majority of studies, however, over half of the studies did not report adjusting for confounding 








This systematic review and meta-analysis aimed to assess studies exploring non-adherence to 
immunosuppressants among renal transplant recipients. The aims were to provide a summary of the 
methods used to measure and assess adherence, identify the prevalence rate of non-adherence, 
0 10 20 30 40 50 60
27. Did the study have sufficient power to detect a clinically important effect
where the probability value for a difference being due to chance <5%?
26. Were losses of patients to follow-up taken into account?
25. Was there adequate adjustment for confounding in the analyses from which
the main findings were drawn?
24. Was the randomised intervention assignment concealed from both patients
and health care staff until recruitment was complete and irrevocable?
23. Were study subjects randomised to intervention groups?
22. Were study subjects in different intervention groups (trials and cohort
studies) or were the cases and controls (case-control studies) recruited over the…
21. Were the patients in different intervention groups (trials and cohort studies)
or were the cases and controls (case-control studies) recruited from the same…
20. Were the main outcome measures used accurate (valid and reliable)?
19. Was compliance with the intervention/s reliable?
18. Were the statistical tests used to assess the main outcomes appropriate?
17. In trials and cohort studies, do the analyses adjust for different lengths of
follow-up of patients?
16. If any of the results of the study were based on “data dredging”, was this 
made clear?
15. Was an attempt made to blind those measuring the main outcomes of the
intervention?
14. Was an attempt made to blind study subjects to the intervention they have
received?
13. Were the staff, places, and facilities where the patients were treated,
representative of the treatment the majority of patients receive?
12. Were those subjects who were prepared to participate representative of the
entire population from which they were recruited?
11. Were the subjects asked to participate in the study representative of the entire
population from which they were recruited?
10. Have actual probability values been reported for the main outcomes except
where the probability value is less than 0.001?
9. Have the characteristics of patients lost to follow-up been described?
8. Have all important adverse events that may be a consequence of the
intervention been reported?
7. Does the study provide estimates of the random variability in the data for the
main outcomes?
6. Are the main findings of the study clearly described?
5. Are the distributions of principal confounders in each group of subjects to be
compared clearly described?
4. Are the interventions of interest clearly described?
3. Are the characteristics of the patients included in the study clearly described?
2. Are the main outcomes to be measured clearly described in the Introduction or
Methods section?
1. Is the hypothesis/aim/objective of the study clearly described?
Downs and Black Quality Assessment
Yes No N/A
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identify factors associated with non-adherence including psychological correlates and explore the 
impact of non-adherence on graft failure.  
 
This review highlights a variation of measurement methods used to assess adherence, including self-
report, electronic monitoring, immunosuppressant blood levels, pharmacy refill and physician rating. 
Self-report was most commonly used as a method of measuring adherence across studies. This is 
similar to that of previous literature reviews (Denhaerynck et al., 2005; Belaiche et al., 2017). This is 
likely due to their ease of administration, lack of cost and feasibility in clinical settings (Schafer-
Keller et al., 2008).  
 
Findings highlight a wide non-adherence prevalence rate of studies included, ranging from 0.06% to 
89.2%. This was dependent on the type of measurement method utilised, supporting DiMatteo (2004) 
who indicated measurement method used can impact non-adherence prevalence rates reported. When 
exploring this within each type of measurement method, prevalence rates remained wide in range. 
Self-report ranged from 7.4% to 89.2%. This is likely due to the fact that studies are using different 
self-report measures to assess adherence, each with differing items and scoring systems to classify 
adherent/non-adherent patients. There are a number of questionnaires available to assess adherence, 
some specific to immunosuppressants and some more broad to assess the medication regimen. A clear 
and standard definition of adherence/non-adherence is needed. Additionally, further research is 
needed to explore the reliability of existing self-report measures in terms of their use within the renal 
transplant population. Researchers should be encouraged to utilise reliable and valid self-report 
measures to assess adherence within this patient population, to improve accuracy of prevalence rates 
and allow for clearer comparisons to be made across studies.  
 
Similarly, clearer guidance in defining non-adherence by other measurement methods is also needed. 
Although electronic monitoring provides a more accurate representation of non-adherence (Kreys, 
2016) clarity in how to interpret the data in order to identify and categorise non-adherent patients will 
assist in consolidating outcomes to make comparisons across studies. Some studies have attempted to 
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do this (Butler et al., 2004; Schafer-Keller et al., 2008), however, this is limited and not consistent 
across studies. This is similar for studies using pharmacy refill data, with one author applying the 
same definition of non-adherence across studies conducted (Chisolm et al., 2000; 2005; 2007; 2016), 
however, wider implementation of this across studies is limited. Use of immunosuppressant blood 
levels are accompanied by similar limitations in terms of how to define and categorise non-adherent 
patients. Clearer guidelines on expected immunosuppressant blood levels should be provided for use 
in research in order to identify target ranges. However, it is important to note that target ranges may 
be individualised to a patient, consider patient factors such as transplant vintage or differ based on 
local trust target ranges.  
 
Findings from this review also highlight areas that could be targeted for intervention in order to 
improve adherence rates. Patients that are younger in age were identified as more likely to be non-
adherent, similar to findings in other literature and reviews (Raiz et al., 1999; Denhaerynck et al., 
2005; Belaiche et al., 2017). Adherence has also been shown to increase with age (Chisolm et al., 
2007; Lin et al., 2011). This may be due to a busier lifestyle at a younger age, such as work and 
family life. Additionally, older aged patients may have other health conditions to manage alongside 
their transplant which may engage them more closely with treatment regimens. Other 
sociodemographic characteristics associated with non-adherence included male gender and 
employment status. Similarly to age, patients in full or part-time employment may balance busier 
lifestyles and may be at risk of non-adherence due to this. Encouraging patients to utilise reminders 
such as via mobile phone alarms or use of diaries may avoid unintentional non-adherence, such as 
forgetting.  
 
As patients move further from date of transplantation, likelihood of non-adherence increases. This 
may be due to complacency and forgetting (unintentional adherence) or may be due to patients 
intentionally not taking medication where function has been stable over a long period of time. Often 
non-adherence is unintentional and occurs when patients forget or find themselves outside of their 
daily routine (Griva et al., 2012). Qualitative studies have shown how perception of medication 
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necessity is important for ensuring successful medication taking (Ruppar & Russell, 2009). Patients 
may benefit from education sessions once they reach a certain number of years post-transplant to 
remind them of the necessity of the immunosuppressant medications they are taking to 
encourage/promote continued adherent behaviour. The majority of studies included in the review 
didn’t report or distinguish between intentional and unintentional non-adherence. Greater 
understanding in relation to this breakdown in adherent behaviour may be captured via qualitative 
work, which wasn’t in the scope of this review.  
 
Some studies included in the review identified an association between donor type and adherence, with 
patients receiving a living donor graft to be more at risk of non-adherence. Denhaerynck et al., (2014) 
reported patients who received a living related donor graft had lower adherence. Patients receiving 
living unrelated donor and deceased donor transplantations had similar adherence levels, indicating 
that relatedness may be an important characteristic. This may be due to dynamics in relationships 
between donor and recipient, and/or significant pressure to be adherent following receiving an organ 
from a relative, which may prove counterproductive. Additionally, it may be due to patient beliefs that 
those receiving a living donor transplant require less immunosuppression e.g. due to a better HLA-
matched kidney and are less likely to experience rejection (Denhaerynck et al., 2014). However, it 
must be noted that some studies report no differences in adherence between recipients of living and 
deceased donor transplants (Griva et al., 2012; Massey et al., 2013; Tielen et al., 2014).  
 
Patients who experience psychological distress may also benefit from intervention in order to improve 
adherence. Depression and anxiety were associated with non-adherence in some of the studies 
included in the review. Previous literature has shown psychological distress (Achille et al., 2006; Lee 
et al., 2015), emotional distress (Jindal et al., 2003) and higher frequency of stress (Brito et al., 2015) 
is experienced by renal transplant recipients and can lead to lower adherence levels. Symptoms of 
depression may also lead to intentional non-adherence (Griva et al., 2012). Additionally, experiencing 
side effects of immunosuppressants (Rosenberger et al., 2005; Cheng et al., 2012) and symptom 
burden (Low et al., 2015) may also lead to non-adherence. Patients often consider transplantation as a 
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treatment that will allow them to return to a more normal life (Tucker et al., 2019) and therefore 
experiencing side-effects or adverse events, such as graft rejection, may be unexpected and 
challenging for patients. Interventions to help patients manage expectations may be beneficial to assist 
in coping with adjusting to life post-transplant.   
 
This review will be updated for publication. Around 1000 citations have been identified from the 
databases following searches for literature published in 2018-2019. Based on the screening process 
reported in the PRISMA flow chart, we can likely expect 1% of the citations to be potentially relevant 
for inclusion. 
 
4.4.1 Strengths and limitations 
This review included a wide range of databases in order to try and capture all relevant existing 
literature eligible for inclusion in the review. Additionally, a comprehensive search strategy was 
devised utilising both free text terms and MeSH terms. Furthermore, this review provides an updated 
synthesis of the literature exploring non-adherence to immunosuppressants among renal transplant 
recipients, updating reviews conducted in 2003 (Jindal et al., 2003), 2004 (Butler et al., 2004) and 
2017 (Belaiche et al., 2017). Measurement methods and definitions of adherence/non-adherence were 
assessed which provides important considerations for the development of future research in this field. 
Additionally, factors associated with increased risk of non-adherence were highlighted, providing 
potential areas for future interventions. Finally, the review was pre-registered, therefore considering 
open and transparent science practice.   
 
Despite these strengths, some of the intended analyses were not feasible due to data related issues 
such as heterogeneity in methods of non-adherence assessment, reported outcomes across studies and 
statistical analysis. Not enough data was available for impact on graft failure, therefore this was not 
explored. However, a pooled estimate of non-adherence prevalence rates using self-report measures 
was included. Additionally, the majority of studies included in the review utilised self-report 
measures to assess adherence. This could impact the accuracy of reported adherence/non-adherence 
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due to the reliance on recall and potential for social desirability response bias (Schafer-Keller et al., 
2008). However, as the most common method used, it is likely that these current estimates are the 
most pragmatic and clinically useful. Finally, we only explored factors identified as associated with 
non-adherence. We did not explore studies reporting no significant associations. Further research is 
needed to verify factors associated with non-adherence to confirm these are representative of the 
patient population.  
 
4.4.2 Conclusion 
It is clear from the literature identified in this review that non-adherence remains a prevalent issue 
within the renal transplant population. When assessed using the most common type of measurement, 
self-report, it can be expected that an estimated 37.6% of patients will be identified as non-adherent, 
however, prevalence rates vary across measures used. There is a lack of consistency in how adherence 
is measured and defined across studies and so it is likely that clear guidelines or consensus would be 
useful for clinical practice to identify which patients are at risk of poorer outcomes. This is necessary 
for all types of measurement methods, including across the different self-report measures available 
and widely used. Additionally, guidance is also needed on how best to combine different 
measurement methods for a more reliable non-adherence prevalence rate using e.g. subjective and 
objective measures. In accordance with previous findings, the review exposed that younger age, 
greater transplant vintage, living related donor grafts, and symptoms such as side-effects and 
psychological distress, are useful targets for intervention in order to improve non-adherence rates. 






Chapter 5: Adherence behaviour in patients on haemodialysis 
is not a clear predictor of post-transplant adherence 
 
5.1 Introduction  
Non-adherence is common in both haemodialysis (HD) patients and kidney transplant recipients. HD 
regimens are complex and demanding, necessitating attendance at HD sessions, adherence to 
prescribed medications, fluid and dietary restrictions (Kammerer et al., 2007; Kim & Evangelista, 
2010). Poor adherence to treatment can lead to complications, poor clinical outcomes, increased risk 
of mortality (Leggat et al., 1998; Saran et al., 2003) as well as adding to healthcare and treatment 
related costs (Cleemput et al., 2004; Kugler, Maeding & Russell, 2011). Due to the high demand of 
HD and associated restrictions, patients may not adhere to the prescribed treatment regime 
(Denhaerynck et al., 2007).  
 
There is a lack of consensus on definitions, which contributes to widely varying non-adherence rates 
in the HD population. A review of previous research examining non-adherence rates to aspects of the 
HD treatment regimen found reported non-adherence rates in this population to vary (Kim & 
Evangelista, 2010). The authors reported ranges in rates of attendance (0-32.3%), medication 
adherence (1.2-81%), fluid adherence (3.4-74%), and diet restrictions (1.2-82.4%). This large 
variation in adherence rates is likely due to inconsistency in the measures used, such as self-report or 
clinical data, a lack of consistency in clinical definitions of non-adherence, and the time period over 
which data is collected (Kim & Evangelista, 2010). Therefore, as is the case in transplant, the 
measurement of adherence in HD is nuanced.  
 
There have been some attempts to achieve consensus. A US renal data system (USRDS) study 
(Leggat et al., 1998) defined non-adherence in the following ways: 1) skipping HD sessions; 2) 
shortening HD sessions by ten minutes or more; 3) an interdialytic weight gain of more than 5.7% of 
patient dry weight; and 4) serum phosphate of greater than 7.5mg/dL. Skipping and shortening HD 
sessions was measured over a one-month period, where patients were classified as non-adherent if 
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they skipped or shortened one or more sessions. These were considered good indicators of adherence 
with HD treatment itself, and as common manifestations of non-adherence to dialysis (Kutner et al., 
2002). The researchers suggested that adherence to HD was almost entirely controlled by patient 
behaviour (Leggat et al., 1998). Phosphate was used as a measure of medication and dietary 
adherence. As HD does not fully remove the extra phosphorous in the blood, most patients are 
required to adhere to dietary requirements or to take phosphate binder medication to control 
phosphorous levels. High levels of phosphorous could indicate non-adherence to dietary requirements 
or medication.  Although these measures of non-adherence are criticised due to occurring within a 
narrow timeframe, longitudinal research has shown that patients classified as non-adherent in one 
month were continuously non-adherent, and those classified as adherent when measured in one month 
remained adherent (Sherman et al., 1994). However, it is important to note that adherence could 
change, and patients categorised as non-adherent during the one-month period of in question could 
become adherent in following months and vice versa. Overall, Leggat et al., (1998) found that non-
adherence ranged from 8.5% - 22.1%, dependent on the measure used. The highest rates of non-
adherence were found for shortening HD by ten or more minutes (20.3%) and serum phosphate of 
greater than 7.5mg/dL (22.1%). A high correlation was found among the different measures of non-
adherence suggesting consistency in outcome. The strongest predictors of non-adherence were 
younger age and smoking status.  
 
Further research exploring non-adherence in HD has utilised the USRDS methodology (Saran et al., 
2003; Hecking et al., 2004) namely as part of the Dialysis Outcomes and Practice Patterns Study 
(DOPPS). DOPPS provided in depth reviews of adherence using European and global data. Similar 
non-adherence levels were found, ranging from 3.8-19.6% for the overall sample and 0.6-20% for the 
European sample only (Saran et al., 2003), and from 0.6-23.8% for the overall sample and 0.8-21.9% 
for the UK sample only (Hecking et al., 2004). Again, the variation in rates was dependent on how 
non-adherence was defined and measured. Saran et al., (2003) also found the following were 
associated with increased odds of non-adherence: younger age; female gender; disabled status; living 
alone; African-American race; smoker; depression; time with ESRD. These determinants support 
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those found by Leggat et al., (1998) and demonstrate that at least in a 4-5 year period, little has 
changed in terms of clinical interventions to enhance adherence behaviour.   
 
Compared with HD patients, kidney transplant recipients have improved quality of life, a less 
restrictive diet, longer life expectancy (Jindal et al., 2003) and less psychological symptoms such as 
depression (Cukor et al., 2009). Nonetheless, these patients are also required to make adjustments in 
their lifestyle such as adherence to immunosuppressants to prevent rejection, alongside attending 
clinic for regular check-ups and generally maintaining a good diet and activity level (National Kidney 
Federation, 2000). However, non-adherence in this context remains common and resultant ill health is 
costly for the NHS and individuals, as services required for dialysis are more expensive than services 
required to support patients with a functioning transplant (Jindal et al., 2003). It is therefore important 
to address issues of non-adherence to ensure graft survival following transplantation. 
 
Non-adherence is a major risk factor for poor outcomes including graft survival (Loghman-Adham, 
2003). Reported rates of non-adherence to immunosuppressants in transplant patients vary and again 
definitions and methods of assessment are inconsistent. Methods such as self-report, electronic 
monitoring, reports from family or healthcare professional observations are most common 
(Denhaerynck et al., 2005). Use of clinical data to assess non-adherence in this setting is less 
frequently used.  
 
It is important to consider how adherence behaviour may transfer from one modality to another. For 
example, if poor adherence in HD patients pre-transplant could be identified and addressed, could 
post-transplant adherence be improved and with it the risks of graft loss? Less research has been 
conducted exploring the relationship between pre and post-transplant adherence among renal 
transplant recipients. Douglas et al., (1996) conducted a longitudinal retrospective chart audit to 
examine this relationship, specifically considering pre-transplant adherence and post-transplant 
outcomes in 126 renal transplant recipients over a three-year period. They defined non-adherence as 
having at least one note indicating pre or post-transplant non-adherence with a therapeutic regimen in 
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the clinical chart. Findings revealed that 61% of patients identified as non-adherent prior to 
transplantation experienced graft loss or died. This research indicated a relationship between pre-
transplant adherence and post-transplant outcomes; however, this method of defining non-adherence 
is not particularly stringent despite being related to severe consequences for patients. 
 
More recently, Dobbels et al., (2009) prospectively followed 141 heart, liver and lung transplant 
recipients, examining pre-transplant predictors of post-transplant outcomes. Patients were followed 
from pre-transplant until one year post-transplant. Independent predictors of non-adherence with 
immunosuppressant’s one-year post-transplant were pre-transplant non-adherence with medication 
taking; lower social support with medication taking; higher education status; low scores on 
personality trait “conscientiousness”. Higher education status, for example, may seem counter 
intuitive as one might consider higher education to be associated with greater understanding for 
medication necessity, however, it may be that those with higher education levels have busier work 
lifestyles which interferes with adherence to treatment regimes. A meta-analysis of 122 studies also 
suggested poor social support with medication taking is a key determinant of non-adherence 
(DiMatteo, 2004). In addition, pre-transplant medication adherence was found to be the only predictor 
of late acute rejection. Although this research was not conducted in the renal transplant population, it 
signals the importance of attending to pre-transplant behavioural patterns in predicting post-transplant 
outcomes.  
 
Research in the renal transplant population has identified socio-economic factors related to non-
adherence similar to those found by Dobbels et al., (2009), including perceiving low social support as 
well as younger age and being unmarried (Denhaerynck et al., 2005). It is also fair to assume that 
transplantation in all of these contexts, as with kidney disease, improves outcomes versus any other 
interim symptom relief. There are parallels therefore to be drawn about the level of non-adherence 
that persists despite a need to preserve and do justice to organs. Moreover, Dobbels et al., (2009) lead 
to the curious question of whether non-adherent HD patients go on to become non-adherent transplant 
recipients without any form of meaningful behaviour change attempts. This would have implications 
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for how patients are prepared for transplantation and beyond. We need, for clinical utility, to therefore 
baseline rates of non-adherence within patients across modalities of treatment and to consider suitable 
points for intervention to be more fruitful.   
 
5.1.1 Aims and objectives 
To our knowledge, there is little previous literature examining the relationship between clinical 
measures of pre-transplant adherence to HD and clinical measures of post renal transplant adherence 
in the renal transplant population. This is important as a high percentage of HD patients go on to 
receive a transplant. Although previous literature has highlighted predictors of non-adherence to HD 
and post-transplant adherence separately, there is little exploration of whether there is a relationship 
that could help clinicians identify aspects of pre-transplant non-adherence that act as potential risk 
factors for post-transplant non-adherence. Additionally, this could highlight patients that need to be 
targeted for intervention to address adherence concerns prior to transplantation in order to modify 
adherence behaviour post-transplant. It is clear from the literature that non-adherence both pre-
transplant when on HD, and post-transplant, is a major risk factor for poor clinical outcomes and 
hence important to address. As such, the current study was designed to address whether non-adherent 
HD patients become non-adherent transplant recipients. It also considers whether there are particular 
patterns of non-adherence to HD, which are more likely to associate with poor adherence following 
transplantation. This question is of interest not only for patient quality of life, but arguably since there 
is a justice issue for donated organs to advance the most benefit.  
 
5.2 Method 
5.2.1 Setting and participants  
This was a retrospective study carried out in a regional renal unit. Data was collected from an 
electronic patient system held at the NHS Trust about adherence to HD regimens in the six months 
prior to transplantation, and for one-year post-transplantation following return transfer to the post-
transplant clinic from the transplanting centre. The system on which data is recorded is unique to the 
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Trust and allows for the recording of data such as clinical tests and patient notes from clinic visits and 
telephone consultations with health care staff. As this data was readily available, it made it a 
pragmatic and cost-effective means through which to address the association between pre-transplant 
and post-transplant adherence.  
 
The study population consisted of 88 adult (aged 18 years and over) kidney transplant patients 
transplanted between 2006 and 2016, who had received HD for a minimum of six months prior to 
transplantation. A minimum of six months was required as this was considered an appropriate time-
period to account for observation of natural behavioural occurrences and to ensure typical behaviour 
(adherent/non-adherent) was captured. Data was obtained from the renal plus database at East and 
North Herts NHS trust for six months prior to transplantation, and for one-year post-transplantation 
following return transfer to the East and North Herts NHS trust renal post-transplant clinic from the 
patients transplanting hospital.  
 
5.2.2 Inclusion/ exclusion criteria 
Patients that returned to the post-transplant clinic prior to 2006 were excluded, as the hospital 
database did not upload electronic notes from clinic visits prior to this year. In addition, patients were 
excluded if they were transferred later than one-year post-transplantation back to the East and North 
Herts NHS Trust transplant clinic from the transplanting hospital. Further exclusions included: 
patients who received HD for less than six months prior to transplantation; patients that received 
home HD or peritoneal dialysis in the six-month period prior to transplantation; patients who did not 
take tacrolimus as their post-transplant immunosuppressant.  
 
Of a sample of 204 kidney transplant patients who had received HD as a treatment at some stage prior 
to transplantation, 88 were eligible for inclusion in the study analysis. The remaining 116 patients 
were excluded, as they did not meet the inclusion criteria. The flow diagram (figure 5.1) illustrates the 
























Figure 5.1: Flow diagram of participant study inclusion/exclusion. 
 
5.2.3 Demographic and clinical data  
A retrospective analysis compared non-adherence in renal transplant recipients prior to transplantation 
when on HD. Data was retrieved on the six-month period prior to transplantation.  
 
Demographics retrieved for each patient included age, sex, ethnicity, age at first dialysis session, age 




Clinical data collected as part of routine care was retrieved that could provide indicators of non-
adherence. Pre-transplant information was retrieved on the following for the six-month period prior to 
transplantation:  
• Most recent dialysis prescription (in minutes of session length) 
88 patients eligible for inclusion in 
the retrospective study analysis. 
204 renal transplant patients who 
had received haemodialysis. 
 
Total excluded: 116 
 
• 61 excluded as transplant was received 
before 2006. 
• 17 excluded as patients had been receiving 
dialysis for less than six months prior to 
transplantation. 
• 12 excluded as patients received Home 
haemodialysis prior to transplantation. 
• 10 excluded as patients were not one-year 
post-transplantation. 
• 8 excluded as patients were not taking 
tacrolimus immunosuppressant post-
transplant. 
• 6 excluded as treatment was peritoneal 
dialysis prior to transplantation. 
• 1 excluded as not returned to post-
transplant clinic from transplanting centre. 
• 1 excluded as transplant failed before 1 




• Mean dialysis prescription (in minutes of session length) 
• Mean time spent on dialysis per session (in minutes of session length) 
• Variance from dialysis prescription (in minutes of session length)  
• Number of missed dialysis sessions  
• Dialysis vintage 
• Residual kidney function (KRU) 
• Most recent patient dry weight 
• Phosphate  
• Parathyroid hormone (PTH)  
• Interdialytic weight gain (IDWG) 
 
5.2.5 Post-transplantation 
Post-transplantation, the following information was retrieved for one-year following return transfer to 
the East and North Herts NHS Trust transplant clinic from the transplanting hospital: 
• Mean Tacrolimus levels and their standard deviation 
• Number of missed clinic appointments 
• Immunosuppression regimen  
• Donor type (Living or deceased donation) 
• Experience of delayed graft function 
 
From collecting the above data, direct comparisons could be made to assess patients adherence levels 
pre-transplant when receiving dialysis, and post-transplant in order to identify if there were any 
change in levels of adherence following transplantation. As different markers were used to measure 
adherence pre-transplant compared to post transplant, a narrative comparison of the data was reported 
using appropriate statistical analyses.  
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5.2.6 Outcome measurements 
Pre-transplantation: 
Variance from dialysis prescription 
To calculate the variance from dialysis prescription, the mean dialysis prescription and mean time 
spent on dialysis per session were calculated for the six-month period prior to transplantation. To 
calculate the mean dialysis prescription, dialysis prescription times for the six-month period prior to 
transplantation were recorded, the mean was calculated for each month, and the monthly means were 
then used to calculate the mean dialysis prescription. To calculate the mean time spent on dialysis per 
session, the time spent on dialysis during each session was recorded in minutes for the six-month 
period prior to the date of transplantation. The mean was then calculated using these values to provide 
an average length of dialysis per session. These two values were used to create the variance from 
dialysis prescription, by subtracting the mean time of dialysis per session from the mean dialysis 
prescription. This showed the mean difference in minutes between the dialysis prescription, and the 
time spent on dialysis for the six-month period prior to transplantation.  
 
Missed dialysis sessions 
Missed dialysis sessions were recorded as the number of sessions missed in the six-months prior to 
transplantation until the date of transplantation (in six months the average number of dialysis sessions 
is 72, based on patients dialysing on a thrice weekly regime). Missed sessions due to hospitalisation or 
periods of dialysis away from base (e.g. holidays) were not included as this was not considered non-
adherence.   
 
Phosphate  
Mean phosphate for the six-month period prior to transplantation was calculated. Phosphate 
measurements were taken on a monthly basis as part of routine medical care. According to the 2016 
renal registry report, the recommended serum phosphate level therapeutic range is between 1.1-
1.7mmol/l (Methven et al., 2017). Previous research which included serum phosphate as a clinical 
measure of non-adherence took a level of >1.8mmol/l to indicate non-adherence (Wileman et al., 
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2011). Based on clinical guidance and previous research, phosphate levels above 1.8mmol/l were 
considered non-adherent in this study.  
 
Parathyroid hormone (PTH) 
Mean PTH was calculated for the six-month period prior to transplantation using the measurements 
taken as part of routine medical care. PTH measurements were recorded every 3-6 months. Patients 
would therefore either have one or two PTH readings for the six months prior to transplantation, of 
which the mean was recorded. PTH is monitored as secondary hyperparathyroidism (high levels of 
PTH) can cause bone disease and can also cause calcium to build up on organs and tissues. 
 
Residual kidney function (KRU) 
Mean residual kidney function for the six-month period prior to transplantation was calculated. KRU 
measurements were recorded on a monthly basis as part of routine medical care, of which the mean 
was recorded for this period. 
 
Interdialytic weight gain (IDWG) 
IDWG is the weight increase between the end of one dialysis session and the start of the next. The 
extent of IDWG in HD patients is usually related to the level of adherence with fluid restriction. The 
mean IDWG for the six-month period prior to transplantation was automatically calculated using the 
database at East and North Herts NHS Trust by entering two dates: start date - six-months prior to 




Mean tacrolimus levels were calculated for the one-year period post-transplantation, following patient 
return transfer to the East and North Herts NHS Trust post-transplant clinic. Immunosuppressant 
levels are recorded prior to clinic appointments, as part of routine medical care. Patients were 
categorised as adherent if they had tacrolimus levels within the therapeutic range of 5-10ng/mL. This 
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range was used based on clinical advice and previous literature (Schafer-Keller et al., 2008) for 
expected ranges within the first two years following transplantation. 
 
Missed clinic appointments 
Missed clinic appointments were recorded as the number of appointments a patient had not attended 
(DNA) in the first year post-transplant following return transfer to the East and North Herts NHS 
Trust transplant clinic from the transplanting hospital (from the date of the first clinic appointment at 
East and North Herts NHS Trust renal post-transplant clinic).  Missed clinic appointments due to 
hospitalisation were not included. The frequency of post-transplant clinic appointments is determined 
on a case-by-case basis. This can generally vary from every 4 weeks,  8 weeks, or 12 weeks.  
 
Delayed graft function 
Delayed graft function was recorded for any patient who experienced an episode that may or may not 
have required treatment (including dialysis) or an episode(s) of acute rejection post-transplant, from 
the time of transplantation to the end of the first year following return transfer to the East and North 
Herts NHS Trust post-transplant clinic.  
 
5.2.7 Defining adherence  
There is no agreed way of defining adherence pre and post-transplant, therefore, using previous 
literature (Leggat et al., 1998; Saran et al., 2003; Hecking et al., 2004; Schafer-Keller et al., 2008) and 
clinical experience, different cut off points were applied to assess the data to uncover any 
relationships between pre and post-transplant adherence.  
 
Pre-transplant (six-month period prior to transplantation) definitions of non-adherence included if 
patients:  
1. On average shortened their dialysis prescription by >10 minutes; 
2. On average shortened their dialysis prescription by >15 minutes; 
3. Missed two or more haemodialysis sessions; 
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4. Had mean serum phosphate levels >1.8mmol/l. 
 
Post-transplant (one-year period following return transfer from the transplanting hospital) definitions 
of non-adherence included if patients: 
1. Mean tacrolimus levels outside of the expected range within the first two years of 5-10 ng/mL 
following transplantation; 
2. Missed one or more post-transplant clinic appointments.  
 
For this study, we used a six-month period to assess non-adherence pre-transplant, whereas previous 
studies (Leggat et al., 1998; Saran et al., 2003; Hecking et al., 2004) defined non-adherence in a 
narrower time frame of one month. Differences were therefore made to some of the pre-transplant 
measures of adherence accordingly. A longer time frame would account for natural changes in 
behaviour overtime that shorter frame measurement cannot untangle.  In addition to using shortening 
dialysis prescription by >10 minutes used in previous research as a definition of non-adherence, we 
also used >15 minutes as a cut-off point, as this represented the top 25% of variance in dialysis 
prescription times for patients in this study. Furthermore, previous studies used a higher non-
adherence cut off point for serum phosphate levels of 7.5mg/dL (this equates to roughly 
~2.42mmol/l). For this research, we chose to use a cut-off point in line with previous research using 
serum phosphate as a measure of non-adherence (Wileman et al., 2011) and in line with the 
recommended renal association serum phosphate level of 1.1-1.7mmol/l in the UK (Methven et al., 
2017). Post-transplant tacrolimus therapeutic range was determined by clinical advice and previous 
research, which used this range (Schafer-Keller et al., 2008).  
 
5.2.8 Statistical analysis 
As different markers were used to measure adherence pre-transplant compared to post transplant, a 
narrative comparison of the data is reported. Demographic data is reported for the study sample using 
means and frequencies. Comparisons of the data were completed using McNemar’s test and 
Cochran’s Q for categorical data and t-tests for continuous data. P-values of less than 0.05 were 
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considered to be significant. Logistic regressions were used to determine potential predictors of non-
adherence both pre and post-transplant. McNemar’s test was used to explore relationships between 
pre and post-transplant adherence. The data was analysed using SPSS version 25.  
 
5.2.9 Approvals 
This study was considered by the institutional review team at East and North Hertfordshire NHS Trust 
(RD2016-82) and determined to be a service evaluation. Departmental agreement was provided for 
the service evaluation to be completed.  
 
5.3 Results 
5.3.1 Patient characteristics 
Patient characteristics for the sample are shown in Table 5.1. Ethnicity is shown for the overall 
sample and by gender. Of the 88 patients, the sample included more males (62.5%) than females 
(37.5%). Mean age at transplant for the overall sample was 48.5 years (SD=12.7), with no significant 
differences between genders. Across the overall study population, 54.5% were from white European 
ethnic backgrounds, although a considerable proportion were from other ethnic groups (45.5%). 
Breakdowns of the different patient ethnicities are shown in Table 5.1. Comparisons were made 
between males and females, and both groups had a fairly equal split of patient ethnic heritage.  
 
Chronic glomerulonephritis (21.6%: N=19), diabetic nephropathy (20.5%: N=18), polycystic kidney 
disease (13.6%: N=12), chronic pyelonephritis (9.1%, N=8), and hypertension (4.5%: N=4) accounted 
for the majority of causes of ESRD in the sample. Aetiology was uncertain for over a quarter of the 







Table 5.1: Demographics for the study sample including ethnicity and comparisons by gender.  







Ethnicity n (%) White European 48 (54.5) 30 (54.5) 18 (54.5) 
 Non-white European 3 (3.4) 2 (3.6) 1 (3.0) 
 South Asian 24 (27.3) 17 (30.9) 7 (21.2) 
 Black 11 (12.5) 5 (9.1) 6 (18.2) 
 Other Ethnic 2 (2.3) 1 (1.8) 1 (3.0) 
 Minority Ethnic total 40 (45.5) 25 (45.5) 15 (45.5)  
 
Deprivation index was also recorded for all patients to examine if there were any differences in social 
deprivation between white and non-white patients (Table 5.2). The indices of deprivation rank every 
postcode in England from 1 (most deprived) to 32, 844 (least deprived). These are split into deciles of 
1-10 from most deprived to least deprived dividing them into 10 equal groups. The most deprived 
10% is represented by 1 and the least deprived 10% by 10. Table 5.2 shows the deprivation deciles for 
the overall sample, and a comparison between white European and patients from minority ethnic 
groups. Across the overall sample, 23.9% (n=21) of patients live in neighbourhoods that fall in the 
20% most deprived small areas in England. Findings differed across ethnicity, with 40% (n=16) of 
minority ethnic patients shown to live in neighbourhoods that fall in the 20% most deprived small 
areas in England, compared to 10.4% (N=5) of white European patients.  
 










Index of multiple deprivation decile     
   1 2 (2.3) 1 (2.1) 1 (2.5) 
   2 19 (21.6) 4 (8.3) 15 (37.5) 
   3 9 (10.2) 5 (10.4) 4 (10.0) 
   4 10 (11.4) 3 (6.3) 7 (17.5) 
   5 5 (5.7) 3 (6.3) 2 (5.0) 
   6 8 (9.1) 6 (12.5) 2 (5.0) 
   7 8 (9.1) 5 (10.4) 3 (7.5) 
   8 4 (4.5) 4 (8.3) 0 
   9 14 (15.9) 11 (22.9) 3 (7.5) 
   10 9 (10.2) 6 (12.5) 3 (7.5) 
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5.3.2 Clinical pre-transplant data  
Non-adherence ranged from 25% to 42% dependent on how it was operationalised. When non-
adherence was defined as shortening dialysis prescription by more than 10 minutes, 39.8% of patients 
were identified as non-adherent. This percentage reduces as the definition of adherence becomes more 
stringent (>15mins = 25% non-adherent). When defining non-adherence using the number of missed 
HD sessions as two or more, 27.3% of patients were identified as non-adherent. When using 
phosphate level as greater than 1.8mmol/l to define non-adherence, 42% of patients were defined as 
non-adherent (Table 5.3). There were no significant demographic differences between groups across 
measures, with the exception that patients categorised as non-adherent based on phosphate levels were 
significantly younger age at transplantation, (t(86)= 1.99, p=.049) than those categorised as adherent 
(Table 5.3). Cochran’s Q was used to determine if there were any differences in patients identified as 
non-adherent across the four pre-transplant measures. There was a statistically significant difference 
in the proportion of non-adherent patients across the four non-adherence measures (c2(3) = 9.79, 
p=.020), indicating differences in patients identified as non-adherent across the four pre-transplant 
measures. 
 
We explored whether pre-transplant clinical data predicted pre-transplant adherence. Dialysis vintage, 
KRU, serum phosphate, PTH and IDWG were compared independently across adherent and non-
adherent patients using the four pre-transplant adherence measures. All measures were skewed with 
the exception of serum phosphate. There was a significant difference for KRU between adherent and 
non-adherent patients, when adherence was defined as shortening dialysis by >10 minutes (U=684.5, 
p=.035), adherent patients having lower residual kidney function than non-adherent (Table 5.3). No 
other significant differences were observed between adherent and non-adherent patients when 
adherence was defined as shortening dialysis by >10mins or by >15mins. Significant differences were 
observed when adherence was defined using serum phosphate levels. Patients categorised as non-
adherent based on their phosphate levels had lower KRU, U=648, p=.011, and higher parathyroid 
hormone levels, U=545.5, p=.002 (Table 5.3). 
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Table 5.3: Demographic comparison of adherent and non-adherent patients pre-transplant. KRU = Urea clearance (ml/min), PTH = Parathyroid hormone 
(pmol/l), IDWG = Interdialytic weight gain (kg) 
    





Pre-transplant missed dialysis 
sessions 2 or more Phosphate ≥1.8mmol/l 
  Adherent  Non-adherent Adherent  
Non-
adherent Adherent  
Non-
adherent Adherent  Non-adherent 
  N=88 (%) N=53 (60.2%) N=35 (39.8%) N=66 (75%) N=22 (25%) N=64 (72.7%) 
N=24 
(27.3%) N=51 (58%) N=37 (42%) 
 
Age at transplant 
M (SD) 
 
Age at first 










































Male 55 (62.5) 32 (60.4) 23 (65.7) 41 (62.1) 14 (63.6) 39 (60.9) 16 (66.7) 31 (60.8) 24 (64.9) 
Female 33 (37.5) 21 (39.6) 12 (34.3) 25 (37.9) 8 (36.4) 25 (39.1) 8 (33.3) 20 (39.2) 13 (35.1) 
 




White European 48 (54.5) 29 (54.7) 19 (54.3) 39 (59.1) 9 (40.9) 32 (50) 16 (66.7) 28 (54.9) 20 (54.1) 
Minority ethnic 40 (45.5) 24 (45.3) 16 (45.7) 27 (40.9) 13 (59.1) 32 (50) 8 (33.3) 23 (45.1) 17 (45.9) 
 
Index of multiple 
deprivation (IMD) 
M (SD) 5.5 (2.9) 5.3 (3.0) 5.9 (2.8) 5.6 (3.0) 5.2 (2.7) 5.3 (3.1) 5.9 (2.6) 6.0 (3.0) 4.8 (2.7) 




(IQR) 26 (16, 49) 26 (16.3, 54) 26 (15, 40) 26 (17, 51) 24 (13, 39) 25 (16, 48) 27 (16, 50) 28 (15, 55) 24 (17, 40) 
 
KRU Median 






37 (25, 57) 
 
35 (22.2, 57) 
 
43 (25, 59) 
 
36 (25, 57) 
 
43 (25, 60) 
 
38 (26, 57) 
 
30 (14, 70) 
 
30 (17, 51) 
 
50 (34, 72)* 
 
IDWG Median 









Logistic regression analyses were conducted to identify possible predictors of non-adherence among 
pre-transplant patients. Factors included in the models were age at transplant, gender, ethnicity, index 
of multiple deprivation and dialysis vintage. No significant predictors of non-adherence were 
identified for any of the non-adherence measures (Table 5.4). 
 
Table 5.4: Predictors of non-adherence pre-transplant. 


















Age at transplant (years) 0.99 (0.95, 1.03) 0.99 (0.94, 1.03) 1.00 (0.96, 1.05) .97 (0.93, 1.01) 
Male (vs. female) 1.17 (0.45, 3.04) 1.23 (0.41, 3.68) 1.75 (0.58, 5.30) 1.15 (0.43, 3.13) 
White European (vs. minority 
ethnic) 0.71 (0.26, 1.91) 0.45 (0.15, 1.38) 1.71 (0.56, 5.16) 1.03 (0.37, 2.88) 
Index of Multiple Deprivation 1.06 (0.89, 1.26) 0.98 (0.80, 1.19) 1.00 (0.83, 1.22) 0.87 (0.72, 1.04) 
Dialysis vintage (months) 0.99 (0.97, 1.01) 0.99 (0.96, 1.01) 1.00 (0.98, 1.02) 0.99 (0.97, 1.01) 
 
5.3.3 Clinical post-transplant data 
Patients with tacrolimus levels outside the range expected within the first two years of 5-10ng/l were 
highlighted. Of the 88 patients, 14 (15.9%) had tacrolimus levels outside of the expected range of 5-
10ng/l. Within this, ten were male and four were female, and there were an equal number of white 
European and minority ethnic patients (N=7). There were no significant demographic or clinical 
differences between adherent and non-adherent patients defined in this way.   
 
When non-adherence was defined using the number of missed post-transplant clinic appointments as 
one or more, 20 patients (22.17%) were identified as non-adherent (Table 5.5). No significant 
demographic differences were observed between groups when post-transplant adherence was defined 
in this way except that non-adherent patients were significantly younger when transplanted, t(86)= 
2.14, p=.035, and significantly younger when starting dialysis, t(86)= 2.07, p=.041, than those 
categorised as adherent (Table 5.5). 
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Table 5.5: Demographic comparison of adherent and non-adherent patients post-transplantation. 
  
Post-transplant tacrolimus levels 
  
Post-transplant missed clinic 
appointments 1 or more  




N=14 (15.9%) N=68 (77.3%) N=20 (22.7%) 
Age at transplant M (SD) 
 















Dialysis vintage (months) 
 
Gender N (%) 
35.9 (27.6)   29.8 (16.7)   35.4 (26.4)  33.1 (26.2)  
Male 45 (60.8) 10 (71.4) 42 (61.8) 13 (65.0) 
Female 29 (39.2) 4 (28.6) 26 (38.2) 7 (35.0) 
 
Ethnicity N (%) 
      
White European 41 (55.4) 7 (50) 37 (54.4) 11 (55.0) 
Minority Ethnic 33 (44.6) 7 (50) 31 (45.6) 9 (45.0) 
 
Index of multiple deprivation  
(IMD) M (SD) 5.7 (2.9) 4.6 (2.9) 5.69 (3.1) 4.9 (2.4) 
*p<.05 
 
Across the overall sample, more patients received a deceased donor transplant (80.7%). Most patients 
took a combination of two or three immunosuppressants, and around one third of the sample 
experienced delayed graft function following transplantation (see Table 5.6).  
 
Table 5.6: Transplant comparison of adherent and non-adherent patients. 
    Post-transplant tacrolimus levels 
Post-transplant missed clinic 
appointments 1 or more 
 Total Adherent  Non-adherent Adherent Non-adherent 
  
N=88 
(100%) N=74 (84.1%) N=14 (15.9%) N=68 (77.3%) N=20 (22.7%) 
No. immunosuppressants      
   1 1 (1.1) 1 (1.4) 0 1 (1.5) 0 
   2 44 (50.0) 38 (51.4) 6 (42.9) 32 (47.1) 12 (60.0) 
   3 43 (48.9) 35 (47.3) 8 (57.1) 35 (51.5) 8 (40.0) 
 
Donor type      
   Deceased 71 (80.7) 62 (83.8) 9 (64.3) 53 (77.9) 18 (90.0) 
   Living 17 (19.3) 12 (16.2) 5 (35.7) 15 (22.1) 2 (10.0) 
 
Delayed graft function      
   Yes  31 (35.2) 28 (37.8) 3 (21.4) 24 (35.3) 7 (35.0) 





Logistic regression analyses were conducted to identify possible predictors of non-adherence among 
post-transplant patients in this study. No significant predictors for non-adherence to tacrolimus 
immunosuppressant medication were identified. Phosphate levels ≥1.8mmol/l pre-transplant were 
identified as predicting higher odds of non-attendance to post-transplant clinic appointments (Table 
5.7).  
 
Table 5.7: Predictors of non-adherence post-transplant. 
  





Post-transplant missed clinic 
appointments 1 or more 
Age at transplant (years) 0.99 (0.93, 1.05) 0.98 (0.94, 1.04) 
Male (vs. female) 2.09 (0.49, 8.88) 0.80 (0.23, 2.86) 
White European (vs. minority ethnic) 0.89 (0.23, 3.46) 1.40 (0.34, 5.82) 
Index of Multiple Deprivation 0.85 (0.66, 1.09) 0.89 (0.70, 1.14) 
Dialysis vintage (months) 0.99 (0.96, 1.02) 1.00 (0.97, 1.02) 
Variance in dialysis time from prescription (mins) 1.01 (0.97, 1.04) 1.05 (0.99, 1.11) 
Missed dialysis sessions >2 (vs. <2) 0.86 (0.19, 3.84) 0.60 (0.14, 2.58) 
Phosphate  ≥1.8mmol/l (vs. <1.8mmol/l) 0.69 (0.17, 2.80) 4.19 (1.15, 15.24)* 




In addition to looking at tacrolimus using the mean levels, the standard deviation and co-efficient of 
variation (CV) was also calculated to examine the variation in tacrolimus levels for each patient for 
the one-year period recorded post-transplantation. A non-adherence cut-off point of SD >2.0 was used 
in line with previous research (Shemesh et al., 2004), and tacrolimus CV% cut-off point of 41% was 
used, again in line with previous research (Hsiau et al., 2011). Logistic regression analyses were 
conducted to identify potential predictors of these parameters. No significant predictors were 
identified. There was no difference between the proportion of non-adherent patients defined in terms 
of highly variable tacrolimus levels (tacrolimus CV% > 41%) and defined in terms of missed clinic 
appointments (p=.47 by McNemar’s test). 
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5.3.4 Comparing pre and post-transplant adherence 
In general the prevalence of non-adherence was greater pre-transplant than post-transplant. The 
prevalence of pre-transplant non-adherence defined by shortened dialysis by >10mins was greater 
than post-transplant non-adherence defined by both tacrolimus levels and by missed post-transplant 
clinic appointments (p= .001 and .029 respectively: McNemar’s test). Likewise the prevalence of pre-
transplant non-adherence determined by phosphate levels was greater than the prevalence of post-
transplant non-adherence determined by both tacrolimus levels (p<.001) and by missed post-
transplant clinic appointments (p=.003). No other significant differences were found when comparing 
pre and post-transplant groups (Table 5.8).  
 
We explored the relationship between pre-transplant demographic and clinical data to post-transplant 
adherence. Of the 28 patients categorised as non-adherent to either one (N=22) or both (N=6) post-
transplant measures, 46.4% (n=13) were non-adherent to two or more pre-transplant measures, 
compared with 32.2% (n=9) who were non-adherent on a single pre-transplant measure. The 
remaining 21.4% (n=6) of non-adherent patients post-transplant were adherent to all pre-transplant 
measures. In general there was only a weak relationship between pre-transplant data and post-
transplant adherence. The exception was that patients who had missed one or more post-transplant 
clinic appointments had higher mean pre-transplant phosphate levels (M=1.92, SD=.41) compared 
with those who had missed none (M=1.69, SD=.40; t(86)= 2.25, p=.027). This finding suggests that 
patients with higher phosphate levels pre-transplant are more likely to miss clinic appointments post-
transplant. There was no relationship of interdialytic weight gain with post-transplant adherence even 







Table 5.8: Comparing pre-transplant adherence to post-transplant adherence measures. 
    
Pre-transplant 
shortening dialysis 
prescription >10mins   
Pre-transplant 
shortening dialysis 
prescription >15mins   
Pre-transplant missed 
dialysis sessions 2 or 
more   Phosphate ≥1.8mmol/l   
  Adherent  
Non-
adherent  Adherent  
Non-
adherent  Adherent  
Non-
adherent  Adherent  
Non-
adherent  
































N=68  40 28 .029*  48 20 .87  49 
 




N=20  13 7    18 2    15 5    6 14   











The primary aim of this single-centre retrospective study was to explore whether patterns of 
adherence behaviour when on HD are indicative of patterns of adherent behaviour post-
transplantation. Our findings do not support the likelihood of a strong direct relationship between 
these behaviours. However, the possibility remains of some overlap of non-adherent behaviours in 
these two settings as evidenced by our finding of a relationship between pre-transplant phosphate 
control and subsequent attendance for post-transplant follow-up. Additionally, the findings do suggest 
there are a proportion of patients that have: (a) missed dialysis sessions, shortened their dialysis 
prescription in the six months leading up to transplantation and have serum phosphate levels outside 
of the recommended therapeutic range; (b) missed post-transplant clinic appointments in the year 
following transplantation; (c) have tacrolimus levels outside of the suggested therapeutic range post-
transplant. This has important implications for patients in terms of their overall health status even if 
there are not always immediate consequences of these behaviours.  
 
The number of patients categorised as non-adherent was dependent on how non-adherence was 
defined. Pre-transplant non-adherence ranged from 25% to 42%, and post-transplant non-adherence 
ranged from 15.9% to 22.7%, dependent on definition. Clearly the general trend seen is that 
adherence behaviour improves on average with a narrower margin across outcome types from pre to 
post transplant. Our finding of a higher non-adherence rate for phosphate control than that quoted in 
the literature (Leggat et al., 1998; Saran et al., 2003) is highly likely to be due to our using a lower 
cut-off point for non-adherence in line with previous research from our unit (Wileman et al., 2011) 
and UK clinical practice guidelines (Methven et al., 2017).  
 
Defining pre-transplant adherence in terms of phosphate control, non-adherent patients were found to 
be younger age at transplant, to have less residual kidney function and to have higher PTH levels. 
Both latter factors have well-established effects on phosphate control. Previous studies have also 
demonstrated negative correlations between age and phosphate control. Longer dialysis vintage was 
also associated with lower phosphate levels (Kim & Evangelista, 2010). In addition, self-reported 
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patient adherence to medication was associated with lower phosphate levels. Nevertheless, our 
findings may help define a group of patients in whom targeted intervention may improve aspects of 
adherence pre-transplant and potentially post-transplant. No other significant findings were observed 
when exploring predictors of non-adherence pre-transplant using clinical data. This is in contrast to 
previous literature.  
 
However, serum phosphate levels are affected by clinical variables and diet, therefore the reliability as 
a measure of non-adherence should be interpreted with caution (Wileman et al., 2015). There are 
multiple factors that could influence adherence to phosphate treatment, such as complex treatment 
regimen, high pill burden, side effects and lack of immediate symptomatic benefit (Wileman et al., 
2015). It has been suggested that dietary and fluid restrictions may require more patient willpower in 
order to adhere. A study found that 57.6% of patients reported difficulty adhering to dietary 
prescription, and 56.3% reported this was due to an inability to resist favourite foods (Kim & 
Evangelista, 2010). In addition, in the same study 62% reported some difficulty adhering to fluid 
restrictions, and 43.7% were unable to control their desire for fluid. This suggests that these aspects of 
the treatment regimen may be more challenging to adhere to and could explain why non-adherence 
rates are higher for these measures of pre-transplant non-adherence. This could indicate that 
phosphate is a better indicator of pre-transplant non-adherence than other measures because of the 
multi-faceted nature of the behaviours required to manage phosphate levels, which encompass dietary 
restriction, phosphate binder medication adherence, and adherence with dialysis protocols. Age may 
be a factor in this relationship as non-adherent patients judged by this parameter pre-transplant were 
significantly younger as were those who missed post-transplant clinic appointments. On the other 
hand, the absence of other significant predictors of post-transplant non-adherence increases the 
possibility that this association was a chance finding. 
 
Post-transplant predictors of non-adherence - defined in terms of number of missed clinic 
appointments - similarly indicated that non-adherent patients were significantly younger at transplant 
and at dialysis initiation. These patients also had higher phosphate levels pre-transplant, above the 
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Renal Association recommended range, indicating inadequate phosphate control. Previous literature 
using serum phosphate as a clinical measure of non-adherence also indicated phosphate control as a 
major issue for HD patients (Wileman et al., 2011; Wileman et al., 2015). This is similar to our 
findings, which showed a mean phosphate level of 1.74 (SD=.41) for the overall sample. Logistic 
regression identified phosphate levels ≥1.8mmol/l predicted higher odds of non-attendance to post-
transplant clinic appointments.  
 
We found that the prevalence of non-adherence was greater pre-transplant by some but not all 
measures. This may suggest that adherence with treatment post-transplant is more manageable than 
adherence to treatment pre-transplant which involves both HD and associated medications. However, 
the measures of adherence used in these setting are, of necessity, very different, so this interpretation 
needs to be treated with caution. 
 
Although clinical data can provide indications of non-adherence both pre and post-transplant, 
previous research has shown that other factors, such as socio-economic, psychological, patient-
related, may lead to non-adherence occurring. Cukor et al., (2009) suggested that depression may play 
an important role in non-adherence among both HD and transplant recipients. HD patients were found 
to be more depressed than patients with an active transplant. In addition, higher depression scores 
significantly correlated with low medication adherence in both HD and transplant recipients. 
Furthermore, HD patients reported lower medication adherence, however, this could be explained by 
the complex aspect of HD treatment and restrictions accompanying the treatment process in patients 
with ESRD. So, it is perhaps unsurprising that non-adherence is more variable in this patient group 
than in transplant recipients.  
 
Overall, these findings suggest that pre and post-transplant adherence are only weakly associated. The 
relationship is complex. The challenges that patients experience with adherence pre-transplant may be 
different following transplantation. There are multiple potential factors. For example, whether a 
patient has received a living or deceased donor organ may play a role in behaviour modification 
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(Terasaki et al., 1995; Denhaerynck et al., 2007). In addition, anxiety, depression (Achille et al., 2003; 
Cukor et al., 2009) and socio-economic factors (NHS BT, 2017) have been associated with non-
adherence. This highlights the complexity of what could contribute to non-adherence, and the 
potential need for a multi-disciplinary intervention to address adherence both pre and post-transplant. 
Pre-transplant, patients on HD are usually entitled to free prescriptions. However, although post-
transplant clinic appointments are covered via the National Health Service (NHS), post-transplant 
medication is not (unless patients meet the criteria for prescription payment exemption). This 
additionally could contribute to differences in non-adherence rates. Our findings do support existing 
literature pertaining to adherence in specific renal replacement therapy (RRT) modalities, for 
example, the relationship between younger age and non-adherence. 
 
5.4.1 Strengths and limitations 
Whilst our study suggests the possibility of a complex relationship between pre and post-transplant 
adherence, the findings should be interpreted with caution. The sample size was small and single-
centred. A power calculation was not performed prior to retrieving the data. As this is a specific 
patient population and data was only available from one NHS site, data was collected for as many 
patients that met the inclusion criteria as possible, however, it is possible findings may have been 
underpowered due to the small sample size. Additionally, this study only included patients that had an 
active transplant and had been attending the post-transplant clinic for one year. As a result of this, 
graft loss and survival differences between adherent and non-adherent patients with aspects of the HD 
treatment were not explored, as in previous studies (Leggat et al., 1998; Saran et al., 2003). As this 
study used patients from one hospital, it is important to consider that this could have impacted our 
findings, as treatment support with non-adherence available to patients can vary from site to site.  
 
Younger age predicted high phosphate levels pre-transplant. We found no other major associations. 
However, the time frame in which non-adherence was assessed pre-transplant was over one month in 
the previous literature (Leggat et al., 1998; Saran et al., 2003; Hecking et al., 2004), whilst this study 
assessed pre-transplant non-adherence over a period of six months prior to transplantation. Our six-
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month assessment of non-adherence may provide a more stable picture of patient behavioural 
patterns. Additionally, a follow-up of one year may be too shorter period for exploring post-transplant 
non-adherence, as research suggests rates of non-adherence can increase as time from transplantation 
increases (Nevins & Thomas, 2009). 
 
Whilst we have attempted to delineate clinically relevant indices of non-adherence in the transplant 
population, there may be other parameters, which may be more relevant. There is limited research 
indicating how non-adherence should be defined clinically pre and post-transplant, therefore it is 
possible that the measures we used to define non-adherence post-transplant were not the most reliable 
and valid. This could indicate the need to identify clinically relevant definitions that accurately 
measure non-adherence rates to ensure this is reported reliably in future research. Notwithstanding 
these limitations, our study is one of the few to consider how patterns of adherence vary within patient 
groups as they transition between RRT modalities.   
 
Certain aspects of the HD treatment regimen, such as diet and fluid restrictions, and symptoms, side 
effects and high pill burden experienced may make regimes more challenging to adhere to, and could 
explain why non-adherence rates are higher for these measures of pre-transplant non-adherence. In 
addition, the challenges that patients experience with adherence pre-transplant may be different or 
even eradicated following transplantation. Further research to identify a clinically relevant, reliable 
and valid definition of non-adherence both pre and post-transplant adherence is needed to help 
address the variation in non-adherence rates reported in the literature.  
 
5.4.2 Future research 
Future research could consider more efficient ways of measuring and defining non-adherence pre-
transplant to help further understand what mediates the relationship between pre and post-transplant 
adherence. Further research with renal transplant recipients via quantitative or qualitative work should 
be considered to explore in more detail why patients are not adhering to particular medications, and 
therefore what areas should be targeted via intervention. Findings highlight serum phosphate levels as 
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a potentially more effective clinical measure of pre-transplant non-adherence and indicate that 
younger patients are more likely to be non-adherent to phosphate medication. This highlights a 
potential target area for intervention to improve pre-transplant medication taking, which could also 
improve post-transplant adherence behaviour. In addition, findings highlight the complexity of 
contributors to non-adherence, and the importance of a multi-disciplinary intervention to address this 
issue in patients both pre and post-transplant. 
 
5.4.3 Conclusions 
Poor phosphate control pre-transplant was associated with some aspects of adherence post-transplant. 
However, our findings do not indicate a strong direct relationship between pre and post-transplant 
adherence. Whatever measure of adherence used pre-transplant, non-adherence is less post-transplant 
and, in some cases, significantly so. However, the only adherence parameter that predicted post-
transplant adherence was pre-transplant phosphate control. Although some patients do improve 
adherence to treatment post-transplant, non-adherence remains an issue for a proportion of patients 
post-transplant. Non-adherent patients pre-transplant should be reviewed on a case-by-case basis for 
transplant eligibility, to determine if adherence behaviour could change following transplantation or if 
interventions are needed pre-transplant prior to wait listing. These findings require confirmation and 
further work to assess whether interventions in relation to pre-transplant adherence may enhance 
adherence post-transplant and hence improve outcomes. Furthermore, enhancing patient 
understanding about the importance of medication and engaging with treatment regimens could help 













Chapter 6: Understanding clinician attitudes towards the 




Qualitative studies in health-related settings allow researchers to highlight participants’ experiences 
and thought processes (Rohleder & Lyons, 2015), and can be used to understand about treatment and 
medication adherence. A recent systematic review of qualitative studies (Tong et al., 2011) explored 
the perspectives of renal transplant recipients on medication taking, as gleaned from studies using 
focus groups and interviews. The following themes were identified: 1) Attitudes to medicine taking – 
this comprised of a range of patient views including major life events, lifestyle, responsibility for 
maintaining health, protecting life and the relationship with the renal donor and health care 
professionals; 2) Unintentional non-adherence; 3) Medication properties – for example, patients often 
altered dosage or requested changes in medications due to side effects. However, patients who viewed 
dialysis treatment as worse than medication side effects would be more likely to adhere to taking 
medication as prescribed; 4) Structure of healthcare services – patients were sometimes conflicted by 
clinical appointments that asked them to alter medication taking for blood testing; 5) Personal efforts 
in managing medications – including strategies to try and improve memory and reminders; 6) 
Availability of external support – patients with strong social support from family members shared a 
sense of accountability which encouraged adhering to prescribed medication regimen. Research from 
quantitative studies support these findings, with non-adherence more often being due to patient 
forgetfulness (Griva et al., 2012), perceiving low social support (Denhaerynck et al., 2005; 
Denhaerynck et al., 2007), lifestyle (Muduma et al., 2016), high emotional distress and high transplant 
related stress (Jindal et al., 2003).  
 
Research exploring patient perspectives on medication taking could lead to the development of more 
effective strategies to improve adherence, resulting in improved treatment outcomes for renal 
transplant recipients (Tong et al., 2011). However, it is not clear from the literature whether clinicians 
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have similar understandings or beliefs about types of factors that influence medication taking, and 
whether research findings inform efforts to improve patient care. Clinician understanding of 
adherence behaviour is important to ensure optimal patient experience and response to treatment, and 
that treatment regimens are adjusted and prescribed with this in mind (Tong et al., 2011; Williams et 
al., 2014; Muduma et al., 2016) to improve patient quality of life and prolong graft survival.   
 
Few studies have explored clinician understanding and attitudes of non-adherence among renal 
transplant recipients. An interview study with nephrology nurses (Muduma et al., 2016) sought to 
understand reasons for non-adherence in this patient population. Nurses identified patients under the 
age of 25 years to be the most non-adherent and suggested that this was due to the transition from 
adolescent to adult care. They also indicated that young people’s lifestyles conflicted with good 
adherence, leading to forgetting to take medication, particularly the evening dose. Young people were 
also suggested to be less aware of the consequences of non-adherence (Muduma et al., 2016). This 
could be due to parents managing medication, resulting in young patients having less awareness of the 
importance of adherence for maintaining their health and wellbeing post-transplant. Elderly patients 
were also highlighted as often forgetting to take their evening dose of medication. However, these 
patients were more adherent with the morning dose (Muduma et al., 2016). Middle-aged patients were 
indicated to be most adherent, notably those with social support from family and partners. Reasons for 
non-adherence were ranked in the following order: 1) Forgetting (unintentional non-adherence); 2) 
Pill burden; 3) Lifestyle (Muduma et al., 2016).  
 
Williams et al., (2014) conducted a qualitative exploratory study focusing on medication taking. They 
interviewed nine renal transplant coordinators from five hospitals in Australia. Staff members 
emphasised the importance of early education in relation to immunosuppressant medication to ensure 
graft survival. Patients started receiving education on medication taking from when they were added 
to the waiting list to receive a deceased donor kidney transplant, or when the “work up” began in 
preparation for a live donor transplantation. Pre-transplant education sessions were run with various 
members of the multidisciplinary team every 2-4 months, covering areas such as renal transplant 
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surgery, staying healthy, medications specific to transplantation, psychosocial aspects and risks of 
renal transplantation. Leaflets on immunosuppressant medication and side effects were also provided. 
Most of the education relating to immunosuppressant medication began following transplant surgery 
when medication taking had started, with renal nurses explaining the function and importance of each 
tablet and the treatment regimen. Post-transplant booklets were also provided detailing the prescribed 
medications, their importance and possible side effects, as well as what to do if patients missed a 
dose. The authors extensively detail the importance of medication education, however, the 
effectiveness of this on adherence levels among their patients was not reported (Williams et al., 2014).  
 
This limited existing literature highlights the need for further research exploring clinician attitudes 
and understanding of non-adherence in this patient population. This will help to identify whether 
providers are aware of factors that are likely to result in non-adherence to medication, and how they 
might work with patients to address this issue in order to improve adherence, patient satisfaction and 
ensure graft survival. Research has shown that patient participation is associated with positive 
outcomes, and clinicians that dominate clinical appointment discussions reduce patient involvement 
(Stevenson et al., 2004). This indicates the importance of shared decision-making. Through 
understanding clinician attitudes to non-adherence, this will provide some evidence of whether 
“shared understanding” and agreement exists between patients and health care professionals.   
 
There is also a need to understand the importance of patient adherence in determining patient 
eligibility for transplantation. Guidelines on pre-transplantation assessment focus mainly on medical 
fitness, including cardiovascular health, obesity, exposure to infections, previous cancers etc. (Dudley 
& Harden, 2011). How adherence behaviour pre-transplant, with for example dialysis or pre-
transplant work-up, is considered as part of this process is less clear. Currently, there is limited 
existing literature exploring the relationship between pre and post-transplant adherence. Some of the 
issues relating to dialysis adherence such as attendance to HD, fluid and diet restrictions (Kammerer 
et al., 2007; Kim & Evangelista, 2010) may be reduced post-transplant, however, the issue of 
medication adherence and clinic attendance remains. It is not yet clear if non-adherence behaviour 
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transfers across treatment modalities. Due to the risks to graft function (Loghman-Adham, 2003) and 
treatment related costs associated with graft failure (Jindal et al., 2003) it is important whether non-
adherent behaviour should be more heavily considered when determining whether patients are eligible 
for transplantation. Additionally, how clinicians may target patients at greater risk for non-adherence 
post-transplant as part of transplant assessments in order to improve chances of graft survival is also 
unclear. It is important to identify why such a prevalent number of patients have issues with 
adherence post-transplant and how clinicians are considering and addressing this issue. There is of 
course a moral reason to understand further whether clinicians take pre-transplant adherence into 
consideration prior to listing for a donor organ. Most if not all healthcare systems are likely to have a 
higher demand for organs than supply. The morality of giving an organ to a candidate who already 
seems to be disengaged from optimising treatment may therefore lend itself to with-holding treatment 
until there are signs of improved adherence. Similar practice already operates for factors such as 
weight, as obese patients are at greater risk of peri and post-operative complications (Dudley & 
Harden, 2011). There is some evidence to suggest that patients who are not suitable for transplant 
waiting lists also favour an efficacy argument to give the donated organ its best chance (Lawrence, 
Sharma, Da Silva-Gane, Fletcher, & Farrington, 2013).  
 
6.1.1 Rationale 
Clearly there is a lack of research into whether or not clinicians feature pre-transplant adherence into 
their decision making as to whether or not to list a patient for transplantation. Yet, such considerations 
about “risk” to the donated organ might shape practices aimed at further encouraging patients to 
engage with treatment modalities to the best of their ability. The current study was designed to 
explore this issue further, importantly taking a qualitative approach to endeavour to gain a rich 
understanding of decision making in this context.  
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6.1.2 Aims and objectives  
The aim of the study was to complete semi-structured interviews with clinicians working closely with 
renal transplant recipients to elicit their: 
• Understanding of the term “non-adherence” in relation to renal transplant recipients; 
• Views on factors that influence adherence to treatment regimens following transplantation; 
• Attitudes towards the importance of patient adherence when determining eligibility for 
transplantation; 





Thirty-six staff members who work closely with renal transplant recipients were recruited from across 
two NHS Trusts: East and North Herts NHS Trust (Lister Hospital) and Royal Free London NHS 
Foundation Trust. Twenty-one were recruited from Lister Hospital and 15 from Royal Free London. 
Staff members included nephrologists, transplant surgeons, registrars, transplant nurse specialists and 
pharmacists. Table 6.1 provides a breakdown of participants across the two NHS sites. In total, the 
sample consisted of 20 (55.6%) females and 16 (44.4%) males. Across the two sites, eight (61.5%) 
consultant nephrologists were male, and five (38.5%) were female. Two (66.7%) transplant surgeons 
were male, and one (33.3%) female. Five (62.5%) renal registrars were male, and three (37.5%) were 
female. Seven (87.5%) of the transplant nurses were female, and one (12.5%) was male. The renal 
pharmacists and dialysis and research nurse were female. Years of experience working with renal 







Table 6.1: Breakdown of clinical staff recruited for interviews  
Lister Hospital 
N=21 
Royal Free London 
N=15 
Consultant Nephrologists N=6 
Renal Registrars N=8 
Transplant nurse specialist N=4 
Pharmacists N=2 
Dialysis and research nurse N=1 
Consultant Nephrologists N=7 
Transplant surgeons N=3 
Transplant nurse specialist N=4 
Pharmacists N=1 
 
6.2.2 Inclusion and exclusion criteria 
The following inclusion and exclusion criteria were applied to ensure that participants had expert 
knowledge to provide in depth and detailed responses during the interview, and to engage with the 
study materials independently. 
 
Inclusion Criteria:  
• Employed by the NHS; 
• Member of the renal transplant team with regular contact with renal transplant patients.  
Exclusion Criteria:  
• Staff who were not employed directly by the NHS;  
• Staff with less than six months experience.  
 
6.2.3 Design 
One to one semi structured interviews were conducted with participants. A qualitative methodology 
was considered the most appropriate in order to gather rich data to address the study aims. Interviews 
were digitally recorded and transcribed verbatim. The transcripts were analysed using thematic 
analysis (Braun & Clarke, 2006). This method of analysis allowed the research team to highlight 
prevalent themes from within the data. Two sites were included to ensure that data was representative 
across more than one NHS trust. One site was a transplanting centre (Royal Free London) and the 
other was a long-term follow up service (Lister Hospital) where patients return for follow-up care 
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after transplantation at a transplanting centre. Staff members were recruited until data saturation was 
achieved across the two sites, therefore meaning that no new themes were highlighted from 
conducting further interviews. A detailed summary of the qualitative method used in the study can be 
found in chapter three of this thesis. 
 
6.2.4 Data collection 
All staff members involved with the renal transplant process both pre and post-transplant, with regular 
contact with patients, were contacted via email and informed of the study aims by a consultant 
nephrologist who was a member of the research team. They were provided with the participant 
information sheet with the researchers contact details. This was then followed up with an email by the 
researcher, to determine whether or not they were interested in participating in the study. A 
convenient time and place were arranged to conduct the interview. All interviews were conducted 
face-to-face in offices at the Lister Hospital and Royal Free London, to ensure privacy and 
confidentiality. Consent was gained prior to starting the interview. Participants were informed that the 
interview was to be recorded, with their permission, however, any resulting data would be 
anonymised when transcribed.  
 
Interviews were conducted using an interview topic guide compiled of questions based on a review of 
the existing literature. Alongside discussion within the project team, this led to a topic guide that 
addressed interpretations of what it means to be non-adherent, the reasons underlying non-adherence 
rates and how these may be managed. In addition, the topic guide considered factors influencing the 
decision of whether a patient is eligible for transplantation, and the importance of pre-transplant non-
adherence in this decision-making process was also covered. All in all, the topic guide not only aimed 
to explore the level of consistency between what patients report as barriers and facilitators of non-
adherence, it also covered the important element of clinician decisions on wait-listing and whether 
this does or should feature within this process.  Staff were encouraged to expand on their responses to 
allow the interviews to go into areas that were not foreseen or could be anticipated. Demographic 
information was also collected at the time of conducting the interview, to allow the homogeneity of 
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the sample to be identified and acknowledged in the analysis. Interviews lasted on average 30 
minutes. 
 
6.2.5 Data analysis 
Interviews were transcribed verbatim. Transcripts were analysed using Thematic Analysis (Braun & 
Clarke, 2006). This systematic method allows researchers to identify recurrent themes within the data, 
demonstrating the issues relevant to clinicians regarding renal transplant recipients in relation to 
eligibility for transplantation and factors associated with non-adherence. Transcripts were read and 
allocated initial codes and themes by the researcher (AH) who also conducted the interviews. These 
codes and themes were discussed and confirmed with the research team. Constant reference to the 
original transcripts throughout the analysis process ensured that the resulting themes were true to the 
data. All analysis was conducted in NVivo version 12. The researcher’s positionality within the 
process was considered in relation to interviews and analysis, recognising that this will impact the 
way the “story” told by clinicians unfolds. Constant reference back to and self-evaluation of being a 
psychologist completing a PhD on non-adherence was required, as well as acknowledging what the 
thesis had shown so far so as to be aware of any biases that might influence interpretation of narrative 
from clinicians. Hosking & Pluut (2010) refer to this as “sources of subjectivity” (p.64-65). As a 
researcher there was constant reflection also on acknowledging that clinical staff make themselves 
vulnerable when sharing their beliefs about what could be a contentious issue, especially whether or 
not they take adherence into account when making decisions about wait-listing.  The interview 
process was highly supportive and non-judgemental by constantly reflecting on language, tone etc., 
and analysis paid attention to representing participants accurately.  
 
6.2.6 Ethical considerations  
Approval was given from the renal departments at the Lister Hospital and Royal Free London to 
conduct this research since low risk research with NHS staff required local approval as opposed to 
Research Ethics, which is required when researching with patients. This study received ethical 
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approval from the University of Hertfordshire Health, Sciences, Engineering and Technology ethics 
committee with delegated authority (UH protocol number: LMS/PGR/UH/03192). 
 
6.3 Results 
Five main themes were identified, which underpin clinician understanding of patient adherence 
behaviour and the role of this in their own transplantation assessment. The themes and their associated 
sub-themes are presented in Table 6.2.  A narrative overview of themes follows, which includes 
illustrative quotes to evidence consistency between what participants said and the extraction of 
meaning.  
 
Table 6.2: Summary of themes extracted from clinician interviews on understanding of adherence  
Theme       Sub-theme 
Barriers to adherence  - Predisposing risk factors  
- Language barriers  
 
Striving for normality 
 
- Regaining day-to-day autonomy 
- Aversion to dialysis 
 
Mutuality in maximising patient adherence 
 
- Multidisciplinary input in treatment 
management 
- Addressing amenable barriers to 
treatment engagement 
- Promoting adherence autonomy  
- Facilitating social capital  
 




- Complexity of subjective assessment 
- Predictability of future behavioural 
patterns 




- Perceptions of wellness 
- Risks driven by fallacy of bodily 
intuition 
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Barriers to adherence  
There was a clustering of risk factors for non-adherence, which featured consistently across all 
interviews. Additionally, clinical staff identified barriers to the formation of a meaningful patient-
physician relationship, which acted to reduce confidence or control in whether or not patients were 
aware of how to adhere. Within this theme, “predisposing risk factors” and “language barriers” were 
identified as sub-themes.  
 
Predisposing risk factors 
The majority of clinicians highlighted age and chaotic lifestyle as major risk factors for non-
adherence. Patients of younger age were considered to be at greater risk of non-adherence, as well as 
those who were trying to manage a busy lifestyle with, for example, work and family commitments. 
 
“I think that patients who have had additional big life events, whether that’s going from child into 
adulthood, or a breakup of a long-term relationship so suddenly they are more isolated or they’ve lost 
their job, those patients tend to be quite vulnerable to non-adherence.” (P007, Consultant 
Nephrologist) 
 
“Young patients I know are at higher risk and chaotic lifestyles, those and any drug or alcohol use 
would be flags that I would maybe be concerned about.” (P023, Consultant Transplant Surgeon) 
 
“How stable they are in their life etc. how chaotic their life is and there is a difference between 
someone who is let’s say elderly retired etc. who has a good financial backing and owns their own 
house etc. compared to someone who might be young, single mother, might have children to look 
after, has a lot of other things going on to try and balance as well as their health.” (P025, Consultant 
Nephrologist) 
 
Young patients with transplantations may be more at risk of non-adherence due to the challenge of 
managing a serious health condition and having to take medication, alongside wanting to have a 
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normal life similar to that of their friends. Additionally, the presence of chaotic lifestyles lead to 
patients experiencing barriers on a daily basis, whether that is a busy work schedule or family 
pressures that impacts their ability to attend clinics, or commonly finding themselves outside of a 
regular routine impacting remembering to take medication.  
 
Language barriers 
Some clinicians described how language barriers and communicating via professional or informal 
translators can cause concern. When family members or friends are used as translators, accuracy of 
translation and information relayed is not known. Such factors acted to reduce confidence and control 
in whether or not patients were well informed about adherence - an added challenge in clinical 
practice.    
 
“So we have to use one of the family members to translate, so it is out of our control exactly what 
information is being delivered to that patient, so it can be difficult sometimes” (P023, Consultant 
Transplant Surgeon) 
 
“Ideally you would have a professional translator when you see some of these patients but in many 
cases you are using a family member to translate, and so whether or not what you are saying is 
actually being translated correctly is a bit unknown to us”. (P010, Consultant Nephrologist) 
 
“I think sometimes if family members who are translating back to their parents for instance and I do 
find that challenging because you can never be entirely clear about what the patients understanding 
is of that” (P011, Renal registrar) 
 
Relying on unofficial translators can be challenging for clinicians when managing language barriers. 
Employing other methods of information transference, such as pictorial materials and information 
leaflets in their own language, could help with this, which was mentioned in some of the interviews. 
Patients where English is not their first language may be at greater risk of non-adherence if there is a 
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lack of understanding, therefore it is important to provide the best support where possible to ensure 
the importance of medication taking is understood. Despite the challenge, a minority of staff had 
considered proactive ways in which to address this barrier, which relates to a theme described later in 
the results section about “mutuality in maximising patient adherence”. 
 
“I think sometimes we need to make sure our information is culturally appropriate, sometimes to 
consider having it translated into, you can’t have it translated into every language, but there are 
definitely some. And then making sure that we also provide content in a non-written format so, 
something again that can be replayed for people, so either videos…” (P024, Consultant 
Nephrologist) 
 
“I think moving to some of the more modern ways of people getting information, electronic resources 
etc. videos… Finding different ways of what’s appropriate not just for different cultures but also 
different ages and health literacies and IT skills” (P025, Consultant Nephrologist) 
 
Striving for normality  
Clinicians described patients as viewing transplantation as a desirable treatment for their kidney 
failure. On the whole, most patients sought transplantation in the hope for a better quality of life. 
Additionally, those who had received dialysis prior to transplantation were often viewed as wanting to 
avoid having to return to that treatment. Within this theme, “regaining day-to-day autonomy” and 
“aversion to dialysis” were identified as sub-themes. 
 
Regaining day-to-day autonomy  
As well as being considered the best treatment option for treating ESRD, clinicians described how 
patients valued transplantation as an opportunity to regain freedom and independence, and an ability 
to live a more normal life. 
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“I think most patients would say they want it to happen because I think it’s a more life changing event 
for them and essentially they get their lives back….it’s as close as they’re going to get” (P023, 
Consultant Transplant Surgeon) 
 
“They see it as something that’s going to give them near normality, live life, work, go on holidays, do 
normal activities as other people.” (P009, Consultant Nephrologist) 
 
“So a lot of them say “at least I can have my life back”, especially if they’ve got families.” (P035, 
Transplant nurse specialist) 
 
Transplantation was viewed as an opportunity to regain independence and return to daily life 
activities, such as returning to work or participating more easily in family commitments.  
 
Aversion to dialysis 
Patients who had experienced dialysis were described as often viewing transplantation as a superior 
and better treatment, and therefore wanted to avoid having to return to receiving dialysis treatment. 
 
“I think the majority of patients who have been on dialysis for them a transplant will completely 
change their lives…...if they have a transplant they can now live normal lives, they can go back to 
work they can go on holidays and all of this. So for those that are on dialysis they do see it as life 
changing basically.” (P034, Renal Pharmacist) 
 
“If they have been on dialysis before and then they have had the transplant, some patients don’t want 
to go back to that phase of where they were on dialysis so they will be quite good with the adherence” 
(P006, Transplant nurse specialist) 
 
“…most of them like they’re really really grateful that they have the transplant and they don’t want to 
go back on dialysis anymore” (P004, Transplant nurse specialist) 
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Patients were described as being grateful for a transplant and the ability to lead a better life compared 
to life when on dialysis. Some described this as a motivator for adherence.  
 
Mutuality in maximising patient adherence 
The majority of participants described responsibilities they considered they have in ensuring that 
patients are prepared and enabled to be adherent to their treatment regimens. This encompassed a 
variety of elements from ensuring patient support was provided via a multidisciplinary team, adjusting 
treatment and follow-up to allow engagement and providing patient education to ensure that patients 
are prepared for managing transplant aftercare. Within this theme “multidisciplinary input in 
treatment management”, “addressing amenable barriers to treatment engagement”, “promoting 
adherence autonomy” and “facilitating social capital” were identified as sub-themes. 
 
Multidisciplinary input in treatment management 
The majority of participants described how patient information surrounding post-transplant treatment 
is conveyed via a multidisciplinary team. This was considered important as patients can gain input 
and expertise from different members of the team and engage with staff with differing regularity, all 
the time hearing consistent messages.  
 
“So most of that (how patients are educated about their medicines and health/wellbeing) is done 
usually by the multidisciplinary team, so we’ve got our pharmacists usually who get 
involved…especially in the transplant centres to go through medications…….nurses are very 
involved, the post-transplant nurse who is a good link for them to have outpatient communication. 
Usually these are the people that provide education for them and tends to be more the doctors 
consulting if they have side effects or issues when they come and see them in the clinic itself.” (P009, 
Consultant Nephrologist) 
 
“Involving other people to ensure that their patients are being adherent, so transplant co-ordinators, 
and other people involved in the follow up process. And even things like involving the pharmacist to 
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ensure the medications are you know, package them all together you know so it’s easier for patients 
to take them.” (P013, Renal registrar). 
 
“So that comes from both the doctors they see in clinic but we also have support from a post-
transplant nurse specialist and support from a renal pharmacist. And so they have the opportunity to 
see all 3 of those people at each clinic visit.” (P007, Consultant Nephrologist). 
 
The role of pharmacists in the transplant centre was also emphasised with patients receiving pictorial 
aids to understand the different medications and dosages that their regime consists of. This alongside 
verbal communication was utilised to ensure that patients understood their medications before being 
discharged. 
 
“The pharmacy we always go through, what’s called a Meds card, which is basically a list of all their 
medicines they’re on, what times to take it, what it’s for, some of the common side effects. And every 
transplant patient will get counselled by us before they go home.” (P034, Renal pharmacist) 
 
Utilising a multidisciplinary team was considered best practice for ensuring patients were prepared for 
post-transplant life and with the knowledge to enact adherent behaviour. Interacting with multi-
disciplinary team members allows patients to gain support with different aspects of their treatment 
management. Regular monitoring and revisiting of medications from different members of the team 
allows for greater monitoring of adherence and potential for engagement. Some participants indicated 
that transplant nurses may have more time to speak with patients, allowing for support and guidance 
to be provided but also opportunities for issues to be highlighted to the wider treatment team if 
necessary. Some patients may additionally feel more comfortable speaking to certain members of the 
treatment team than others, and having a multi-disciplinary team allows for patients access to a range 




Addressing amenable barriers to treatment engagement 
Clinicians discussed how it was important to establish reasons for non-adherence and provide 
reasonable adjustments to treatment where possible to allow patients to be more engaged. This was 
discussed in terms of medication and clinics, with some suggestions specifically related to the 
previously identified pre-disposing risk factors and some more general. Consideration of telephone 
clinics or off-site clinics were suggested to allow people greater flexibility in managing follow-up 
care alongside commitments such as work. 
 
“…trying to facilitate for instance telephone clinics if that’s appropriate and offering the patient as 
many chances and opportunities to adhere.” (P011, Renal registrar) 
 
“You can certainly do things like tele-clinics to try and speak to people directly at the house or when 
they are at work, make things easier for them. I think a lot of it is about making things as easy as 
possible for the person.” (P010, Consultant Nephrologist) 
 
“Whether you could do more tele-clinics or virtual clinics, or maybe doing satellite clinics in areas 
where patients tend to be, so there is less travelling. Out of hours clinics. Those might be innovative 
ideas to try to see patients, so we can keep communications, so that they can lead a normal life.” 
(P009, Consultant Nephrologist) 
 
With patients struggling with adherence to immunosuppressants, treatment could be altered in an 
attempt to improve this. This could include changes to dosage, such as from a twice day regimen to a 
once daily regimen in cases where certain medication doses are regularly forgotten or are difficult to 
incorporate alongside daily lifestyle pressures.  
 
“I think we can try to make it easier for them by having things like once a day medication, maybe 
even by combining pills together.” (P026, Consultant Nephrologist) 
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“…Or it could be that they find it difficult to take medication twice a day whereas if we switch them to 
a once a day regimen that might help because they might remember first thing but not in the 
evening…”. (P006, Transplant nurse specialist) 
 
One participant noted the cost-burden associated with this, however, which is often considered and 
presents restrictions in terms of the number of patients that can be allocated to this regimen. 
 
You do find that if they’re really non-compliant and they can’t take medicines twice a day or whatever 
there are preparations that they can go onto once a day slow release tacrolimus but again it’s more 
expensive, so we have to look at cost burden as well. So those we would reserve for the really non-
compliant. (P034, Renal Pharmacist) 
 
Alternatively, side effects of medications can be addressed by spreading doses across the day or 
changing the immunosuppressant medication that is being taken. 
 
“some of the once of a day ones, you get a high trough which is associated with a lot of tremor, so 
can we put them on a twice a day regime where they get a less peak of the drug and less side effects.” 
(P015, Renal pharmacist) 
 
Clinicians acknowledged a responsibility to monitor adherence behaviour and consider approaches to 
target and address barriers to adherence to ensure patients have the best opportunity to engage with 
their treatment. Additionally, this involves having discussions with patients to explore how patients 
are managing their treatment, however, it was noted that it is not always possible to do this at length. 
Addressing barriers and ensuring regimes are as clear and simple as possible allows patients the best 
opportunity to engage and adhere, without experiencing confusion or having to navigate around 




Promoting adherence autonomy 
Almost all clinicians emphasised the importance of patient engagement and communication to 
promote patient understanding and self-management of their treatment regime, whether that was 
continuing education that was already being implemented or considering improvements that could be 
beneficial.  
 
“They have to be in control essentially. And ideally from day one, they know what they were given, 
not just give them a cup of tablets to take. They have to understand them.” (P18, Renal registrar) 
 
“Patients taking charge of their health to a certain extent, so they are interested in knowing the blood 
result, their blood pressure, diabetic control, how to manage their tablets. I think a lot of it you need 
the patient to be very involved in their care post-transplantation.” (P009, Consultant Nephrologist) 
 
“…there are a lot of things patients can do looking after themselves, taking their medications, making 
sure to have blood tests and attending clinics. If they do you know own these, there are things that we 
can pick up early on, rather than after something has happened.” (P006, Transplant nurse specialist) 
 
“I think it comes down to communication…..clear and good communication, making sure your 
patients understand the importance of it and spending that time talk them openly about it” (P019, 
Consultant Nephrologist) 
 
It was considered that improving understanding of treatment necessity would lead to greater 
engagement with the treatment process and as a result, adherence. Encouraging patients to feel in 
control of their health, treatment and having the power to influence the outcome of their kidneys was 





Facilitating social capital 
Some participants highlighted the benefits of peer support, and how speaking with other patients that 
have experienced transplantation, whether a positive or negative journey, might be beneficial for 
transmitting adherence messages to prospective or newly transplanted patients, rather than just 
hearing them from clinicians. As such, clinicians were making efforts to enhance the social capital of 
patients by recognising the power of peer support.  
 
“It’s interesting when patients come to the support evening they won’t remember anything that the 
clinician said, but they will remember what the other patients have said that have been through it and 
I think that’s really powerful and if you choose the right peer support I think that’s a really good way 
of people understanding it.” (P025, Consultant Nephrologist) 
 
“To have patients to be able to speak to another patient who has gone through the transplant, what 
the journey has been, to see it from another patient but in a similar situation can give them some 
insight into not just what they think has gone really but to actually see someone for whom it’s not 
gone really well as well”. (P006, Transplant nurse specialist)  
 
“I think one of the main ways we could do is peer support actually speaking to other patients who 
have had a transplant, patients who have had a failed transplant and back on dialysis….What they 
need is peer support. Doctors can bang on about things but in many times it will not go into the 
patients head actually. They would be more receptive if someone who’s had a transplant is speaking 
to them” (P008, Consultant Nephrologist) 
 
Hearing from other transplant recipients may provide patients with a more realistic understanding and 
appreciation of the process when hearing experiences from someone who has actually undergone the 
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process and treatment. However, this would need to be structured and monitored to ensure appropriate 
advice and support was being provided and not encouraging negative beliefs.  
 
Complexity of shining light on adherence in wait listing 
Discussions surrounding the relationship between pre and post-transplant adherence resulted in 
differing views across clinicians in relation to the role of adherence as part of the transplant eligibility 
assessment and whether adherence to dialysis can be viewed as an indicator of post-transplant 
adherence. Despite this, some clinicians did consider the importance of ensuring the potential organ 
resource was respected and given the best chance of survival- recognising the scarcity of organs. 
Within this theme, “complexity of subjective assessment”, “predictability of future behavioural 
patterns” and “justice to scarce resource” were identified as sub-themes. 
 
Complexity of subjective assessment 
Clinicians described differing views in the role of non-adherence as part of the transplant assessment 
process in determining eligibility for listing. A few indicated it would have little impact in 
determining suitability. 
 
“For me it would have very minimal influence on them being suitable to be on the transplant list, 
other than them not engaging with the process of assessment to confirm that there is not a medical 
reason why they wouldn’t be able to have the transplant safely.” (P007, Consultant Nephrologist) 
 
“All patients are put forward for transplantation, so if we have concerns about their adherence we 
would see them in clinic and we would discuss them at a multidisciplinary team level, so I wouldn’t 
expect anybody just to be knocked out because they maybe haven’t turned up to clinics or they haven’t 
turned up to dialysis sessions. That would certainly raise red flags and therefore it would be 




“obviously the evidence of their adherence pre-transplant is relevant, but it’s not the be all and end 
all.” (P010, Consultant Nephrologist) 
 
Others recognised that perhaps it is overlooked and should be considered as part of the wider 
transplant work-up. 
 
“The psychological assessments may be overlooked and so you may actually just go through with 
someone transplant work-up and then actually realise they might be non-adherent without really 
working that out beforehand.” (P013, Renal registrar). 
 
“Do you know I think it (adherence) gets lost. I think it gets lost and we don’t focus on it and it is 
incredibly important. I think it only really gets looked at when it’s the second time around.” (P025, 
Consultant Nephrologist) 
 
A number of clinicians described how non-adherence to certain aspects of the treatment regimen pre-
transplant would have cause for concern, however, this might lead to patients not being listed until 
they could demonstrate an improved level of adherence.  
 
So if you’ve got someone who’s not adherent to the treatment their creatinine is going to be way high, 
and they may not be suitable for them to be put through to the transplant list, so the transplant team 
would usually advise that they demonstrate some degree of adherence before they get transplanted. 
(P006, Transplant nurse specialist) 
 
I think it depends how bad their noncompliance was beforehand. We’ve certainly had people where 
we have felt that they need to kind of understand what it would involve a bit better and be compliant 
for a while before we put them through it. (P026, Consultant Nephrologist) 
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“So yes we will stop patients from being transplanted if we don’t think they are going to be adherent 
and we do ask them to demonstrate adherence and we do write that on their clinic notes and will say 
not to be activated until can demonstrate adherence to dialysis and actually write that on their 
letters.” (P029, Consultant Nephrologist) 
 
It seems that the role of adherence as part of the transplant assessment process and eligibility for 
listing is unclear, and clinicians may take a differing view based on prior experience of patient cases. 
Among those who considered demonstrating a period of adherent behaviour appropriate prior to 
listing, this time period was often set individually with patients in mind, but often six months was 
considered suitable to confirm longer term adherence.    
 
Predictability of future behavioural patterns 
Clinicians considered the relationship between pre-transplant dialysis adherence and adherence post-
transplantation in different ways. Some considered the treatments were very different and therefore 
not comparable in terms of viewing as a predictor of future behavioural patterns. 
 
“I think sort of coming to dialysis for instance they are coming to the hospital three times a week for 
dialysis four hours at a time that’s a very different scenario I guess to coming for a clinic appointment 
post-transplant.” (P011, Renal registrar) 
 
“Now for me if someone is on dialysis and they’re not very good at taking their kidney medications 
and they’re not great at turning up for dialysis that tends not to worry me so much, because I think 
when you are transplanted it’s different. And I don’t think past performance is a guide to the future 
you know, when it comes to dialysis patients.” (P022, Consultant Transplant Surgeon) 
 
“But having a history of non-adherence doesn’t mean they’re not going to be adherent after they’ve 
had the transplant.” (P035, Transplant nurse specialist) 
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On the other hand, some clinicians felt that adherence to aspects of the pre-transplant treatment could 
be taken as indicators of non-adherence, and considered that this behaviour would likely, but not 
always, continue post-transplant. 
 
“So I think some are, many are. Some change their pattern because they realise they have been given 
an opportunity, but many are, many remain non-compliant to some extent, and I think it’s the extent of 
it that is the problem.” (P026, Consultant Nephrologist) 
 
“Most of them I would say yes in one way or another, it’s how bad they will be non-adherent post-
transplant. On the whole I would say mostly yes, some people less so.” (P025, Consultant 
Nephrologist) 
 
I think it’s likely but not a given. I think we have patients where there has been evidence of non-
adherence, but they seem to be reformed characters and then they are put on the list, transplanted, 
and then there is clear evidence of non-adherence post. But that’s not always the case. (P024, 
Consultant Nephrologist) 
 
Clinicians recognised that we can use adherence to aspects of pre-transplant treatment, such as 
dialysis attendance, phosphate binder/blood pressure medication adherence, attendance at clinic 
appointments/assessments etc. but the influence of these elements on transplant outcomes and 
transplant adherence is unclear. It was considered that elements of non-adherence may translate, 
however, there are instances where patients appreciate the “gift” of transplantation and recognise the 
importance of adherence for preserving graft function. Therefore, the predictability of future 





Justice to scarce resource 
Some of the clinicians considered adherence in transplantation eligibility in relation to the organs as a 
precious resource. Due to a limited availability of organs, it was considered that these should be 
distributed not only to a patient that was going to get the best use out of them, but also in respect to 
the donor themselves.  
 
“Many centres of course do think about compliance issues as well which is very important because 
you are taking an organ from someone else and giving it to someone, especially people who have 
been very non-compliant to dialysis more centres will think twice before thinking about giving a 
transplant” (P008, Consultant Nephrologist) 
 
“It is also not ethical because then maybe this kidney could have gone to someone else. So you know I 
think it is our job to make sure that whoever is put through is suitable for it.” (P018, Renal registrar) 
 
“…it’s normally the people who stand out as non-compliant that you would worry about, and that’s a 
sort of red flag, and then that’s something I do worry about in terms of what’s going to happen 
afterwards. Especially if you are taking a, it’s all about resources being limited” (P026, Consultant 
Nephrologist) 
 
However, it was interesting that some participants commented on this in relation to live donation, 
indicating that the issue relating to use of resource is removed when you have a living related donor. 
 
“that’s partly overcome if they have got someone in their family donating to them, although I think 
you would need to make it clear to the person donating that this is what happened the last time, this 
could happen again, and they understand that.” (P022, Consultant Transplant Surgeon) 
 
“It’s slightly different if you’ve got a relatively non-adherent patient where someone is a live donor, 
say a family donor who is willing to donate, because they are not reducing the pool of organs 
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generally. And we do occasionally get that, so you’ve got somebody who is relatively non-adherent, 
but their family member wants to give them a kidney and you know, so that aspect of it is much less 
relevant then.” (P010, Consultant Nephrologist) 
 
Considering the scarcity of the organ resource should be an important factor when assessing patients 
at risk of non-adherence post-transplant. This is particularly notable in relation to deceased donor 
transplants as organs could go to someone else, however, how this is viewed in relation to living 
related donation is less clear. It might be considered that it should be viewed in the same way as every 
kidney is a precious resource, and living donors are healthy individuals putting themselves at risk of 
an operation that is not to their benefit.  
 
Post-transplant normalization 
Most of the participants considered that non-adherence to immunosuppressants and clinic attendance 
increases with transplant vintage due to patients becoming complacent in how closely they monitor 
their treatment regimen. This was considered due to established stability of kidney function meaning 
medical input is reduced over time and patients returning to what they perceive to be a more normal 
life. Within this theme, “perceptions of wellness” and “risks driven by fallacy of bodily intuition” 
were identified as sub-themes.   
 
Perceptions of wellness 
The majority of participants described how successful transplantation leads to patients feeling well 
again. This experience of feeling well coupled with the ability to return to a more normal life post-
transplant, such as returning to work, may result in a busy lifestyle where treatment management is 
not considered as important or necessary.  
 
“There are a few who just think that oh I feel fine not realising that you have to take this for the rest 
of your life even though we’ve informed them.” (P035, Transplant nurse specialist) 
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“I think it comes down to, as I said, people feel better over time and if they haven’t had any problems 
within the first couple of years. I think that probably ascents this feeling of well things are going well 
and actually so far so good and everything’s been fine.” (P019, Consultant Nephrologist)  
 
“I think they start to feel well, they start to go back to work, start to do things they weren’t able to do 
before, generally life starts to get busy again in that respect for them and it just becomes another pill I 
think.” (P012, Transplant nurse specialist) 
 
“If their condition is stable and there’s not much exciting things happening, they sometimes forget 
about, you can forget about the transplant.” (P004, Transplant nurse specialist) 
 
Due to the complexity of pre-transplant treatment, particularly the debilitating nature of HD, patients 
who have successful transplantation and an uncomplicated adjustment in terms of renal function may 
forget or place less emphasis on the importance of the medication in terms of its role in preventing 
rejection as time progresses. Many patients consider transplantation as an opportunity to “get their life 
back” and as they transition back into how their life was before ESRD or HD they may focus on 
enjoying greater freedom and opportunities they have, with medication management taking less 
precedence. As medical appointments and interventions become less frequent with graft stability, 
there are additionally fewer opportunities for clinicians to monitor this behaviour. 
 
Risks driven by fallacy of bodily intuition 
Perceiving a lack of consequences with graft function was considered by the majority of participants 
as explanations for reduced adherence with immunosuppressants over time. Patients will likely 
experience at some stage a situation where they accidentally forget to take a tablet or take it late, and 
as a result may perceive that when nothing happens and they remain feeling well, the medication has 
little impact. This could occur as missing a tablet may not have immediate consequences. 
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“I assume that some people get more confident in their transplant working well and that occasionally 
may be in a position where they miss a medication or miss an appointment and not had a serious 
consequence and that’s made them feel less concerned about that happening again in the future.” 
(P007, Consultant Nephrologist) 
 
“So they will rapidly learn that if they miss one tablet, not much happens and so, whereas at the start 
after a transplant they probably, their anxiety levels are quite high, and they are much less likely to 
do things like miss medications and miss clinics.” (P010, Consultant Nephrologist) 
 
“And also there will be a degree of experimentation, so they will have possibly accidentally forgotten 
to take it one time and nothing bad happened, so you feel less stressed about you know if you forget 
again”. (P022, Consultant Transplant Surgeon) 
 
Over time patients become less anxious about the transplant function as it has been working well for a 
long period of time. Circumstances that have led to occasional forgetting or late taking of medication 
may have resulted in minimal perceived consequences or symptoms leading to repetition of this 
behaviour. This may be particularly notable for patients who experience other issues relating to their 
medication, such as side effects. As patients are followed up less frequently, there are less 
opportunities for transplant function to be monitored and checked, therefore the patient continues 
thinking their function is fine based on their treatment taking behaviour, perpetuating non-adherence. 
However, this may be a fallacy. Patients are also told that their body adjusts to the transplant and that 
clinicians wean down their immunosuppression over time and this may further add to their confidence 
in adjusting treatment regimens. In addition to this, they may speak to other patients at clinic who 
have had their medication dosage reduced who are still experiencing stable function and consider the 





The aim of this study was to explore clinician understanding of non-adherence among renal transplant 
recipients, including factors associated with adherence to treatment and the role of adherence in 
transplant eligibility. The study yielded a range of findings. Clinicians reported predisposing risk 
factors for non-adherence consistent with previous literature, citing younger age and chaotic lifestyle 
as major barriers (Denhaerynck et al., 2005; Muduma et al., 2016). Managing medications in light of 
lifestyle events was also discussed by patients and highlighted in a systematic review by Tong et al., 
(2011). Interestingly, language barriers were also considered challenging in ensuring messages of 
adherence are conveyed accurately to patients when using a family member as a translator, and 
introduces a third person into the patient-physician relationship that has to be managed. The 
proportion of patients from minority ethnic groups at the centres where clinicians were recruited from 
is higher than the overall proportion of renal service users from minority ethnic groups across the UK 
(Gilg, Methven, Casula & Castledine, 2017). As such, it is noteworthy but perhaps unsurprising that 
participants in this study considered the ability to directly form a relationship with patients as a major 
barrier to adherence as they simply could not be sure that patients had access to the right information.  
 
Clinicians perceived patients as viewing transplantation as an opportunity for a better quality of life 
and to regain day-to-day autonomy, close to how their life was prior to ESRD. This was captured by 
the ability for patients to return to work and re-engage with activities they were once unable to due to, 
e.g. HD. This finding supports recent literature in transplant recipients where transplantation was 
associated with improvements in health and lifestyle in the majority of patients (Tucker et al., 2019). 
Other studies of renal patients have shown the majority report the ability to re-establish everyday life 
following transplantation (Nielson et al., 2019). 
 
Many of the clinicians described feeling a sense of responsibility to ensure patients are prepared to 
manage expectations associated with transplantation and educated in order to adhere appropriately to 
prescribed treatment regimens. As such, there is mutual responsibility towards supporting adherence.  
The value of multidisciplinary input in delivering information was considered essential in educating 
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patients. Different health care professionals can all provide expertise to assist patients in managing 
their transplant follow-up care and also consistently share similar messages about self-care. 
Transplant nurses were considered to perhaps having more time to spend with patients to discuss 
transplantation, and pharmacists were essential in providing detailed education on prescribed 
medications. Clinicians also felt a responsibility to address amenable barriers patients experience, 
such as side-effects or challenges impacting adherence, in order to facilitate the ability to engage. This 
was considered through altering medication doses or flexibility with clinics. Peer support was also 
considered a method they should utilise to encourage adherence behaviour. Although it was not 
termed so by participants, what they perhaps have not realised is that by encouraging peer support, 
they are helping patients to build “social capital”, with social support consistently aiding strategies 
and motivation for managing treatment regimens (Parker, Ferreira, Vernon & Cardone, 2017). This 
emphasis on education mirrors that of Williams et al., (2014) where patient education was 
implemented both pre and post-transplantation verbally and through the use of information leaflets, 
ensuring patients have the best opportunity to be adherent and are aware of how to look after their 
kidney graft. 
 
The notion that patients become more non-adherent over time with transplant vintage was considered 
by clinicians as normalization relating to perceptions of wellness and experiencing a lack of 
consequences when tablets or doses are missed. This view supports similar patient findings among the 
renal transplant population (Griva et al., 2012; Nevins, Nickerson & Dew, 2017). Additionally, due to 
feeling well and the ability to return to a more normal life, patients may want to forget that they have 
been transplanted or have been unwell, identifying as a “normal person”. This doesn’t involve taking 
tablets on a daily basis. Jamieson et al., (2016) reported that patients want to free themselves from the 
patient role following transplantation and from continuous contact with health care professionals, 
which places them at risk for non-adherence. Patients reliance and need for regular contact with health 
care professionals also decreases over time (Nielson et al., 2019). All in all, changes in regularity of 
health service contact alongside a lack of bodily feedback may render a fallacy that “all is well”, 
which was seen as a concern by participants for future adherence.   
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Finally, the importance and role of pre-transplant adherence as part of the transplant assessment was 
contentious. Clinicians considered this aspect as having different levels of importance. Where the 
medical work-up has clear and concrete guidelines in regard to suitability for transplantation (Dudley 
& Harden, 2011), how adherence fits into this is less clear cut. Some clinicians reported pre-transplant 
adherence as having minimal input when assessing patient eligibility, and others recognised that it is 
perhaps overlooked. A larger number of clinicians discussed how certain pre-transplant non-
adherence behaviours are potential indicators of post-transplant adherence, such as attendance at 
dialysis, adherence to medications, such as phosphate binders or antihypertensives, or attendance at 
pre-transplant work-up. In these cases, patients would be asked to demonstrate a period of adherence 
before being listed, often reported as around 6 months. It is important to note, however, this was 
evaluated on a case-by-case basis and considered alongside the risks of prolonged dialysis on patient 
outcomes. This was viewed as appropriate not only for the patient in terms of graft outcomes once 
transplanted, but to ensure the best use of the organ due to the limited number of deceased donor 
transplants as a resource. So, clinicians were aware of medical ethics in their practice.  
 
In addition, although clinicians could identify potential pre-transplant predictors of post-transplant 
adherence behaviour, the relationship between pre and post-transplant adherence remains unclear. 
There is limited existing literature in this area to evidence if adherence behaviour is transferred across 
modalities. Some clinicians suggest it might, but it is not always the case. One study, completed 
within this programme of work, exploring relationships between HD and post-transplant adherence 
did not support the likelihood of a strong direct relationship between these behaviours (Hucker et al., 
2019). However, this was a small sample and the most effective objective measures of adherence are 
not yet clear. Despite this, it highlights a need for greater understanding in this area coupled with 
greater agreement among clinicians. Further research is needed to establish the relationship between 
pre and post-transplant adherence behaviour to allow this to be appropriately considered as part of the 
transplant assessment process. Additionally, consistent agreement is needed for transplantation in how 
best to manage pre-transplant non-adherence in order for transplanted kidneys to be given the best 
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chance of survival, but also to ensure patients are treated equally and fairly. So whilst it appears that 
there may be some strength in the suggestion that pre-transplant non-adherence could indicate issues 
post-transplantation, without further evidence and concrete guidelines driving consistency across 
patients, it is unsurprising that clinicians are fragmented in how much importance they place on 
adherence behaviour. But, this in itself indicates that patients may not be getting a consistent 
experience as some clinicians might expect a change in behaviour over 6 months, whilst others only 
look to medical “fitness”. There is clearly room for further consensus work on the role of adherence, 
if at all, in transplant listing.  
 
 
6.4.1 Strengths and limitations 
There were a number of strengths to this study. Firstly, a range of clinicians covering different roles 
and responsibilities in working with renal transplant recipients were recruited. This ensured that wide 
experiences were shared to contribute to the understanding of the topic area. Secondly, few studies 
have been conducted with clinicians to unearth their understanding of non-adherence; much of the 
literature has focused on understanding patient experiences. In doing so, the study has demonstrated 
consistency in some of the barriers and facilitators of adherence, but also uniquely been the first to 
raise the contentious issue of what clinicians additionally may place emphasis on in the wait-listing 
processes. As such, the research has identified a number of avenues for future research, including the 
reduced sense of ethical obligation that some clinicians voiced when managing living related organs.  
 
There are still a number of caveats that should be considered when interpreting the findings. 
Participants were recruited from two NHS sites only, and therefore views may not be generalisable to 
the wider community of clinicians working in this setting, especially as geographically, the Trusts 
were both located in either central or greater London. However, the study included a large sample size 
for a qualitative investigation including a range of employees within clinical teams. The data reflected 
a degree of shared and individual thoughts, which could be explored further in a larger scale 




Non-adherence post-transplant is a prevalent issue that clinicians have to manage with their patients. 
This study demonstrates that clinicians recognise and understand the barriers that patients can face 
with adherence, and often attempt to work on individual circumstances and find options for making 
treatment management easier. Enhancing patient understanding and engagement was considered an 
effective way to promote adherence, and clinicians felt a sense of duty in doing so alongside 
providing continued patient education and implementing greater use of peer support. Agreement on 
how adherence is viewed as part of transplant eligibility is lacking, with clinicians managing pre-
transplant non-adherence in different ways. This is a juxtaposition since on the one hand, clinicians 
felt that non-adherence is a subjective judgement, but at the same time, it is already being used in 
different ways and possibly leads to inconsistency in patient management, even if over a short 
duration of time (e.g. 6 months). Although the patterns of beliefs, attitudes, and behaviours exposed in 
this qualitative study could be helpfully followed up with a quantitative approach, it is likely that the 
findings signal need for consensus in the renal community about how non-adherence features in the 

























Chapter 7: The relationship between self-reported adherence 
and clinical parameters in transplant recipients 
 
7.1 Introduction 
Non-adherence among renal transplant recipients is a complex issue. It is a major risk factor for poor 
outcomes, including health complications and mortality (Leggat et al., 1998; Saran et al., 2003; 
Denhaerynck et al., 2007). It brings with it added healthcare and treatment related costs (Cleemput et 
al., 2004; Kugler, Maeding & Russell, 2011). For example, non-adherence has been identified as the 
second most common cause of late graft failure in renal transplant patients (Loghman-Adham, 2003). 
 
There is little previous research exploring the relationship between self-reported adherence and 
adherence recorded as part of routine care. It is common practice for transplant clinics to record serum 
levels of immunosuppressants in order to gauge how well patients are maintaining their treatment 
regimen. Self-reported non-adherence is often inaccurate and under-reported (Massey et al., 2013). 
Measures such as electronic monitoring are regarded as the most reliable and accurate form of 
measuring non-adherence (Schafer-Keller et al., 2008). However, as discussed earlier, even this 
method of measurement can be inaccurate as patients could open the bottle therefore recording 
medication as being taken but not actually take the medication itself. Electronic monitoring is also 
expensive, and so self-report is the most pragmatic alternative.  
 
Schafer-Keller et al., (2008) investigated the diagnostic accuracy of measurement methods to assess 
non-adherence to immunosuppressants in renal transplant recipients. The researchers found a 
significant association between adherence reported via blood assay and self-reported adherence. This 
suggests that whilst some research argues that self-reported adherence may fall short of objective 
assessment, there is reasonable concordance between the two.  Importantly, Schafer-Keller et al., 
(2008) also advanced the idea that combing measurement methods was in fact the most optimal 
option. Given that transplant clinics routinely record serum levels of medications such as tacrolimus, 
this offers the opportunity to further explore both agreement between self and objective reports of 
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adherence, and to further scope the usefulness of combining different outcome measures. There is a 
caveat that clinical methods of measuring adherence require careful interpretation (Schafer-Keller et 
al., 2008). Nonetheless, combining methods of measurement could allow for better evaluation of 
whether patients have a good and in-depth understanding of how they should be following their 
treatment regimen.  
 
Surprisingly, there is also a dearth of previous research exploring the role of psychosocial factors, 
such as medication beliefs and illness perceptions, in treatment and medication adherence among 
renal transplant recipients. Illness perceptions/ representations can be understood through the self-
regulation model (Leventhal, Nerenz & Steele, 1984), and refer to organised beliefs surrounding a 
health condition. The SRM suggests these beliefs then guide coping procedures in an attempt to 
control the illness threat, suggesting how patients perceive their illness may influence how they then 
manage it, including adaptation, coping and health behaviour. Research has identified the cognitive 
representations and behaviour that form illness representations (Moss-Morris et al., 2002; Broadbent, 
Petrie, Main & Weinman, 2006). The model consists of five key components of illness 
representations (Cameron & Moss-Morris, 2013). These include illness identity, consequences, 
timeline, control or cure and cause, with later versions of the model (Illness perceptions 
questionnaire-Revised: IPQ-R) including further components representing perceptions in relation to 
illness coherence, the cyclical timeline of illness and emotional representation (Moss-Morris et al., 
2002). Illness concern has also been included in refined versions of the scale (Brief IPQ) (Broadbent, 
Petrie, Main & Weinman, 2006). Previous literature has highlighted that patient behaviour is 
influenced by illness representations and could therefore be used to inform interventions in chronic 
illness groups (Petrie, Broadbent & Meechan, 2003).  
 
Illness perceptions have been explored in the context of a variety of chronic health conditions, 
including dialysis patients and to a lesser extent in renal transplant recipients. Among HD patients, 
previous literature has reported higher scores in a number of the illness perceptions domains 
(timeline, consequences, personal and treatment control and emotional perceptions) (Kim & 
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Evangelista, 2010). Relevant to the current research, patients believed that they could control their 
illness by receiving treatment (dialysis) to some extent. Therefore, it is plausible that patients 
perceiving low treatment control, curability or consequences could be non-adherent to their treatment 
regimen. In terms of treatment adherence, patients with more negative illness perceptions were more 
likely to be non-adherent to diet restrictions (Kim & Evangelista, 2010). The extent to which illness 
perceptions has been seen as crucial to illness experience in dialysis is further signalled by a 
systematic review which found five studies on the topic (Parfeni, Nistor & Covic, 2013). 
 
Some previous literature in renal transplant recipients has explored the association between illness 
perceptions and quality of life (Griva et al., 2009). Illness perceptions have also been explored in 
relation to treatment transitions between dialysis and transplantation (Griva et al., 2012). Changes in 
treatment from dialysis to transplantation are highlighted as having a significant impact on illness 
perceptions and quality of life. Receiving a kidney transplant was shown to lead to greater positive 
perceptions of illness identity, consequences, intrusiveness and controllability (Griva et al., 2012). 
This likely reflects the ‘gold-standard’ nature of transplantation over dialysis as a treatment modality 
that restores most normality for patients due to the reduction in symptoms, reduced treatment 
demands and improvements in kidney function (O’Connor et al., 2009). Griva et al., (2012) also note 
that positive illness perceptions post-transplant are associated with improved quality of life. Graft 
failure or graft loss was associated with decreased quality of life and negative changes in illness 
perceptions. Negative illness perceptions, poor health status and engagement in maladaptive coping 
techniques have also been associated with lower levels of quality of life and psychological distress, 
including anxiety and depression (Knowles et al., 2016).  
 
Research exploring the role of illness perceptions in self-reported adherence following renal 
transplantation (Massey et al., 2013), assessed patients six weeks following transplantation and again 
at six months using the Brief IPQ. At six weeks post-transplant, patients who perceived their graft to 
have a longer timeline reported higher adherence. Higher adherence was also associated with greater 
perceived personal control and emotional response. Perceived consequences were rated significantly 
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higher among patients categorised as non-adherent using the “Basel assessment of adherence to 
immunosuppressive medications scale” (BAASIS) (Dobbels et al., 2010). The authors changed the 
open-ended causes of illness question on the Brief IPQ to perceived causes of graft rejection. Non-
adherence to immunosuppressants was reported as a cause of graft rejection by 83% of the patients at 
both six weeks and six months post-transplant. These findings demonstrate that patient beliefs and 
perceptions about their illness may have an impact on medication adherence and a decline in 
adherence over time. This puts patients at greater risk of poor clinical outcomes. Further research by 
Massey et al., (2015) identified that patients who have good illness coherence relating to the 
transplantation process also have high perceptions of treatment and personal control. Low perceptions 
of symptoms and emotional response were reported, with emotional response reducing over time. All 
in all, such data suggests that illness perceptions are essential when trying to unpack patient responses 
to kidney disease and their treatment engagement. This becomes even more apparent given that illness 
perceptions have been shown to be amenable to change and so may offer a useful mechanisms for 
patient support (Jansen et al., 2013).  
 
Previous literature has also explored associations between patient beliefs about medication (BMQ) 
and adherence. Beliefs about medication in relation to adherence are suggested to be more strongly 
associated with specific medications prescribed, with a cost-benefit analysis of the necessity of 
medications for maintaining health assessed against concerns regarding adverse effects of medications 
(Horne & Weinman, 1999). It is suggested that decisions regarding adherence behaviour are 
influenced by this assessment. In a study of asthmatic, dialysis, cardiac and oncology patients, strong 
beliefs about the necessity of medications for maintaining health were identified (Horne & Weinman, 
1999). Patient beliefs about medication explained a significant proportion of the variance in adherence 
alongside type of illness and patient age. Dialysis and oncology patients were more adherent than 
asthmatic or cardiac patients. This may be due to perceptions of medication concerns outweighing the 
necessity (Horne & Weinman, 1999). Additionally, beliefs about medication were stronger predictors 
of adherence than sociodemographic or clinical variables. Patients who reported higher scores on the 
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concern scale compared to the necessity scale in relation to prescribed medication had lower levels of 
adherence. 
 
In a meta-analysis of the necessity-concerns framework in predicting adherence to medication, Foot, 
Caze, Gujral and Cottrell (2016) assessed this in relation to a variety of different conditions, which 
included studies of dialysis and transplant patients. Adherence to medication was positively correlated 
to necessity beliefs and negatively correlated to concern beliefs via the BMQ, with those perceiving 
their medication as necessary for maintaining health and wellbeing were more adherent compared 
with those who do not. Patients who perceive greater concerns from medications, such as increased 
side effects, disruption to daily life and normal routines and medication dependency are more likely to 
be non-adherent. This supports the findings reported by Horne & Weinman (1999) in relation to the 
cost-benefit analysis. 
 
Among renal transplant recipients, patients report higher levels of perceived necessity of 
immunosuppressant medication and lower levels of concern, with the perceived benefits of the 
medication outweighing the costs in treating and managing post kidney transplant care (Massey et al., 
2013; Massey et al., 2015). This is similar to literature that has explored a variety of health conditions 
(Horne & Weinman, 1999; Foot et al., 2016). Over time, perceptions of immunosuppressant 
medication necessity were shown to significantly decrease, however, this did not impact the cost-
benefit view towards immunosuppressants. No significant differences were reported between adherent 
and non-adherent groups in beliefs about medication. Lennerling & Forsberg (2012) report similar 
findings within this patient population, with perceptions of immunosuppression necessity found to be 
high and for concerns, low. Additionally, this study measured adherence via the BAASIS self-report 
measure and reported high levels of adherence among renal transplant recipients, which is reflected 
through the high perceptions of immunosuppressant medication reported via the BMQ necessity scale. 
Patients demonstrated understanding of this medication and the importance of taking it for 
maintaining health and wellbeing. However, despite this, no significant relationships were observed 
between the BAASIS and the BMQ, which suggests that medication beliefs and actual adherence may 
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be independent to some degree. This was supported by Massey et al., (2015) who additionally found 
no significant relationships between adherence and medication beliefs. The feeling of low social 
support from family and friends was the only factor related to self-reported adherence. 
 
7.1.1 Rationale 
Adherence behaviour is essential for maintaining kidney function, including for transplant recipients 
in order to prevent decline or rejection of grafts.  The best measure of adherence behaviour remains a 
key question for clinical providers, with some suggestion that combining objective measures such as 
routine blood serum/ assay levels of immunosuppressants with self-reports offering a useful avenue to 
explore. At the same time, whilst there is some research on the importance of illness perceptions and 
medication beliefs for transplant populations, still less is known about how these factors impact on 
engagement with treatment and crucially, whether they form a basis for patient support.  This study 
was designed to explore these considerations.  
 
7.1.2 Aims and objectives 
The first aim of the study was to determine whether self-reported adherence is associated with 
markers of adherence obtained from clinical data. The second aim was to determine which illness 
perceptions are associated with adherence to immunosuppressants in a sample of kidney transplant 
recipients. The third aim was to determine whether medication beliefs are associated with adherence 
to immunosuppressants in this patient group. The final aim was to investigate how patients 
conceptualise their post-transplantation treatment.  
 
7.2 Methods 
Adult patients from the renal service of the East and North Hertfordshire NHS Trust were invited to 
participate in the study. Eligible renal transplant recipients who attend the post-transplant clinic at 
Lister Hospital were approached for inclusion in the study. The weekly post-transplant clinic was 
 176 
attended by the researcher over a period of 7 weeks throughout April and May 2019. Clinical data was 
retrieved from the patient electronic database following completion of the study questionnaire. 
 
7.2.1 Participants 
Of 160 participants approached, 128 consented and completed the questionnaires, of which 109 were 
returned fully complete. Thirty participants declined/refused to take part when approached in clinic 
and two participants contacted the researcher prior to their clinic date asking not to be approached for 
participation. A power calculation was performed for sample size estimation. With up to five 
covariates for a linear regression model, an alpha of =.05, power =0.80 and effect size = 0.15, the 
projected sample size needed was approximately N=92. Therefore, our sample size collected was 
adequate for the study. 
 
7.2.2 Inclusion/exclusion criteria 
The following inclusion and exclusion criteria were used to ensure all participants could engage with 
the study materials independently and to ensure that clinical data was available for all participants via 
patient electronic records at the Trust.  
 
Inclusion criteria included:  
• Aged 18 years or over;  
• Good English language skills;  
• Renal transplant recipient attending the post-transplant clinic at Lister Hospital 
• Capacity to consent  
 
Exclusion criterion:  
• Patients who did not have sufficient English language skills to access study materials or to 
complete self-report questionnaires accurately 
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7.2.3 Design and procedure 
A cross-sectional design was used. Potential participants were informed about the study via letter 
prior to their clinic appointment date. They were advised that a researcher may approach them during 
clinic. The participant information sheet was included with the information letter for potential 
participants to read in their own time ahead of clinic. Eligible patients were approached during their 
transplant clinic appointment waiting time. The study aims and implications of participation were 
explained to patients. Patients were asked if they had received and read the participant information 
sheet sent to them via post, and were provided with a participant information sheet to read again if 
necessary and given time to decide whether to participate. They were informed that the study was 
voluntary, and that they could withdraw from the study at any time without explanation. Potential 
participants were informed via the information sheet that clinical data collected as part of routine care 
would be accessed as part of the research, and provided consent for this via the consent form to 
indicate they were happy for their clinical data collected as part of routine care to be accessed as part 
of the study. Patients were also informed and assured of the confidentiality of their data.  
 
Patients provided informed consent by signing a consent form, to show they understood the research 
they were participating in and consented to take part. Patients were given an anonymity code to use on 
their questionnaires, to ensure data was collected anonymously and could be identified should the 
participant wish to withdraw. Once consented, patients completed the questionnaires. They were 
provided with instructions on how to do so and were asked to complete them on their own. 
Questionnaires were completed via paper copy, allowing patients to complete questionnaires during 
clinic whilst waiting for their appointment with the consultant nephrologist.  
 
Data was also retrieved from the patient record database at Lister Hospital for each patient, in order to 
compare self-reported adherence from the questionnaires to clinical measures recorded as part of 
routine care. This included immunosuppressant levels from routine blood tests, attendance at post-
transplant clinic appointments, and a range of other information that was deemed useful for further 
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analysis namely: donor type and whether patients were transplanted pre-emptively or following 
receiving dialysis.  
 
7.2.4 Materials/ Measures  
The following self-report measures were completed: demographics (including date of birth, gender, 
ethnicity, level of education attained, work status/occupation and relationship status), the medication 
adherence report scale (MARS-5) (Horne & Weinman, 2002), the beliefs about Medicines 
Questionnaire (BMQ) (Horne, Weinman & Hankins, 1999) and the brief illness perceptions 
questionnaire (Brief IPQ) (Broadbent , Petrie, Main & Weinman, 2006). The measures were adapted 
to fit the context of what was being specifically measured among renal transplant recipients. All 
scales were brief and easy to complete i.e. tick box only and have been widely used with patients with 
ESRD. Detailed summaries of each of the measures used (MARS-5, BMQ, Brief IPQ) can be found 
in chapter three of this thesis. 
 
Open-ended questions 
Additional open-ended questions were included for patients to provide detailed written responses 
relating to adherence to treatment. Developed through discussion within the research team, the 
questions were aimed at providing more depth of understanding about trends within the quantitative 
data that was being collected. The items received feedback from members of the public involvement 
in research group (PIRg) hosted within the school of health and social work at the University of 
Hertfordshire in order to assess clarity. Suggested revisions were included and the final questions 
were:   
 
1. Were you on a different renal replacement treatment modality prior to your kidney transplant? 
(e.g. haemodialysis, peritoneal dialysis). If yes, what Renal Replacement Therapy did you 
receive? 
2. Can you describe how you found following/sticking to that treatment regime? 
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3. Can you describe how you find following your post-transplant treatment regime? 
(Immunosuppressant medication, clinic appointments etc.) 
4. Do you think that you have got better or worse in how well you follow your treatment regime 
over time? 
5. Has how you engage with treatment and advice you have been given changed over time? 
 
Clinical Data 
Clinical data collected as part of patient routine care was retrieved from the patient electronic 
database for analysis in the study to compare to the questionnaire study data. This included transplant 
donor type, number of immunosuppressants taken for treatment regimen, immunosuppressant blood 
levels (tacrolimus or ciclosporin), number of missed clinic appointments and whether patients were 
transplanted pre-emptively or following receiving dialysis. For immunosuppressant blood levels, an 
average was taken for the 6 months prior to completing the questionnaire or at least three readings if 
this was under 6 months. The number of missed clinic appointments was also recorded for the 6 
months prior to completing the questionnaire or at least three appointments if this was under 6 
months. Clinical expected therapeutic ranges of immunosuppressant blood levels were also used in 
order to calculate the percentage of readings outside the expected range during the data collection 
period (6 months prior to completing the questionnaire). These were determined via input from the 
project team, which included two Consultant nephrologists, local practice protocol and cross checking 
with previous research. For tacrolimus, a therapeutic range of 5-10ng/mL in the first year following 
transplantation was used (Schafer-Keller et al., 2008) and a therapeutic range of 5-8ng/mL for those 
>12 months post-transplant (NHS Royal Berkshire, 2014). For ciclosporin, a therapeutic range of 50-
100ng/mL was used for patients >12months post-transplant based on local practice protocol. No 
patients in the study taking ciclosporin were <12 months post-transplantation.   
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7.2.5 Ethical Approvals 
This study received NHS and HRA ethical approval (IRAS number 254246) and was approved by 
East and North Hertfordshire NHS trust to commence. Ethical approval was also granted by the 
University of Hertfordshire (UH protocol number LMS/PGR/NHS/02924). Permissions were sought 
from the author for use of the MARS-5 and BMQ. The brief-IPQ is freely available within the public 
domain.  
 
Risk Assessment for Patient Participants 
The risks for patients in completing these questionnaires were deemed minimal. It was unlikely that 
completing the questionnaires would be sensitive or upsetting for participants as we were only asking 
about their treatment and medication experiences. However, the researcher was available whilst 
participants were completing the questionnaires should they have had any questions or queries they 
wished to discuss. In addition, participants were given a study debrief form and provided with details 
of the research team and a member of the local post-transplant team should they have had any 
questions following participation.  
 
Risk Assessment for Researcher 
There was minimal risk to the researcher. The researcher had undergone the relevant GCP training to 
take consent from patients and had experience of conducting research with this patient population. 
  
7.2.6 Confidentiality  
Questionnaires were completed via paper versions to aid ease of participation during clinic time. 
Questionnaires and consent forms were kept in a locked filing cabinet in separate files at the 
University of Hertfordshire. The data was anonymised and password-protected in excel, and 
anonymised in a statistics package when entered for analysis, to ensure that patients were not 
identifiable. Clinical patient data was retrieved from patient records using an NHS computer at the 
Lister Hospital, East and North Hertfordshire NHS Trust. This data was also anonymised and 
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password-protected in excel, and anonymised in a statistics package for analysis, to ensure that 
patients were not identifiable. Patients were only identifiable via an anonymity code used on the 
consent form and questionnaires, to ensure questionnaires could be identifiable should a participant 
have wished to withdraw their data following participation.  
 
7.2.7 Statistical Analysis 
Descriptive statistics were used to characterise the study sample and to calculate mean adherence, 
beliefs about medicines and illness perceptions rates. Correlation analyses was used to explore 
relationships between self-reported adherence (MARS-5) and adherence recorded in clinical data (1: 
Immunosuppressant blood levels [as immunosuppressant mean scores, z-scores of the mean, 
variability via z-scores of standard deviation of immunosuppressant levels and percentage outside 
expected immunosuppressant blood level ranges]; 2: post-transplant clinic attendance) for renal 
transplant recipients. For example, self-reported immunosuppressant medication adherence was 
compared to immunosuppressant levels to assess if there was a correlation between what patients 
report and their recorded adherence level via routine blood tests. Linear regression models were used 
to determine whether illness perceptions predict adherence among renal transplant recipients. 
Additional regression analyses were used to determine whether beliefs about medication predict 
adherence among renal transplant recipients. All tests were two-tailed and p-values of less than 0.05 
were considered to be significant. The data was analysed using SPSS version 25. Feedback on open-
ended questions were reviewed and analysed using thematic content analysis, and anonymised quotes 





Patient characteristics are shown in Table 7.1. Mean age for the sample was 55.5 years (SD=13.34; 
range 20 – 86 years). The majority of the sample were male (N=81, 63.3%), married (N=73, 57%) 
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and of white ethnicity (N=95, 74.2%). Patients reported mixed employment status with a roughly 
equal split of employed (N=61, 47.6%) or retired (N=43, 33.6%), with a range of different education 
levels.  
 
Table 7.1: Demographic characteristics of patient study sample  
  N=128 
Age M (SD) 55.5 (13.3) 
 
Gender N (%)  
Male 81 (63.3) 
Female 47 (36.7) 
 
Ethnicity N (%)  
White European 95 (74.2) 
Minority ethnic 32 (25) 
Missing 1 (0.8) 
 
Relationship Status N (%)  
Single 28 (21.9) 
In a relationship 7 (5.5) 
Living with partner 8 (6.3) 
Married/civil partnership 73 (57) 
Divorced 9 (7.0) 
Widowed 3 (2.3) 
 
Occupation N (%)  
Unemployed 17 (13.3) 
Employed 47 (36.7) 
Self-employed 14 (10.9) 
Retired 43 (33.6) 
Student 3 (2.3) 
Other 4 (3.1) 
 
Education level N (%)  
No formal qualifications 25 (19.5) 
GCSE or equivalent 33 (25.8) 
A-level or equivalent 20 (15.6) 
University or college degree  38 (29.7) 
Post-graduate qualification 9 (7.0) 




Treatment characteristics of the sample are summarised in table 7.2. The majority of the patients 
received a deceased donor transplant (N=94, 73.4%) and were transplanted following receiving renal 
replacement therapy via dialysis (N=111, 86.7%). The average transplant vintage for the sample was 
just under eight years (M=7.96, SD=6.43). Post-transplantation, the majority of patients were taking a 
combination of two immunosuppressant medications (N=70, 54.7%). In terms of clinic attendance, 
the sample reflected an adherent group with 89.9% (N=115) of patients having missed no post-
transplant clinic appointments in the six months prior to taking part in the study. Nine patients (7%) 
had missed clinic appointments in the previous six months prior to taking part in the study, with only 
a few patients having missed more than two. The majority of patients were taking tacrolimus as their 
main immunosuppressant (N=109, 85.2%). Mean tacrolimus level for patients for the six months prior 
to the study was 5.99 ng/l (SD=1.52). Of those taking ciclosporin (N=15, 11.7%), mean level for 
patients for the six months prior to the study was 73.4 ng/ml (SD=31.1). Using the 
immunosuppressant therapeutic expected ranges, 81 (65.9%) patients were found to have blood levels 
outside the expected range for more than 25% of the readings during the study data collection period 



















Table 7.2: Treatment characteristics of patient study sample 
  N=128 
Donor type N (%)  
Deceased 94 (73.4) 
Living 34 (26.6) 
  
Transplant Vintage (years) M (SD) 7.96 (6.43) 
 
No. immunosuppressants N(%)  
1 13 (10.2) 
2 70 (54.7) 
3 45 (35.2) 
 
Pre-emptive vs. post-dialysis transplant N (%)  
Pre-emptive 17 (13.3) 
Post-dialysis 111 (86.7) 
 
No. Missed clinic appointments N (%)  
0 115 (89.8) 
1 9 (7.0) 
2 1 (0.8) 
3 1 (0.8) 
4 2 (1.6) 
 
Immunosuppressant levels M (SD)  
Tacrolimus ng/1 (N=109) 5.99 (1.52)  
Ciclosporin ng/ml (N=15) 73.4 (31.1) 
Missing (N=4)   
  
Percentage outside immunosuppressant expected 
therapeutic range N (%)  
>25% 81 (65.9) 
>50% 48 (39) 
>75% 21 (17.1) 
Missing (N=5)  
 
Data Screening 
All variables were tested for normality using the Shapiro-Wilk test. The test showed that the data did 
not meet the assumption of normality for most parameters, with the exception of BMQ specific-
concern and BMQ necessity-concern differential (see table 7.3). All non-normally distributed 
variables were transformed using both log transformation and square root transformation to see if the 
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normality issues could be resolved. All variables remained significantly non-normally distributed, 
therefore further analysis was conducted using the original non-normally distributed variables. 
 
Table 7.3: Shapiro-Wilk test of normality for questionnaire items. 
 p-value 
MARS-5  
MARS 1 (N=121) <.001 
MARS 2 (N=116) <.001 
MARS 3 (N=116) <.001 
MARS 4 (N=116) <.001 
MARS 5 (N=116) <.001 




Item 1: Consequences (N=127) <.001 
Item 2: Timeline (N=125) <.001 
Item 3: Personal control (N=125) <.001 
Item 4: Treatment control (N=127) <.001 
Item 5: Identity (N=125) <.001 
Item 6: Concern (N=127) <.001 
Item 7: Coherence (N=127) <.001 
Item 8: Emotional representation (N=126) <.001 




BMQ Specific: Necessity (N=125) <.001 
BMQ Specific: Concern (N=123) .07 
BMQ Necessity-Concern differential (N=123) .38 
BMQ General: Overuse (N=126) .042 
BMQ General: Harm (N=126) .001 
NB: MARS-5 = Medication Adherence Report Scale; Brief IPQ = Brief Illness Perceptions 
Questionnaire; BMQ = Beliefs about Medicines Questionnaire 
 
Reliability of the Scales Used  
The internal reliability of the scales, indicated by Cronbach’s alpha, is displayed in table 7.4. The 
Brief IPQ scale total had a good reliability score of 0.77. The beliefs about medicines sub-scales had 
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good reliability scores of above 0.70, with only the general-harm scale having a score below this of 
0.66, albeit still acceptable. The MARS-5 had a poor internal reliability score of 0.38. When exploring 
correlations between the five items on the scale, item 1 and item 2 failed to have a correlation 
coefficient of above 0.30 with at least one other item in the scale. A benchmark of 0.30 is commonly 
used in scale development and assessment. When items 1 and 2 were removed from the scale, internal 
consistency improved to 0.69. It is possible that the items within the scale could be interpreted as 
measuring different types of non-adherence, and this may have caused lower internal reliability. Item 
1 “I forget to take them” could be viewed as measuring unintentional non-adherence, whereas the 
other items are on intentional non-adherence. Item 2 “I alter the dose” may not be viewed as having 
serious consequences if patients are longer since transplantation and are therefore confident in 
medication taking or may have agreements with clinicians on when and how to alter doses if required 
dependent on patient needs. Items 3, 4 and 5 could be viewed as more serious in terms of non-
adherent behaviour. It is possible in this patient sample that although patients may forget to take 
medication or may alter doses, they may be less likely to stop taking them for a while (item 3), decide 
to miss out a dose (item 4) or take less than instructed (item 5). It is therefore possible that in the 
context of the patient sample used in this study, patients understood the questions relating to different 
types of non-adherence with differing consequences of non-adherent behaviour. However, this scale 
has been validated in a number of long-term conditions and other previous studies using the MARS-5 
have found good internal reliability of the scale, including studies of HD (Wileman et al., 2015) and 
transplant populations (Butler et al., 2004; Griva et al., 2012). Therefore, based on this consideration, 
the total scale using all five items will be used in this analysis. Analysis was conducted using the 
modified MARS items 3-5 only to explore if the data would change. Similar outcomes were observed 








Table 7.4: Internal consistency shown by Cronbach’s alpha for each questionnaire scale 
Scale Cronbach’s a 
MARS-5 (N=114) 0.38 
MARS items 3-5 (items 1 & 2 deleted) (N=115) 0.69 
  
Brief IPQ items 1-8 (N=119) 0.77 
  
Beliefs about medicine  
BMQ Specific: Necessity (N=125) 0.80 
BMQ Specific: Concern (N=123) 0.73 
BMQ General: Overuse (N=126) 0.75 
BMQ General: Harm (N=126) 0.66 
MARS-5 = Medication Adherence Report Scale; Brief IPQ = Brief Illness Perceptions Questionnaire; 
BMQ = Beliefs about Medicines Questionnaire 
 
Mean scores for the three questionnaires administered in the study are displayed in table 7.5. Scores 
on the MARS-5 reflect high self-reported adherence to immunosuppressants, with a total MARS-5 
mean score of 24.25 (SD=1.10) out of a total score of 25. Responses on the beliefs about medicines 
questionnaire indicate that patients felt their illness has an infinite timeline (M=9.38, SD=1.76). 
Patients indicate they felt treatment is extremely helpful in helping their illness (M=8.73, SD=1.87) 
and that they understand their illness clearly (M=8.80, SD=1.63). Responses relating to other 
elements of the brief IPQ reflect a moderate view. An overall score for the brief IPQ was computed 
representing the degree to which illness is perceived as threatening or benign. The total score reflects 
a moderate threatening view of illness (M=35.57, SD=13.38). Responses on the BMQ specific-
necessity indicate that patients have strong perceptions of the need for the immunosuppressant 
medication they are taking to maintain their kidney transplant health now and, in the future, 
(M=21.70, SD=3.27). Scores on the BMQ specific-concerns scale indicate patients have uncertain 
views about the potential negative effects of immunosuppressant medication. The relative importance 
of these attitudes (necessity and concerns) was obtained by calculating the necessity-concerns 
differential. The differential score indicates patients perceive the benefits of their immunosuppressant 
medication to outweigh the costs (M=9.40, SD=5.17). Responses on the BMQ general-overuse scale 
indicate an uncertain view about how medicines are prescribed and beliefs that they are overused by 
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clinicians (M=10.21, SD=2.85). Scores on the BMQ general-harm scale are low indicating a more 
positive view about medicines, perceiving them as less likely to be harmful (M=7.98, SD=2.47). 
 
Table 7.5: Overall patient mean scores for adherence, illness perceptions and treatment beliefs 
  M (SD) 
MARS-5  
MARS 1 (N=121) 4.45 (0.77) 
MARS 2 (N=116) 4.88 (0.42) 
MARS 3 (N=116) 4.95 (0.22) 
MARS 4 (N=116) 4.98 (0.13) 
MARS 5 (N=116) 4.93 (0.32) 
MARS Total (N=114) 24.25 (1.10) 
 
Brief IPQ  
Item 1: Consequences (N=127) 4.46 (3.04) 
Item 2: Timeline (N=125) 9.38 (1.76) 
Item 3: Personal control (N=125) 5.90 (2.96) 
Item 4: Treatment control (N=127) 8.73 (1.87) 
Item 5: Identity (N=125) 4.48 (3.12) 
Item 6: Concern (N=127) 5.67 (3.26) 
Item 7: Coherence (N=127) 8.80 (1.63) 
Item 8: Emotional representation (N=126) 4.63 (3.33) 
Brief IPQ Total (N=119) 35.57 (13.38) 
 
BMQ  
BMQ Specific: Necessity (N=125) 21.70 (3.27) 
BMQ Specific: Concern (N=123) 12.28 (3.85) 
BMQ Necessity-Concern differential (N=123) 9.40 (5.17) 
 
BMQ General: Overuse (N=126) 10.21 (2.85) 
BMQ General: Harm (N=126) 7.98 (2.47) 
MARS-5 = Medication Adherence Report Scale; Brief IPQ = Brief Illness Perceptions Questionnaire; 
BMQ = Beliefs about Medicines Questionnaire 
 
Correlation Analyses 
Spearman’s correlation was used to explore associations between total MARS-5 adherence scores 
with both the illness perceptions from the brief IPQ and the BMQ sub-scales (see table 7.6). 
Consequences, personal control, treatment control and emotional representation were all found to 
significantly correlate with total MARS-5 adherence score. Brief IPQ total score was found to 
significantly correlate with total MARS-5 adherence score. None of the BMQ sub-scales were found 
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to correlate with total MARS-5 adherence score, however specific-necessity and general-overuse were 
marginally non-significant. Additionally, correlations were conducted exploring associations between 
clinical data and MARS-5 adherence (see Table 7.6). No significant correlations were found between 
mean tacrolimus levels, mean ciclosporin levels or clinic attendance and total MARS-5 adherence 
score. In addition, standardised z-scores of the mean, z-scores of the standard deviation of 
immunosuppressant levels for variability comparisons and percentages outside the expected range for 
immunosuppressant blood levels were calculated to correlate with adherence. Similarly, no significant 
correlations were found between any of the immunosuppressant variables and total MARS-5 
adherence score. When exploring transplant vintage, no significant correlations were observed 
between adherence, illness perceptions or beliefs about medications and transplant vintage. 
 
Donor type was also considered to see if this impacted on adherence or psychological factors. Mann-
Whitney U test was used due to the difference in patient numbers between the donor type groups and 
the non-normal distribution of the measures. No significant differences were observed in illness 
perceptions and beliefs about medicines between deceased donor and living donor recipients. A 
significant difference was found in MARS-5 adherence scores between deceased donor (M=24.11, 
SD=1.19) and living donor (M=24.63, SD=0.67) recipients, U=940.0, p=.022, with deceased donor 












Table 7.6: Spearmans correlations between Brief IPQ and BMQ scales with adherence  
   MARS-5 Total 
  rs p 
Brief IPQ   
Consequences -0.28 .003* 
Timeline -0.002 .99 
Personal control 0.26 .005* 
Treatment control 0.24 .009* 
Identity -0.11 .27 
Concern -0.13 .19 
Coherence 0.13 .17 
Emotional representation -0.21 .024* 
Brief IPQ Total -0.31 .001* 
   
BMQ   
BMQ Specific: Necessity 0.18 .058 
BMQ Specific: Concern -0.13 .18 
BMQ General: Overuse -0.18 .055 
BMQ General: Harm -0.15 .11 
   
Tacrolimus .05 .61 
Ciclosporin -.50 .11 
Missed clinic appointments -.02 .85 
Z-score immunosuppressant mean -.003 .98 
Z-score immunosuppressant SD -.086 .37 
Percentage outside expected range -.130 .18 
MARS-5 = Medication Adherence Report Scale; Brief IPQ = Brief Illness Perceptions Questionnaire; 
BMQ = Beliefs about Medicines Questionnaire 
 
Linear Regression Analyses 
Illness perceptions (Brief IPQ) and self-reported adherence (MARS-5) 
Simple linear regressions were used to determine whether illness perceptions were predictive of self-
reported adherence behaviour. These were conducted exploring each illness perception independently 
as a predictor of adherence measured by the MARS-5. Consequences was found to be a significant 
predictor of adherence, with a 1 point increase in perceived consequences associated with a -.11 
decrease in adherence (b= -.11, p=.001). Consequences explained 9.4% of the variance in adherence. 
Personal control was a significant predictor of adherence, with an increase in perceived personal 
control associated with an increase in adherence (b=.13, p<.001), explaining 11.4% of the variance in 
 191 
adherence. Similarly, treatment control was a significant predictor of adherence, with an increase in 
perceived treatment control associated with an increase in adherence (b=.17, p=.002), explaining 
8.3% of the variance in adherence. Coherence was a significant predictor of adherence, with an 
increase in perceived coherence associated with an increase in adherence (b=.16, p=.011) explaining 
5.6% of the variance in adherence. Finally, emotional representation was a significant predictor of 
adherence, with an increase in emotional representation associated with a decrease in adherence (b= -
.09, p=.006), explaining 6.7% of the variance in adherence. No other illness perceptions were 
identified as significant predictors of adherence (timeline, identity, concern). 
 
A multiple regression was then used to predict the combined predictive value of consequences, 
personal control, treatment control, coherence and emotional representation in explaining self-
reported adherence. This also allowed exploration of whether these illness perceptions remained 
significant predictors when entered alongside the other predictor variables. These domains were found 
to significantly predict adherence, F(5, 105) = 5.79, p<.001, R2 = .216. However, when looking at 
individual parameters, only personal control remained a significant predictor of adherence (b=.08, 
p=.041). This means that whilst the overall model was significant, when taking into account 
multicollinearity, personal control was the most important predictor of adherence. 
 
A linear regression was conducted using the Brief IPQ total score as a predictor of self-reported 
adherence (MARS-5). The total brief IPQ score was a significant predictor of self-reported adherence, 
with a 1-point increase in perception of illness as threatening is associated with a -.03 decrease in self-
reported adherence score (b= -.03, p<.001). 
 
Beliefs About Medicines (BMQ) and self-reported adherence (MARS-5) 
Simple linear regression was used to explore if specific beliefs about immunosuppressant medication 
predicted adherence. Necessity and concern were both not significant individual predictors of 
adherence (specific-necessity: p=.08; specific-concern: p=.20). This remained the same when both 
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variables were entered as a multiple linear regression, with the same p values. Similarly, general 
beliefs about medication was explored as predictors of adherence. Overuse was a significant predictor 
of adherence, with a 1-point increase in perceptions of overuse of general medication associated with 
a -.07 decrease in self-reported adherence score (b= -.07, p=.048) explaining 3.5% of the variance in 
adherence. Harm was a significant predictor of adherence, with an increase in perceptions of harm 
caused by general medication associated with a decrease in adherence (b= -.08, p=.049) explaining 
3.5% of the variance in adherence. When both variables were entered together in a multiple 
regression, overuse and harm were both no longer significant predictors of adherence (general-
overuse: p=.39; general-harm: p=.40).   
  
Open-ended Questions: Qualitative Analysis  
Question 1: Were you on a different renal replacement treatment modality prior to your kidney 
transplant? (e.g. haemodialysis, peritoneal dialysis). If yes, what Renal Replacement Therapy did 
you receive? 
 
Answers to this question included a response about previous treatment modality and so were 
straightforward to analyse thematically as there was naturally a high level of similarity in descriptions 
of treatment. Responses were provided to this question by 117 (91.4%) patients. The majority of 
patients reported receiving dialysis prior to their kidney transplant. Some patients reported receiving 
more than one type of dialysis, e.g. HD and peritoneal dialysis, whereas some report receiving only 
one type of dialysis treatment. This was confirmed via the quantitative statistics which showed 86.7% 
of the sample received their transplant post-dialysis. 
 
Question 2: Can you describe how you found following/sticking to that treatment regime? 
A total of 100 patients (78.1%) provided a response to this question. When asked to describe how 
they found following/sticking to their dialysis treatment regime prior to their transplant, three themes 
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emerged representing the majority of patient responses. These included “Physical, behavioural and 
mental challenges”, “Space for living a normal life” and “Bitter lifeline”.  
 
Physical, behavioural and mental challenges  
The majority of patients described the physical and mental challenges of coping with dialysis. This 
was raised in relation to adjusting to the restrictive nature of the treatment, particularly diet and fluid 
intake restrictions, and the impact the treatment requirements had on patient quality of life. This is 
clearly demonstrated via the quotes below.  
 
“Very difficult to go through. The fluid restrictions were very difficult. Emotionally and physically 
dialysis disrupts and is very difficult.” (P133, M, 49yrs) 
 
“Very difficult, both mentally and physically. Diet and fluid restrictions impacted in social life” 
(P021, M, 67yrs) 
 
In addition to reporting the restrictions associated with dialysis and the impact of these, patients also 
reported the side-effects experienced as a result of treatment, notably fatigue.  
 
“Very restrictive ie. Diet, fluid intake, spending almost the whole day travelling to, in and home from 
hospital, being sick, headaches, tiredness” (P018, M, 30yrs) 
 
“Very hard and I used to feel very weak when I came off the machine, I passed out sometimes. 
Constantly thirsty….” (P008, F, 62yrs) 
 
“Very restrictive of what food and drink could be consumed, also very tiring. Also not able to move 
much as attached to the machines” (P136, M, 61yrs) 
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It is clear from patient responses that there are a number of common challenges with following 
treatment requirements that have to be managed in order to adhere to dialysis treatment. These present 
as challenges in managing behavioural requirements as part of adhering to treatment, including diet 
and fluid restrictions, as well as managing side-effects as a result of treatment, such as fatigue. It is 
also interesting that patients talk about mental challenges, suggesting that they have a common 
language for expressing their difficulties. This highlights the complexity of this treatment regime, and 
how the presentation of these challenges can impact patient’s quality of life. 
 
Space for living a normal life 
The majority of patients described how dialysis treatment disrupts routines and daily life. This is 
likely due to treatment demands, for example in the case of HD patients must make arrangements to 
attend treatment three times per week for 3-4 hours per session dependent on fluid removal needs. In 
the case of peritoneal dialysis, treatment is required more frequently. This is demonstrated via the 
quotes below. 
 
“It takes over your life. Everything revolves around your 3 days of dialysis” (P098, M, 71yrs) 
 
“I felt this was crucial treatment so accepted the disruption to my life accordingly. My employer was 
very accommodating, however it was difficult holding down a senior position” (P110, M, 58yrs) 
 
“…Haemo took up my entire life. I could only exist not really live” (P117, F, 29yrs) 
 
Patients describe how the treatment demands of dialysis can have a large impact on both work and 
home life. If working full-time, arrangements have to be made with employers in order to attend 
treatment. In terms of home life, arrangements may have to be made regarding, for example, travel, 
childcare and/or carer duties etc. Due to these demands and also the side-effects of receiving the 




Patients also reported feeling a lack of choice in their dialysis treatment due to the necessity of the 
treatment in order to maintain health and wellbeing as much as possible. This was often viewed 
negatively by patients. This is demonstrated via the quotes below: 
 
“It just became a way of life and had no choice but to have dialysis – if I wanted to stay as healthy as 
I could be…” (P094, F, 44yrs) 
 
“Awful – it was necessary, but tiring, hard work, time consuming, life limiting, upsetting for myself 
and family” (P044, F, 46yrs) 
 
“Very challenging at first, scary too. But it was to keep me well and alive, so you have to get over 
that” (P023, F, 50yrs) 
 
Although patients often disliked dialysis treatment, they recognised the necessity of the treatment in 
order to maintain their health. This highlights the patients’ attempts to see the benefits of receiving the 
treatment as outweighing the costs and negatives in terms of treatment demand and side-effects of 
what is seen as a debilitating treatment. 
 
Question 3: Can you describe how you are finding following your post-transplant treatment regime 
now? (Immunosuppressant medication, clinic appointments etc.) 
A total of 121 patients (94.5%) provided a response to this question. When asked to describe how 
they were finding their post-transplant treatment regime, two themes emerged representing the 
majority of patient responses. These included “Improvements in quality of life” and “Challenges 





Improved quality of life 
In response to post-transplant treatment, patients often described how the treatment regime became a 
part of their daily routine and how receiving the transplantation had allowed them to return to what 
they saw as more of a normal life, particularly in comparison to dialysis. Within this theme, 
“normalising the life of a transplant recipient” and “regaining autonomy” were identified as sub-
themes.  
 
Normalising the life of a transplant recipient 
The majority of patients described how managing and following the post-transplant treatment regime 
had become a part of their normal daily routine.  
 
“Taking tablets twice a day is routine, like brushing your teeth” (P057, M, 59yrs) 
 
“This has been my life for 16 years since I was 19. It’s so routine now it’s just normal. I have never 
missed a clinic appointment and never miss my medication. Morning and evening religiously!” 
(P031, F, 36yrs) 
 
“I’m 15 years past post-transplant it’s normal now to following instructions and regime” (P061, F, 
27yrs) 
 
“Since it’s been a long time I find it quite easy to do. It’s now become part of a natural easy routine.” 
(P133, M, 49yrs) 
 
Normalising treatment could be an important process for patients in adjusting to post-transplant 
management but additionally to allow patients to feel less like an unwell “sick patient” and to identify 
as an ordinary well person who simply checks in with health care professionals every now and then to 
ensure renal function is stable and that there are no concerns. This could ensure there is limited 
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anxiety and time spent worrying about the transplant and its function and allows patients to focus on 
living as normal a life as possible.  
 
Regaining autonomy 
Patients described how receiving a transplant provided a sense of freedom in escaping dialysis and 
feelings that they had gained their life back. This was particularly notable in comments from patients 
who had received dialysis treatment prior to transplantation. 
 
“…the transplant has given me back my life ie. Working full-time as a teacher!” (P020, F, 55yrs) 
 
“…in 100% better health. Can live a more normal life………I can just take my medication and can 
live a normal life. Very glad I had the transplant” (P008, F, 62yrs) 
 
“Much easier and able to enjoy a normal life” (P017, M, 65yrs) 
 
Due to the complexities and challenges in managing a dialysis treatment regime, it is evident that 
transplantation can provide patients with a greater ability to live life as they once did prior to 
receiving dialysis. Medications are managed by patients at home and once renal function becomes 
stable, clinic appointments and blood tests to monitor function and medication levels can become as 
little as once every three or four months. This can allow patients to return to work and remove the 
feeling of reliance on clinicians towards positive patient self-management. This treatment option also 
allows fewer restrictions with diet and fluid. These changes from when receiving dialysis can be 
important for improving patient positivity and quality of life.   
 
Challenges adjusting to treatment 
Although there are clear benefits for patients in receiving a kidney transplant, a number of patients 
described some of the challenges experienced in adjusting to their post-transplant treatment regime. 
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Within this theme, “freedom within boundaries”, “unintentional forgetting in treatment management” 
and “psychosocial impact of treatment side-effects” were identified as sub-themes. 
 
Freedom within boundaries 
A large proportion of patients described the burden of being required to attend a high number of clinic 
appointments post-transplant. This frustration may partly be due to patient expectations of greater 
freedom following transplantation. Although following stabilisation of renal function appointments 
can become more infrequent, the burden of needing to attend the transplant clinic regularly 
particularly within the first-year post-transplant or during times of unstable kidney function was 
described as an issue by patients. In relation to this, complaints were particularly raised surrounding 
the time spent on travelling to and from the hospital, parking costs and waiting times when 
appointments can often be quite short. 
 
“A continuous stream of appointments and the travelling to and from – 50 mile round trip, also the 
cost of travel and the parking, sometimes for just 90 minutes.” (P006, M, 78yrs) 
 
“…Clinic appointments sometimes are a waste of time. Very short consideration for which you travel 
2 hours” (P059, M, 49yrs) 
 
Frustration was also raised surrounding needing to travel for blood tests prior to clinic appointments, 
sometimes on a different day to ensure results are available to discuss with consultants, therefore 
disrupting daily routines for multiple days. 
 
“…not being able to get tests done at Bedford locally is a pain as I have to travel to do them, not 
having a local clinic means an entire day is taken for 10-15 min” (P064, M, 59yrs) 
 
Although appointments become less frequent, as some patients have to travel a considerable distance 
to the hospital for their appointments, this was raised as a major negative aspect of post-transplant 
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care. At the trust in which this study was conducted, issues surrounding car parking limitations and 
cost of parking were also raised as problematic. Additionally, if blood tests could not be performed 
locally this was also described negatively by patients. Although these aspects were raised as a 
nuisance for patients, the benefits and importance of attending the clinic to monitor transplant 
function as part of their post-transplant care appeared to be recognised, which seemed to encourage 
attendance despite the irritants. 
 
Unintentional forgetting in treatment management 
Some patients described occasional forgetting in relation to taking their immunosuppressant 
medication. This was often due to lifestyle factors making tracking medication taking more 
challenging. 
 
“Hard to remember varying doses of medicines while living a busy family life” (P065, M, 73yrs) 
 
“It’s hard as I seem to forget that I have medication to take. Forgetting I have appointments.” (P120, 
F, 20yrs) 
 
“…Sometimes I forget and am late with the day time dose no more than 1.5 hours” (P057, M, 59yrs) 
 
Patients who were longer since receiving their transplantation described forgetting due to 
complacency or forgetting whether medication has already been taken as it becomes embraced as a 
normal part of the daily routine. 
 
“I often forget medication. I have been on medication for 23 years and often feel like I have already 
taken my medication” (P117, F, 29yrs) 
 
“…sometimes I think too easy as it makes me complacent and I forget both medication and 
appointments quite often” (P032, F, 58yrs) 
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This highlights some of the challenges in managing treatment regimes, and how simple lifestyle 
factors and changes to daily routines can impact on remembering to take medication at the times 
prescribed or to attend clinic appointments. This suggests that developing and having strategies in 
place to manage and remember treatment requirements, such as taking medication and attending 
appointments, could be beneficial for patients to promote adherence.  
 
Psychosocial impact of treatment side-effects 
A challenging aspect described by some patients was managing and accepting side-effects of 
immunosuppressant medications. Patients described the physical side effects experienced and the 
irregularity in feelings of health and well-being.  
 
“…However I get depressed with the tremors which are a severe side effect of the tacrolimus” (P086, 
F, 75yrs) 
 
“up and down. With lots of warts” (P060, M, 49yrs) 
 
“…when I first started I experienced a multitude of adverse side effects. The worst being hair loss” 
(P091, M, 20yrs) 
 
Patients also described feelings of tiredness and fatigue as a physical side effect of taking the 
immunosuppressant medication, but additionally the mental fatigue associated with managing 
multiple medications required to ensure transplant function, and the fluctuation in feelings of being 
well whilst following this treatment regime.  
 
“…I am usually very fatigued and can feel quite poorly just after taking meds a.m – so can be a bit 
difficult” (P096, F, 61yrs) 
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“Find the drugs very tiring. Up and down with health is very hard to take. I was on an even health 
level on dialysis.” (P030, M, 50yrs) 
 
This demonstrates that although transplantation is often considered the best treatment option for most 
patients with ESRD, there are still challenges both physical and psychological that may be 
experienced and have to be managed as a result of treatment. This can be particularly challenging for 
patients who have been transplanted pre-emptively and perhaps felt fairly well prior to 
transplantation, or for patients who experienced fewer or less notable side-effects when receiving 
dialysis. Additionally, if patients considered prior to transplantation that following receiving the 
transplant their life would return to normal and they would feel healthy and well, managing these 
expectations when experiencing treatment side-effects may also be challenging. 
 
Question 4: Do you think you have got better or worse in how well you follow your treatment 
regime over time? And Question 5: Has how you engage with treatment and advice you have been 
given changed over time? 
Analysis for question four and five were combined. When asked whether they have got better or 
worse in how well they follow their treatment regime over time, and whether how they engage with 
treatment and advice they have been given has changed over time, patients answered with brief 
responses. Responses were provided by 121 (94.5%) patients for question four, and by 117 (91.4%) 
for question five. The majority of patients identified as having always been engaged with treatment 
since transplantation or having improved over time. However, some patients described becoming 
worse in how well they follow their treatment regime. 
 
The” ideal” patient 
A number of patients described following treatment in the same manner with no changes in 
engagement with treatment and advice over time. Any changes described were in relation to 
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medication dosage changes but engagement with advice and treatment was described as not changing. 
Some patients described this in relation to their relationship with clinicians and health care 
professionals and how this relationship was important for engagement with treatment and advice.  
 
“The same. I’m not a rule-breaker – have always and will always do as the doctors ask – it gives me 
the best chance of staying well” (P031, F, 36yrs) 
 
“No - I’ve always been very good at taking medication and following doctors’ advice – it helps to 
have a doctor you trust. I think this makes you more confident in the treatment they prescribe” (P074, 
F, 33yrs) 
 
“Not really, I’ve always been inquisitive and fully engaged with my treatment and the advice I 
receive” (P022, F, 57yrs) 
 
The “progressive” patient 
A large number of patients described having improved in how well they follow their treatment 
regime, and that this got better as time progressed since transplantation.  
 
“Better over time. Obviously in the beginning you don’t fully understand your condition, so you 
follow directions. The longer it goes on it becomes more day to day” (P133, M, 49yrs) 
 
“Better – I know my medication, what it does, how to manage it effectively” (P074, F, 33yrs) 
 
“Better. More you do something it becomes second nature” (P010, M, 41yrs) 
 
This improvement was often described in relation to gaining familiarity and understanding with post-
transplant treatment requirements, allowing for improved engagement.  
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Barriers to treatment engagement 
A few patients did describe becoming worse in how well they follow their treatment regime. This was 
often mentioned in relation to lifestyle factors, changes in routine, longer time since transplantation in 
remembering to take medication or medication side-effects. 
 
“As time passes, sometimes (it’s) difficult remembering medications. Stressful if going away or out for 
the day” (P044, F, 46yrs)  
 
“Much worse. I used to take medications at a particular time of the day and now I never follow this 
regime” (P032, F, 58yrs) 
 
“Worse!! I felt better before the transplant. Med drugs are very hard to take.” (P030, M, 50yrs) 
 
Challenges adjusting to treatment, side-effects/pill burden, and remembering to take medication 
alongside a busy lifestyle were described as barriers to engagement. A few patients described feeling 
more unwell post-transplant, and this impacted on how well they followed their regime.  
 
7.4 Discussion 
This study aimed to explore whether psychosocial factors, including illness perceptions and beliefs 
about medication, were predictive of adherence to immunosuppressants. Findings from this study 
highlight some interesting outcomes relating to illness perceptions and beliefs about medication as 
predictors of adherence. Increases in perceived personal and treatment control were found to predict 
increases in adherence to immunosuppressants. There was an inverse relationship between perceived 
consequences and emotional representation with adherence to immunosuppressants. These findings 
are similar to previous literature that has identified receiving a kidney transplant to be associated with 
positive perceptions of illness controllability (Griva et al., 2012), including personal control 
associated with improved adherence (Massey et al., 2013). Additionally, Massey et al., (2013) found 
perceived consequences to be rated significantly higher among non-adherent patients. This relates 
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closely to the study’s findings where increases in perceived illness consequences predicted decreases 
in adherence. However, where this study identified increases in perceived emotional response to 
predict decreases in adherence, Massey et al., (2013) found the opposite with higher perceptions 
resulting in improved adherence. This may relate to the level of emotion experienced by patients and 
whether they are able to cope with this in the context of managing a chronic health condition. 
Additionally, the studies used different measures of adherence and different study designs (cross-
sectional vs. longitudinal), which could contribute towards different findings. Other illness 
perceptions have also been associated with receiving a kidney transplant, including positive 
perceptions of identity (Griva et al., 2012), and longer perceived illness timeline to increase adherence 
(Massey et al., 2013), however, this study found no association between these items and adherence. 
Taken with existing research, the findings indicate that illness perceptions are essential to patients 
framing their illness experiences and provides consistent support for them having a role in treatment 
adherence. 
 
Patients reported higher scores on the necessity sub-scale and lower scores on the concerns subscale 
of the BMQ, indicating a greater perception in necessity of immunosuppressant medication, and a 
lower perception of concerns, such as medication dependency or side-effects. This supports existing 
literature that has found patients report higher necessity beliefs and lower concern beliefs (Horne & 
Weinman, 1999; Lennerling & Forsberg, 2012; Massey et al., 2013; Massey et al., 2015; Foot et al., 
2016). Findings relating to the necessity-concerns differential indicated a positive score representing 
patients as recognising the benefits of immunosuppressant medication as outweighing the costs. This 
finding is also observed in other literature using this measure (Horne & Weinman, 1999; Lennerling 
& Forsberg, 2012; Massey et al., 2013). Specific beliefs about immunosuppressant medication in 
terms of necessity and concerns, were not identified as predictors of adherence. Although Horne & 
Weinman (1999) found medication beliefs to be stronger predictors of adherence, compared to 
sociodemographic and clinical factors, other literature has found no significant associations between 
these two factors (BMQ and adherence) (Lennerling & Forsberg, 2012; Massey et al., 2015). When 
explored independently, both subscales of general beliefs about medication (overuse and harm) were 
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identified as significant predictors of adherence, where an increase in perceived overuse and harm of 
medications predicted a decrease in adherence. However, these were both only marginally significant, 
and when both variables were entered as a multiple regression, they were no longer significant. This is 
an interesting finding as it suggests that perceptions of general medication could be important in 
determining adherence behaviour. However, much of the previous literature exploring medication 
beliefs have focused on the BMQ-specific subscales, therefore exploration of these findings is needed 
to clarify this outcome.  
 
No significant correlations were identified between clinical data and total MARS-5 adherence score. 
This included both immunosuppressant blood levels exploring mean tacrolimus and ciclosporin 
levels, and also clinic attendance. The same was also found when using z-score of mean 
immunosuppressant level, z-score of SD immunosuppressant and percentage of immunosuppressant 
readings outside the expected range. This is an interesting finding considering previous literature has 
identified combining measurement methods as more effective and reliable in defining and 
determining non-adherence (Schafer-Keller et al., 2008), including combining self-report with blood 
assay. This perhaps needs to be explored in relation to measures used to assess self-reported 
adherence and definitions used to assess adherence via clinical data. Additionally, a high number of 
patients had immunosuppressant blood level readings outside of the expected therapeutic ranges 
during the study data collection period (6 months prior to completing the study questionnaire) which 
could indicate non-adherence. However, therapeutic target ranges can often be individualised on a 
patient by patient basis and dependent on transplant vintage. It may be that the therapeutic ranges 
presented in the existing literature (Schafer-Keller et al., 2008) and by local practice at NHS trusts 
may not be representative or applicable to patients at all trusts providing post-transplant follow-up 
care. Target levels may also be individualised based on patient factors.   
 
No significant correlations were observed between adherence or psychological factors and transplant 
vintage. This is of particular interest as existing literature exploring long-term adherence suggests 
adherence declines over time (Nevins & Thomas, 2009; Tsapepas et al., 2014), however, no 
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associations were found in this study which reflects this. It is possible the sample recruited were a 
particularly adherent group of long-term survivors, and those with poor adherence may be back on 
dialysis. Or arguably could suggest a need to look at practice patterns in support at different centres to 
understand this further. Finally, patients who received a deceased donor transplant were found to have 
a significantly lower adherence score compared to those who received a transplant from a living 
donor. This finding differs to existing literature which has suggested non-adherence levels to be 
higher among those with living donor grafts (Denhaerynck et al., 2007; 2014). However, it should be 
noted that the adherence scores between the two groups did not differ largely, with the mean score for 
deceased donor recipients only slightly lower than that of living donor recipients.  
 
The qualitative comments via open-ended questions provided a mixed view towards experience of 
renal transplantation within this patient sample. Those who reported positive experiences in relation to 
transplantation described feelings of regained life and ability to return to normal routines, including 
work and family life, prior to other forms of renal replacement therapy, such as dialysis. This could be 
interpreted as an increase in quality of life, which has been identified to improve following transition 
to post-transplantation from dialysis (Griva et al., 2012). However, as transplantation is often viewed 
as better than HD or not as taxing, it’s downside often gets overlooked. Therefore, for some patients it 
does not provide the positive outcomes expected. Of those who described negative experiences in 
relation to their transplant, this was often described in relation to physical and psychological 
challenges associated with managing treatment, including experiences of side-effects. Negative 
experiences of post-transplant care and graft failure or loss has been associated with lower quality of 
life and negative illness perceptions (Griva et al., 2012). Higher perceptions of concerns of 
immunosuppressant medication is associated with lower levels of adherence (Foot et al., 2016). 
Therefore, patients who have expressed qualitative comments of challenges with post-transplant care 
and treatment may be at risk of non-adherence. Additionally, aspects relating to the burden of follow-
up care in relation to blood tests and clinic appointments was also noted (despite the requirements 
often being less demanding than other renal replacement therapy types such as HD or peritoneal 
dialysis). Other literature has identified patients can feel overwhelmed by medication side-effects and 
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health decline post-transplant (Pinter et al., 2017). This could be a determining factor in whether 
patients engage with the treatment regimen and clinician advisements, however, the findings from the 
necessity-concern differential highlight that patients recognise the benefits of immunosuppressants 
outweigh the costs in maintaining health, which may make them more likely to engage with, for 
example, medication taking, clinic appointments and blood tests.  
 
The findings from both the questionnaire measures and open-ended questions highlight the 
complexity in managing treatment and adjusting to life post-transplantation. Exploring how patients 
are coping with medication and how they perceive their illness may be useful to signal those who may 
be at risk of disengagement who may benefit from support via an intervention to improve treatment 
adherence.  
 
7.4.1 Strengths and limitations 
There is limited previous literature which has explored the role of illness perceptions and beliefs 
about medications among renal transplant recipients and specifically how this relates to adherence. 
The study adds to this growing pool of evidence exploring psychological aspects in relation to 
adherence. Additionally, the study utilised mixed questions, providing in depth analysis of answers as 
well as exploring patterns in data. As such, research of this nature has a useful contribution to make 
towards strategies to support patient adherence. Furthermore, the sample size exceeded the 
requirements identified for adequate analysis via a power calculation.  
 
There were a number of limitations to be considered when interpreting findings. Firstly, the study 
relied on self-report measures, which previous literature indicated may lead to under reporting of non-
adherence (Massey et al., 2013). However, in consideration of this issue, clinical data relating to 
adherence behaviour was also collected via immunosuppressant blood levels and clinic attendance to 
compare with self-reported adherence rates. Secondly, poor internal validity was identified via 
Cronbach’s alpha for the MARS-5 total adherence score in this patient sample. This may be due to 
perceptions of adherence in this particular patient sample recruited for this study. The questions may 
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have been perceived in different ways by patients relating to different severity levels of non-
adherence with differencing consequences. This could lead to different reporting rates between the 
items. However, analysis was conducted removing the items that were problematic, with similar 
outcomes shown in relation to multiple regression analyses. The MARS-5 has been used in other 
chronic illness contexts, including HD, but less commonly among renal transplant recipients. An 
alternative adherence measure may need to be considered in future studies. Thirdly, most of the 
variables used in the linear regression analyses were non-normally distributed. Although log and 
square root transformation were used, this did not resolve the issues with normality. Analyses was 
therefore conducted using the original non-normally distributed variables. Interpretation of the study 
findings should be considered with this in mind. Finally, the post-transplant clinic at the trust in which 
the study was conducted is not a transplanting centre, therefore patients are often more experienced 
transplant patients with longer transplant vintage. Patients who are longer since transplantation are 
more likely to be non-adherent, particularly with unintentional non-adherence (Griva et al., 2012), 
which could influence reporting on the measure.  
 
7.4.2 Conclusion 
Certain illness perceptions may play an important role in adherence to immunosuppressants within the 
renal transplant population. Perceived personal control and treatment control predicts an increase in 
adherence. Perceived consequences and emotional response predict decreases in adherence. Specific 
beliefs relating to necessity and concerns surrounding immunosuppressants are not predictive of 
adherence, however, patients recognise the benefits of this treatment as outweighing the costs in 
managing and treating their condition. Whilst combined estimates of clinical adherence behaviour 
have advanced as a useful step to accurate measurement, the current study did not support this. The 
research has highlighted the continued role of illness perceptions and medication beliefs in further 
understanding health experiences and behaviour in an ESRD population, specifically adding to the 
dearth of research in this area for transplant recipients. The outcomes pave the way for considering 
whether illness perceptions in particular should be routinely assessed to signal patients who may 
 209 
struggle to engage with treatment regimens, and who may benefit from exploring their illness 














































Chapter 8: General Discussion 
 
8.1 Introduction 
The aim of this thesis was to present a programme of research that provides clinically useful insights 
into adherence in renal transplant recipients. It achieved this aim using a range of research 
methodologies including systematic review, quantitative data analysis, and qualitative methods to 
provide further depth of enquiry. Furthermore, the findings were drawn from multiple sources 
including clinical data collected as part of routine care, and engaging with both patients and health 
care professionals who work with this patient population. A brief summary of the main findings from 
each study chapter from this thesis are provided below: 
 
Systematic review (Study 1) 
Findings from the systematic review highlight that non-adherence remains a prevalent issue within the 
renal transplant population. A total of 60 studies were included in the review. Studies varied in how 
they measured adherence, including self-report, electronic monitoring, pharmacy refill, blood levels 
and collateral report, with some studies combining more than one measure in an attempt to increase 
reliability. The overall non-adherence prevalence ranged across studies from 0.06% to 89.2%, 
dependent on how adherence was measured and operationalised. The most commonly utilised 
measurement method to assess adherence behaviour was self-report. Meta-analysis of 38 studies 
revealed the pooled prevalence of self-reported non-adherence was 37.6%, however prevalence rates 
vary across measures used. Findings highlight a clear lack of consistency in how adherence is defined 
and measured across studies. Clear guidelines or consensus is needed for clinical practice to identify 
patients at risk for poorer outcomes. The review also found that younger age, greater transplant 
vintage, living related donor grafts, and symptoms such as side-effects and psychological distress, are 





Retrospective data analysis (Study 2) 
Non-adherence ranged from 25%-42% pre-transplant and 15.9%-22.7% post-transplant dependent on 
how it was operationalised. Across all measures of adherence used pre-transplant, non-adherence was 
less post-transplant, and in some cases, significantly so. However, although some patients do improve 
adherence to treatment post-transplant, a proportion of patients remain non-adherent. Poor phosphate 
control pre-transplant was associated with post-transplant clinic attendance. Patients who had missed 
one or more transplant clinic appointments had higher mean pre-transplant phosphate levels. In 
addition, non-adherent patients with high phosphate levels pre-transplant were significantly younger. 
Despite this, the findings did not indicate a strong direct relationship between pre and post-transplant 
adherence. The findings require confirmation and further research to assess whether pre-transplant 
adherence interventions may enhance post-transplant adherence and patient outcomes. 
 
Qualitative interviews (Study 3) 
Post-transplant non-adherence remains a prevalent issue clinicians have to manage with their patients. 
Five main themes were identified on the understanding of non-adherence: “Barriers to adherence”, 
“Striving for normality”, “Mutuality in maximising patient adherence”, “Complexity in shining light 
on adherence in wait listing” and “Post-transplant normalization”. The findings demonstrate clinicians 
recognise and understand the barriers patients can face with adherence, and work to try and make 
treatment management easier, considering individual circumstances where possible. Improving 
patient understanding of medication taking and engagement was considered an effective way to 
promote adherence. Clinicians felt it was important to deliver this alongside providing continued 
patient education and implementing how to better use peer support. Clinicians felt patients viewed 
transplantation as an opportunity to return to what they perceived as a normal life and to avoid 
dialysis. However, as patients transplant function becomes stable over time, perceptions of wellness 
and a lack of immediate consequences following missed medication can lead to non-adherent 
behaviour. Agreement on how adherence is viewed as part of transplant eligibility was lacking, with 
clinicians managing pre-transplant non-adherence in different ways. The findings highlight the need 
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for agreement among the renal community about how non-adherence should be managed in the 
decision-making process for wait-listing. 
 
Cross sectional questionnaire (Study 4) 
The findings showed no correlations between clinical data and MARS-5 self-reported adherence 
score. Illness perceptions may play a role in adherence to immunosuppressants among renal transplant 
recipients. Perceived personal control and treatment control were found to predict an increase in self-
reported adherence. Perceived consequences and emotional response were found to predict decreases 
in self-reported adherence. Renal transplant recipients perceived the “benefits” of immunosuppressant 
medication to outweigh the “costs” in managing and treating their condition, however, specific beliefs 
relating to necessity and concerns surrounding immunosuppressants did not significantly predict self-
reported adherence. The qualitative comments indicated a mixed view and experience of 
transplantation. Positive experiences reported included feelings of regained life, however, for some, 
symptom burden or side effects, for example, meant life after transplantation did not meet 
expectations. The findings highlight areas for potential intervention by considering whether illness 
perceptions in particular should be routinely assessed to signal patients who may struggle to engage 
with treatment regimens and who may benefit from exploring these further via intervention. 
 
To summarise, the overall findings from this thesis as a whole make a contribution towards moving 
clinical practice and research forward. They include:  
1. The value of mixed methodology as a method of enquiry;  
2. The importance of multiple perspectives from both patients and providers (health care 
professionals); 
3. The need for clear methods for defining and measuring adherence; 
4. The complex relationship between pre and post-transplant adherence; 




8.2 Overall findings 
8.2.1 Value of mixed methodology  
The mixed-method approach utilised within this programme of research provided a wide breadth of 
data and allowed exploration of patterns of behaviour as well as in depth understanding of experience. 
When both quantitative and qualitative methods are used within one study, these can be used to 
corroborate findings (Johnson et al., 2007). Mixed-methods research is becoming increasingly 
common and popular in health-related research (Protheroe et al., 2007) and can provide greater insight 
into specific issues. These are being utilised in exploratory work as well as alongside interventions 
and randomised controlled trials (Protheroe et al., 2007; O’Cathain et al., 2014). In these contexts, 
qualitative research, such as interviews, can be used to understand the benefits and limitations 
surrounding interventions, and whether they are successful or not. Utilising a range of methodologies 
is important in order to understand and evaluate complex issues (O’Cathain et al., 2007), such as non-
adherence. In relation to this programme of research, a combination of approaches was considered 
appropriate to explore non-adherence in depth to provide a clear understanding of this topic area, 
including a systematic review, retrospective analysis of clinical data, questionnaires and qualitative 
interviews. A systematic review methodology provided a comprehensive way to identify and capture 
existing literature exploring non-adherence to immunosuppressants, providing an updated knowledge 
base of existing studies among adult renal transplant recipients. A retrospective data analysis of 
clinical data provided exploration of adherence behaviour using objective measures, without 
limitations of subjectivity, such as self-report. This provided a novel way of exploring patterns of 
behaviour between pre and post-transplant adherence. Qualitative interviews were appropriate and 
necessary for exploring the role of adherence in transplantation, as understood by clinicians and 
health care professionals. There is limited existing literature exploring the role of adherence behaviour 
pre-transplant when determining transplant eligibility, therefore rich and detailed responses were 
needed to understand this fully. Finally, questionnaire methodology allowed for wider scoping of 
behaviour patterns among renal transplant recipients in relation to adherence, clinical data and 
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psychological factors relating to how they perceive transplant and immunosuppressant medication and 
manage their treatment in relation to taking pills and timing. This provided a broad understanding of 
the topic area, highlighting areas for further exploration or development areas for intervention in 
future work.  
 
8.2.2 Importance of multiple perspectives 
The programme of research considered different perspectives on adherence behaviour among renal 
transplant recipients, by consulting both patients and clinicians/health care professionals. This was 
considered essential as it allowed for exploration of whether health care professionals understanding 
of non-adherence was similar to that of their patients’ experiences. Establishing this match is 
important for ensuring medical professionals are able to support patients if they experience barriers 
that impact adherence in order to address and rectify issues and preserve graft function. Both patients 
and care-provider ultimately have a role to play within shaping outcomes and the extent to which they 
are “on the same page” is likely to be important. For example, a primary care study found that the 
level of concordance between patients and physicians about a presenting issue and how it should be 
managed predicted medication taking at follow-up (Kerse et al., 2004).  
 
Additionally, different health care professionals were consulted as part of the qualitative interview 
study, including consultant nephrologists, transplant surgeons, registrars, specialist nurses and 
pharmacists. It could be considered that these health care professionals have different relationships 
with renal transplant recipients based on their interactions and roles. Nurses may have greater 
involvement with patients and be in contact with them more regularly regarding their health, well-
being and medication, whereas consultant nephrologists and registrars may only see patients when 
they attend for their routine clinic visits or experience adverse events. It is possible that patients may 
share differing or alternative views and experiences with different health care professionals regarding 
treatment adherence or be more open with some staff compared to others. Understanding of patient’s 
experiences and of barriers to adherence may have been different based on these encounters. 
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A direct comparison between patient and health care professionals’ perspectives via one study was not 
provided as part of this programme of research, however, this would be useful in future research 
within this patient population. Previous literature using focus groups of patient and clinician 
perspectives explored what patients want to know about their medications, finding a disparity in 
understanding of how much information patients should receive in relation medication (Nair et al., 
2002). The authors indicated that patients want more information relating to medication side-effects, 
however the use of evidence-based information sheets was considered beneficial. Clinicians and 
pharmacists highlight concerns over detailed discussion surrounding side-effects due to risks of 
leading to non-adherence (Nair et al., 2002). Although this research was not conducted within the 
renal transplant population, it highlights the importance of exploring expectations across these 
multiple perspectives considering and comparing views from patients and health care providers 
relating to medication taking.  
 
This programme of research did provide an understanding via a qualitative interview study of how 
health care professionals understand and manage patients exhibiting signs of non-adherence, and 
barriers they consider may impact medication taking. Findings from the quantitative studies 
(retrospective and questionnaire study) using patient related data highlighted patterns of adherence 
behaviour and predictors of non-adherence, providing supplementary information to add to health 
care professional’s knowledge base. This consolidation of findings takes into consideration both 
patients and health care providers perspectives in relation to non-adherence, and further supports the 
need for interventions and for identifying patients that should be targeted for intervention to improve 
adherence rates.   
 
8.2.3 Measurement methods for adherence 
This thesis clearly highlights a lack of consistency in measurement methods used in the literature 
when exploring adherence to immunosuppressant medication. As highlighted in the systematic 
review, researchers exploring adherence use different forms of measurement, for example, self-report, 
electronic monitoring, collateral report, blood assay and pharmacy refill, leading to different levels of 
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non-adherence reported as a result. The systematic review found an overall non-adherence prevalence 
rate ranging from 0.06% to 89.2%, dependent on how adherence was measured and operationalised. 
This is a similar or wider range than previous reviews, which found prevalence rates ranging from 2% 
to 67% (Denhaerynck et al., 2005) and 1.6% to 96% (Belaiche et al., 2017). This may be due to the 
increase in number of studies included in the systematic review compared with previous reviews and 
therefore a wider range of measurement methods and definitions utilised.  
 
Additionally, studies that have aimed to capture adherence behaviour via self-report have used a 
variation of different self-report measures (including validated and unvalidated measures). These may 
include differing items/questions to assess adherence which define and score adherence using 
different cut-off points for categorising non-adherent behaviour. This results in a lack of ability to 
understand and compare reported non-adherence rates across the published literature. The systematic 
review found across studies using self-report measures non-adherence prevalence rates ranged from 
7.4% to 89.2%, with an overall pooled estimate of 37.6%. Previous reviews have reported prevalence 
rates over studies including self-report measures, with one review reporting a weighted mean 
prevalence of 27.7% (Denhaerynck et al., 2005) and a median of 22% (Butler et al., 2004). Again, the 
overall prevalence rate in this review may be higher due to an increase in number of studies included 
and a greater variation in self-report measures used.  
 
Although electronic monitoring is considered the most reliable and efficient way of measuring 
adherence behaviour to immunosuppressant medication, due to the expense associated with this 
measurement method it is used less frequently (Kreys, 2016). As a result, studies often rely on 
alternative, and more cost-effective methods, such as self-report. Due to the limitations that come 
with using self-reported measures, such as potential under-reporting of adherence rates from patients 
(DiMatteo, 2004; Kreys, 2016), researchers have attempted to use a combination of measurement 
methods to assess adherence. Most commonly, researchers combine self-report alongside blood assay 
and collateral report from physicians (e.g. Schafer-Keller et al., 2008). Although a composite score 
can be more reliable, again there are challenges in comparing these across studies due to differences 
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in assessment and definition of non-adherence used via these other methods, and how these are 
combined to create the composite score.  
 
Future developments in the measurement of adherence behaviour should include encouraging 
researchers to use validated reliable self-report measures. This would provide better consistency of 
self-report measures that can be utilised to yield reliable non-adherence rates and allow for 
comparisons to be made across studies. Additionally, clearer definitions and cut-off points when 
categorising adherent and non-adherent patients via clinical data is also needed to provide clear target 
ranges for researchers to classify patients. This would also allow for comparisons to be made across 
studies using clinical data such as immunosuppressant blood levels and clinic attendance to assess 
adherence in this patient population. Some studies have used target blood ranges (e.g. Schafer-Keller 
et al., 2008; Gelb et al., 2010; Griva et al., 2012; Hucker et al., 2019), however, this is often defined 
based on existing literature or clinical guidance. Clear guidance on how to assess adherence via 
clinical data e.g. target ranges (with consideration for differing patient factors such as transplant 
vintage) would be useful to provide clarity for researchers on how to use this measurement method. 
This is also necessary for defining adherence via other methods, including electronic monitoring, 
pharmacy refill and physician ratings.  
 
As electronic monitoring is often too expensive for researchers to utilise, clearer guidelines on how to 
implement other more cost-effective measurement methods should be considered. Additionally, 
guidelines on composite scores including which measurement methods should be combined to 
provide the most reliable adherence rates and how to combine outcomes from each measure to create 
a total measure should be considered. This would provide a clearer and more streamlined way to 
measure adherence that could then be more easily compared across published literature. Taking a 
more strategic approach to how transplant researchers and clinicians explore and report adherence is 
one suggestion that could unite efforts and provide a bank of more comparable data for the future.  
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8.2.4 Comparing pre and post-transplant adherence 
The thesis included one of the few existing studies exploring the relationship between pre and post-
transplant adherence (Hucker et al., 2019). It is important to consider how adherence behaviour may 
transfer from one treatment modality to another. This study used clinical data as an objective measure 
of adherence behaviour. Although it may be considered that a non-adherent dialysis patient will 
become a non-adherent transplant patient, the findings highlight that a strong direct relationship in 
these behaviours is unlikely. The prevalence of non-adherence was greater pre-transplant by some but 
not all of the measures utilised. This may suggest that adherence with treatment post-transplant is 
more manageable than to treatment pre-transplant which involves adherence to HD, associated 
medications and fluid and diet restrictions. Additionally, side-effects, symptom burden and impact on 
quality of life may also be reduced (Jansz et al., 2018). These findings are important for clinicians 
when considering whether non-adherent HD patients are eligible for transplantation. However, the 
study was limited by a small sample size and further research is needed to support these findings. 
Additionally, pre-transplant and post-transplant definitions of adherence were determined based on 
previous literature (Leggat et al., 1998; Saran et al., 2003; Hecking et al., 2004; Schafer-Keller et al., 
2008; Wileman et al., 2011; Methven et al., 2017) and clinical experience. A clear agreed way of 
defining adherence using clinical data would be beneficial for future research.  
 
Previous studies have shown a relationship between adherent behaviour prior to transplantation and 
graft loss or mortality (Douglas et al., 1996) reporting 61% of the patients identified as non-adherent 
pre-transplant experienced graft loss or death. Studies exploring this behaviour pattern in other organ 
transplant types (heart, liver, lung) found pre-transplant non-adherence with medication taking, higher 
education and low conscientiousness were predictors of non-adherence to immunosuppressants at 
one-year post-transplant (Dobbels et al., 2009). In addition, low social support with medication taking 
and pre-transplant medication adherence have been associated with non-adherence and late acute 
rejection respectively (Di Matteo et al., 2004). Findings across other organ transplant types highlight 
the need to attend to pre-transplant behavioural patterns in predicting potential post-transplant 
outcomes. Further research is needed within the renal transplant population comparing pre and post-
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transplant adherence in order to identify a reliable pattern of behaviour to interpret and consider in 
clinical practice. Alternatively, drawing on the findings of the qualitative study within this thesis, it 
might be plausible that patients try to “escape HD” with a promise of a better life, which at least in the 
short term might impact on better adherence post-transplant. Whether this changes over time would 
require a higher-powered study considering adherence behaviour over a longer duration, and ideally 
in a longitudinal rather than retrospective design. This would allow for using mixed-methods to track 
the changes in life circumstances, beliefs and attitudes that impact on adherence over-time. For 
example, whilst Taber et al., (2017) found that missing appointments was related to graft outcomes in 
kidney transplantation, a lack of qualitative follow-up with patients means that reasons for missing 
appointments are unknown and this restricts the design of suitable interventions to address 
behavioural confounds.  
 
8.2.5 Importance of adherence in decision making to wait-list for transplantation 
Findings from the qualitative interview study highlight a lack of consistency in the role of adherence 
behaviour when determining transplant eligibility. Whilst there are clear guidelines on the medical 
and surgical assessment required to assess fitness for the transplant operation (Dudley & Harden, 
2011), compatibility tests and psychosocial assessments in relation to coping with the physical and 
emotional transplant aspects, the role of adherence and how non-adherent behaviour should be 
considered as part of this process is unclear. Where some health care professionals consider all 
patients should be given the opportunity of a transplant as their behaviour may change post-operation, 
others consider demonstration of improved adherent behaviour pre-transplant, whether that be to 
dialysis or to transplant work-up appointments, is important prior to activation on the transplant 
waiting list. Ironically, those who did not consider adherence in the decision-making process felt that 
this would lead to inconsistency due to subjectivity but clearly this is already happening in routine 
care. The research might suggest benefit in opening a dialogue on this issue in transplant care teams. 
 
In addition to considering the importance of pre-transplant behaviour as part of the transplant work-up 
assessment, patients additionally need to be well informed and prepared for when transplantation may 
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take place. Available kidneys can turn up at any time with no warning, which could result in patients 
not necessarily being fully prepared. It is essential that patients have the best opportunity to be well, 
and therefore require the knowledge and ability to enact behaviours in order to ensure this. Greater 
resources or education sessions available to patients could be increased during the transplant work-up 
period, given that care teams are providing the best service possible within the time and resource 
constraints that many NHS services contend with. This could ensure the best usage of resources, not 
only in terms of patient outcomes but additionally in terms of cost-effectiveness for health services, 
such as the NHS, due to the higher cost burden of dialysis treatments compared with 
immunosuppressant medication required for transplant recipients (Jindal et al., 2003). Currently, there 
are more patients on the waiting list for kidneys than organs available for transplantation. It is clear 
from the literature that non-adherence to immunosuppressants can lead to graft rejection and graft loss 
(Loghman-Adham, 2003; Butler et al., 2004). If clinicians want the best outcomes for patients in 
terms of graft function and survival, consistent agreement on adherence is needed for transplantation.  
 
The law change in England from Spring 2020 to an opt-out system aims to improve organ donation 
rates and reduce the number of patients on the waiting list. Adults will be considered as consenting to 
donating their organs unless they have recorded to opt-out or fall into a category meaning they are not 
eligible to donate (Department of Health and Social Care, 2019). This change in law could lead to an 
increased availability of kidney organs available for transplantation, however success is dependent on 
patients’ families supporting the decisions of their deceased relatives regarding organ donation 
(Noyes et al., 2019). Although this could lead to a positive development in improving kidney organ 
availability, it is important to ensure that assessment of suitability is still maintained and respected by 
patients and clinicians. Clinicians will need to ensure that although an increased number of organs 
may become available, patients are still suitable for transplantation and likely to utilise and benefit 
from the organ in terms of graft function and survival. This point becomes even more important given 
that qualitative enquiry revealed that clinicians were less worried about adherence when a live related 
organ was being used. It is plausible that an increase in organs could bring about the same wider 
spread attitude. Additionally, in relation to patients who have experienced graft loss, careful 
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consideration should remain when determining eligibility for re-activation on the transplant waiting 
list considering why the graft failed, as transplant outcomes and graft function have been shown to 
deteriorate with increasing number of re-transplantations (Ahmed et al., 2008; British Transplantation 
Society, 2014). Finally, patients will need to ensure that although waiting times for a suitable organ 
may reduce, they are prepared to adhere to treatment requirements and do their best to ensure graft 
longevity and survival.  
 
8.3 Clinical implications and future research 
The findings from this thesis have useful clinical implications that could guide future research and 
clinical practice. The need for clear operationalised definitions of non-adherence for the commonly 
used measurement methods is demonstrated. This should include how to measure and categorise 
patients as adherent and non-adherent, and is important for improving the quality and reliability of 
research being conducted in this field, allowing for comparisons to be made across studies. This is not 
a novel finding per say, but given that the field has not yet moved towards consistency in 
operationalizing non-adherence (Belaiche et al., 2017), an important contribution to highlight. 
Additionally, as self-report remains the most commonly used form of measurement method, 
researchers should be encouraged to use validated and reliable measures in order to provide accurate 
non-adherence rates in their studies. Research and clinical practice could benefit from experts in the 
field of adherence providing agreement and guidance on how and what should be used to measure 
adherence behaviour to improve accuracy of reported findings. 
 
The findings from this thesis demonstrate there are challenges in identifying accurate ways of 
measuring adherence using clinical data. Mean tacrolimus levels of a range of tacrolimus blood test 
result values, for example, may not be reliable, as there are multiple factors that could influence 
results. Additionally, findings suggest a strong relationship between pre and post-transplant adherence 
is unlikely. A longitudinal study is needed to further explore the relationship between pre and post-
transplant adherence, following patient behaviour through the transplantation journey. Although 
further research is needed on the use of clinical data as markers of adherence and the reliability of 
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using this to identify adherent and non-adherent patients, the initial findings from this thesis are useful 
and should be considered in clinical practice.  
 
The thesis also highlights areas that could be targeted for intervention in order to try and improve 
adherence rates. Patient education sessions could be utilised to promote self-management and 
empower treatment autonomy, providing more in-depth information to better educate patients about 
their medicines and the importance of taking these to prolong graft survival. Additionally, placing 
emphasis on this prior to transplantation will ensure patients are better prepared for managing 
expectations for life post-transplant. The questionnaire study revealed that patients with greater 
perceptions of personal control over their kidney transplant were more adherent, therefore instilling 
autonomy in patients prior to transplantation could better prepare them for adjusting and managing 
treatment post-transplant. Patients may also benefit from reminder/refresher education sessions every 
few years to try and prevent adherence from decreasing as transplant vintage increases. Longitudinal 
follow-up is needed to see how and at which point adherence changes as time progresses post-
transplantation.  
 
Research has highlighted the importance of patient education sessions when making decisions about 
kidney transplantation (Wilson et al., 2012) considering patient factors and best practices such as 
individually tailoring education, culturally competent and making it understandable for those with low 
health literacy (Skelton et al., 2015). Providing peer support for patients could also be beneficial for 
promoting adherence and consciously or not, the clinicians contributing to this thesis made efforts to 
add to patient social capital through peer support. Experienced patients with greater transplant vintage 
are able to provide useful advice based on their treatment journey to patients both with ESRD 
preparing for transplantation and those more recently transplanted, to promote the importance for 
taking immunosuppressant medication and following treatment regimens. Broader formalised support 
in this way should be considered and implemented in clinical practice. Peer support may be 
particularly effective in young patients as they transition from paediatric to adult care services 
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(Harden & Sherston, 2013). As well as face-to-face, today’s digital world offers a better way to do 
this online, which could also benefit younger people.   
 
Factors associated with non-adherence have also been highlighted. Targeting those at risk with 
adherence promotion messages may help encourage and improve adherence. Interventions could be 
simple reminders during appointments or via telephone, providing information or encouraging 
engagement with a face-to-face intervention, such as patient education. These could be easily 
implemented and should be considered in clinical practice among renal care teams. Additionally, 
providing support for patients experiencing side-effects of medication or psychological distress could 
also lead to improvements in adherence rates. The questionnaire study highlighted that patients 
experiencing physical or mental challenges may be at greater risk for non-adherence. Exploring and 
monitoring these issues regularly with patients could reveal individuals who would benefit from 
support. The quantitative patient studies provide an insight into non-adherence among this patient 
population, however, further research using qualitative methods, such as interviews or focus groups, 
could provide greater in-depth understanding of patient treatment experiences. A qualitative 
methodology would also allow for further exploration of factors associated with non-adherence 
providing greater insight into how to support patients with barriers they are experiencing to 
medication taking. Further research of this nature is needed with patients to explore these issues.  
 
Future research is also needed to develop guidance for clinicians and health care professionals 
surrounding the role of non-adherence in patient eligibility for transplantation alongside the medical 
and psychological assessments. Findings from the qualitative study indicate there is a lack of 
consistency in how non-adherent patients are assessed and managed pre-transplant, with some 
differences in how pre-transplant non-adherence is viewed dependent on prospective donor type. 
Further work is needed to develop these findings. Patients are often treated on a case by case basis by 
a multidisciplinary team; however, it might be that encouraging patients to demonstrate adherent 
behaviour to either dialysis or transplant work-up appointments for a particular period of time may be 
beneficial for encouraging behaviour change and support improved behaviour post-transplant. These 
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preliminary findings should be considered in clinical practice to ensure staff agreement and 
consistency in how patients exhibiting pre-transplant non-adherence are managed when determining 
eligibility for transplantation.  
 
8.4 Strengths and limitations 
Some of the key strengths of the thesis have already been signposted. Specifically, the mixed methods 
nature and individual study contributions to the field. Another major strength is the multidisciplinary 
team that were involved in planning the programme which has arguably yielded many avenues to 
pursue further. The thesis has and could continue to impact the field of study. The thesis set out to 
inform clinical practice and has achieved this in a pragmatic way. The body of research generated, 
and avenues to take forward are a testament not only to mixed methods, but multidisciplinary research 
teams with different approaches towards answering the same question. A major strength of the 
research is therefore not only what it has contributed to the field of study, but where it can be taken in 
the future. 
 
Despite the strengths of this work, it is acknowledged that there were some limitations. The majority 
of the data was collected from one NHS trust which should be considered when interpreting and 
generalising to the wider renal transplant population. Further, a cross-sectional study was utilised to 
explore the relationship between self-reported adherence and clinical parameters, including 
psychological factors such as medication beliefs and illness perceptions. A longitudinal design would 
have been beneficial to explore adherence behaviour over time, particularly considering that the risk 
of non-adherence increases with transplant vintage (Chisolm-Burns et al., 2008; Griva et al., 2012; 
Burkhalter et al., 2014; Hamedan & Aliha, 2014). However, due to the timeframe available to 
complete a patient related study, a cross-sectional questionnaire study was deemed most appropriate. 
Additionally, no qualitative interviews were conducted with patients. It may have been useful to 
conduct a more in-depth understanding of patient experiences and perspectives on the topic; however, 
it was not pragmatic in the time frame alongside the other studies within this programme of research.  
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The self-report measures utilised for the questionnaire study were brief versions or shorter measures. 
This was due to the nature of the data collection method necessary for the study. Patients were asked 
to complete the questionnaires during the post-transplant clinic whilst waiting for their appointment, 
therefore questionnaire length needed to consider this to ensure patients would not be discouraged 
from completing it if they felt it was too long to complete during this time. It is possible that due to 
the short nature of the measures utilised, behaviour/beliefs may not have been fully captured. 
However, patient burden is a key consideration to avoid questionnaire fatigue. Additionally, the 
MARS-5 (Horne & Weinman, 2002) had poor internal reliability in the study. It is possible that in the 
context of the patient sample explored, patients understood the questions relating to different types of 
adherence with differing consequences for non-adherent behaviour. However, this scale has been 
validated in a number of long-term conditions, and other previous studies using the MARS-5 within a 
renal population have found good internal reliability of the scale (Butler et al., 2004; Griva et al., 
2012; Wileman et al., 2015). 
 
Finally, definitions for non-adherence utilised in the retrospective study were based on previous 
literature and clinician experience. There is limited existing research indicating how non-adherence 
should be defined clinically pre and post-transplant, therefore it is possible that the measures used to 
define non-adherence were not the most reliable and valid. There may be other parameters which may 
be more relevant. This highlights the need to identify clinically relevant definitions that accurately 
measure non-adherence rates to ensure reliable reporting in future research. Additionally, the study 
only explored adherence patterns between HD and post-transplantation. We did not explore patterns 
between patients on other RRT modalities, such as PD and home HD, and post-transplantation. This 
would be useful to identify if similar patterns are observed among patients who experienced other 
RRT modalities prior to transplantation. The sample size was small as this was a specific patient 
population using data from one NHS trust, including only patients with an active transplant who had 
been attending the post-transplant clinic for one year. It is possible findings may have been 
underpowered. However, data was collected for as many patients that met the inclusion criteria as 




The findings from this programme of research support previous literature in confirming that non-
adherence to immunosuppressants and the wider treatment regimen remains a prevalent issue for renal 
transplant patients. It is clear that there is a lack of consistency in how adherence is measured and 
defined in the literature, which needs to be addressed in future research to ensure reliability of 
reported non-adherence prevalence rates. Patients at risk for non-adherence should be targeted for 
intervention pre-transplant where possible in order to improve post-transplant behaviour. To enable 
this to happen, further research is needed to confirm the relationship between adherence behaviour pre 
and post-transplantation and verify pre-transplant risk factors. Finally, consistent agreement is needed 
on how non-adherence should feature in decision making on eligibility for transplantation in order to 
ensure that organs are given the best chance of long-term survival and that patients being listed have 
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